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Summary 
This thesis was devoted to the synthesis of novel heterocycles and more particularly 
fused rings in order to develop a number of libraries aiming to be screened towards 
different kinases incorporated in ongoing projects of Galapagos. 
In the first chapter of this PhD research, a brief introduction concerning protein kinases 
and kinase inhibition is described. 
The second chapter deals with the synthesis of a library of pyrazolo[1,5-a]pyrimidine 
derivatives from the elaboration of the strategy to the biological evaluation. Moreover, the 
development of a facile approach to 3-fluoro pyrazolo[1,5-a]pyrimidine has been 
described. 
The third chapter is devoted to the synthesis of pyridazines and related fused rings, a 
convenient methodology to functionnalized pyridazine derivatives has been elaborated 
allowing the introduction of ester, ketone or sulfonyl groups. The extension of this strategy 
led to the synthesis of novel fused pyridazines such as 5H,6H,7H-pyridazino[4,3-
e][1,4]diazepine. A final part describes the development of the first catalytic Diaza-Wittig 
reaction and a novel catalytic Aza-Wittig applied to the synthesis of pyridazines and 1,4-
benzodiazepine. All the analogues have been screened against a number of kinases. 
The fourth chapter discuss about the three different isomers of triazolopyridine, in a 
first part efforts have been directed towards the synthesis of triazolo[4,3-a]pyridine, two 
patterns of substitution have been considered but only one has been pursued due to 
synthetic problems. During the elaboration of the library, the formation of an isomer has 
been observed and then identified as the triazolo[1,5-a]pyridine obtained by the possible 
Dimroth rearrangement enhanced by the presence of a nitro group in our starting material. 
A route has been studied in order to synthesize this isomer. The last isomer explored was 
the triazolo[4,5-b]pyridine. Three libraries have been developed and screened by 
Galapagos. 
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Samenvatting 
Dit doctoraatsonderzoek is gewijd aan de synthese van nieuwe heterocyclische 
verbindingen en meer in het bijzonder gefuseerde ringen dit om verschillende 
bibliotheken te screenen dit gericht zyn naar verschillende kinases dewelke opgenomen 
zyn in lopende projecten Galapagos. 
In het eerste hoofdstuk van dit promotieonderzoek, een korte inleiding over proteïne 
kinasen en wordt kinaseremming beschreven. 
Het tweede hoofdstuk behandelt de synthese van een bibliotheek van pyrazolo[1,5-
a]pyrimidine derivaten en de uitwerking van de strategie voor de biologische evaluatie. 
Hiervan, Bovendien is de ontwikkeling van een gemakkelijke benadering voor 3-fluor 
pyrazolo[1,5-a]pyrimidine beschreven. 
Het derde hoofdstuk is gewijd aan de synthese van pyridazinen en aanverwante 
gefuseerde ringen. Een handige methode om gefunctionaliseerd pyridazine derivaten is 
uitgewerkt, waardoor de introductie van ester, keton of sulfonylgroepen mogelijk. De 
uitbreiding van deze strategie leidde tot de synthese van nieuwe gecondenseerde 
pyridazinen zoals 5H, 6H, 7H-pyridazino[4,3-e][1,4]diazepine. Een laatste deel gaat 
over de ontwikkeling van de eerste katalytische Diaza-Wittig reactive en een nieuwe 
katalytische Aza-Wittig reactie die toegepast is op de synthese van pyridazines en 1,4-
benzodiazepine. Alle analogen zijn gescreend tegen een aantal kinasen. 
In het vierde onderdeel behandelen we drie verschillende isomeren van triazolopyridine, 
in een eerste gedeelte zijn pogingen gericht op de synthese van triazolo[4,3-a]pyridine, 
twee patronen van substitutie warden beschouwd, maar slechts één is uitgevoerd door 
synthetische problemen. Bij de uitwerking van de bibliotheek, is de vorming van een 
isomeer waargenomen en geïdentificeerd als het triazolo[1,5-a]pyridine. Dit isomer 
werd verkregen door de Dimroth omlegging versterkt door de aanwezigheid van een 
nitrogroep in ons uitgangsmateriaal. Een route is bestudeerd om deze isomeer 
synthetiseren. De laatste die isomeer verkend werd was het triazolo[4,5-b]pyridine. Drie 
bibliotheken werden ontwikkeld en gescreend door Galapagos. 
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List of abbreviations 
p-ABSA p-acetamido benzene sulfonyl azide 
Ac acetyl 
Ac2O acetic anhydride 
ATP adenosine triphosphate 
Bn benzyl 
Boc tert –butyloxycarbonyl 
BuLi n-butyl lithium 
CDK9 cyclin dependent kinase 9  
Dabal-Me3 Bis(trimethylaluminum)–1,4-diazabicyclo[2.2.2]-octane adduct 
DABCO 1,4-diazabicyclo[2.2.2]octane 
DBU 1,8-Diazabicyclo[5,4,0]undec-7-ene 
DIPEA diisopropylethylamine 
DMF dimethylformamide 
DMF-DMA dimethylformamide-dimethylacetal 
DMSO dimethyl sulfoxide 
DPPA diphenylphosphorylazide 
EDCI N-ethyl-N’-(3-dimethylaminopropyl)carbodiimide 
Et ethyl 
GABA g-aminobutyric acid 
GSK3 glycogen synthase kinase 3 
HIV human immunodeficiency virus 
HMPT hexamethyl phosphorus triamide 
IBX 1-hydroxy-1,2-benziodoxol-3(1H)-one 1-oxide 
IC50 half maximal (50%) inhibitory concentration 
i-Pr isopropyl 
i-Pr2O diisopropyl ether 
IRAK4 interleukin-1 receptor-associated kinase 4 
JAK Janus kinase 
K3PO4 potassium phosphate 
LiHMDS lithium hexamethyldisilazane 
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LRRK2 Leucine-rich repeat kinase 2 
MAP4K4 mitogen-activated protein 4 kinases 4 
Me methyl 
NBS N –bromosuccinimide 
NMP N-methyl-2-pyrrolidinone 
NOESY nuclear overhauser effect spectroscopy 
Nu nucleophile 
OEt ethoxy 
p38 MAP p38 mitogen activated protein kinase 
PBu3 tributylphosphine 
PDE phosphodiesterase 
PEt3 triethylphosphine 
Ph phenyl 
PIM proviral integration site of moloney murine leukemia virus 
PKA protein kinase A 
POCl3 phosphorus oxychloride 
P(OEt)3 triethylphosphite 
PPA polyphosphoric acid 
PPh3 triphenylphosphine 
rt room temperature 
SNAr nucleophilic aromatic substitution 
TBTU N,N,N’,N’-tetramethyl-O-(benzotriazol-1-yl)uronium tetrafluoroborate 
TFA trifluoroacetic acid 
TGF b II tumor growth factor b II receptor 
THF tetrahydrofuran 
TLC thin layered chromatography 
VEGFR vascular endothelial growth factor receptor 
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Chapter I. General introduction 
1. Protein kinases 
The Phosphorus has been identified as a very important element in cellular 
metabolism since more than 100 years, the first example has been observed in the 
fermentation by yeast, in fact the phosphate group was described as a prerequisite.
1
 
During the following decades, high energy phosphate esters and particularly the 
adenosine triphosphate known as ATP, have been identified as main sources of energy 
for cells. The concentration of ATP in cells is known to be high, generally between 1 to 
5 mM,
2
 and most of the cellular processes and pathways depend on the hydrolysis of 
ATP which is converted into inorganic phosphate and adenosine diphosphate (ADP). 
In 1955, Krebs and Fischer published
3
 a study concerning the biochemistry of 
glycogen phosphorylase, the critical role of this enzyme was the release of glucose in 
order to provide energy for the cells. At the time of their discovery, this phosphorylase 
was previously known in two forms, the active glycogen phosphorylase a and the 
inactive glycogen phosphorylase b. The study of Fischer and Krebs demonstrated that 
the conversion from the inactive form to the active form was catalyzed by an enzyme. 
The phosphorylase kinase was the name chosen for the discovered enzyme, the kinase 
transferred the -phosphate of adenosine triphosphate towards the protein.4 This report 
was the first demonstration showing the essential role of kinases in the regulation of 
biochemical signaling pathways. This discovery was awarded by the Nobel Prize in 
physiology/medicine in 1992 "for their discoveries concerning reversible protein 
phosphorylation as a biological regulatory mechanism".
5
 
After the research of Fischer and Krebs, many groups have tried to identified 
phosphorylation of aminoacid residues different than serine or threonine and in 1980,
6
 it 
was demonstrated that the tyrosine residue was also phosphorylated. Various tyrosine 
kinases have been identified during the 1980s, it was shown that these kinases can be 
receptor tyrosine kinases but also non receptor tyrosine kinases. This variety of enzymes 
was recognized as having a key role in cellular signaling functions but also having an 
important role in oncology. Due to large amount of kinases (518 kinases), a 
classification has been established dividing them in two sub-families tyrosine kinases 
and serine/threonine kinases, themselves sub-divided in other families. Although, 
12 
 
kinases are divided in two main families corresponding to the residue phosphorylated, 
several examples showed that particular kinases can phosphorylate both classes such as 
mitogen activated protein kinase kinases (MAPKKs or MAP2Ks), it was observed that 
phosphorylation was performed with threonine and tyrosine residues. 
 
 
Figure 1. Kinase phosphorylation and phosphatase dephosphorylation. 
 
In mammalian species, it was described that the protein kinases are highly 
conserved and share also a high degree of homology with other species from the 
eukaryotic kingdom.
7
 A number of studies on eukaryotes led to the identification of 
twelve subdomains in kinases. Moreover, X-ray crystal structures of protein kinases 
have shown that these domains are between two major lobes comprising the ATP 
binding site. These two lobes correspond to the N-terminal lobe constituted by 
subdomains I-V and the C-terminal lobe comprising the subdomains VI-XI. Each 
subdomain contains an important feature to make in order the catalytic machinery of the 
kinase, the role of the subdomain I is to bind the nucleotide with the help of its glycine 
region. The subdomains I and III interact with the ATP by forming a salt bridge with 
their respective lysine and glutamate region. The salt bridge formed to interact with the 
ATP by these 2 subdomains is very important for the regulation of most of the kinases.
8
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Figure 2. ATP binding site. 
 
All the studies performed during the last decades have demonstrated the importance 
of the phosphorylation by the kinases. It has been clearly identified as a universal 
activation mechanism that controls the regulation of most of the cellular processes. The 
role of the phosphatases
9
 has also been described as crucial for such regulation, in fact 
the dephosphorylation of protein (inverse reaction than kinase) is complementary to the 
phosphorylation catalyzed by the kinases.  
Protein kinases have been classified in different classes.
10
 The classification has 
been based on the specificity of the substrate phosphorylated by the catalytic domains, 
in fact such classification associates kinases to the amino acids they phosphorylate. Two 
main classes have been created, the first one phosphorylating tyrosine residue is 
tyrosine kinases (TKs), and the second one phosphorylating serine or threonine residue 
is serine-threonine kinases. The structure of these two classes has many homologies 
such as a glycine-rich region in the N-terminal lobe and an ATP-binding pocket.
11
 
The two classes previously discussed are themselves divided in sub-families, the 
tyrosine kinases for example are divided into two large families, the receptor tyrosine 
kinases and the non-receptor tyrosine kinases. The receptor class corresponds to the 
transmembrane proteins with an extracellular domain, which bind the ligands and an 
intracellular kinase domain, the non-receptor tyrosine kinases do not possess a 
transmembrane domain and are located in the cytoplasm, the nucleus and the plasma 
membrane. The catalytic machinery involved for the two sub-classes of tyrosine kinases 
is highly regulated in order to avoid the uncontrolled proliferation of phosphorylated 
tyrosine residue. The first class identified was the tyrosine kinases and many studies 
have led to partial understanding of this family. To date, around 90 tyrosine kinases and 
43 tyrosine kinases like have been identified. Amongst the tyrosine kinases, 58 have 
14 
 
been identified to be receptor, the receptor tyrosine kinases are subdivided based on 
their different properties such as structural organization, 20 subclasses have been 
numbered. The remaining tyrosine kinases (32) correspond to the non-receptor type and 
have been themselves classified into 10 subfamilies according to their properties. As 
previously mentioned, these kinases regulate various cellular processes such as 
differentiation, survival, cellular proliferation, mobility and functions. A large amount 
of malignant human cancers are due to uncontrolled receptor tyrosine kinases. Manning 
et al. was able to classify all the kinases into a human kinome divided into seven 
families: AGC, CAMK, CK1, CMGC, STE, TK and TKL.
12 
Some of the kinases are receptor types and are located on the cell membrane, other 
kinases have a role of signal mediator and are found in the cytosol of the cells. The 
receptor kinases are activated by ligands at the cell surface transmembrane, this 
activation leads to a cascade of intracellular mechanisms in order to modify the gene 
transcription and a cell response. The unregulated activity of the kinase can lead to a 
loss of mediators controlling the inhibition or the formation of mutations which can lead 
to abnormal cell proliferation, one of the symptoms involved in cancer.
13
 In receptor 
tyrosine kinases, the catalytic domain has been well described and the different 
processes involved in the phosphorylation such as the ligand binding and the activation 
of the domain have been also detailed.
14
 In most of the cases, a ligand activates the 
receptor tyrosine kinase by binding to an external region, the activation of the 
intracellular kinase domain is followed by an autophosphorylation of the residue and the 
activation of a cellular pathway or phosphorylation cascade.
15
  
Two conformations have been put in evidence in receptor tyrosine kinases, the 
catalytic domain can be active or inactive (open or close form). These two 
conformations differ by the position of the activation loop. While the conformation is 
active, the activation loop is turned outside of the ATP binding pocket, allowing the 
binding of protein residue. In the inactive conformation, the activation loop is blocking 
the entrance of the ATP binding pocket, in this closed conformation no substrates can 
be phosphorylated.
16
 The inactive state for a receptor tyrosine kinase is obtained while 
no ligands are bound, the kinase stays in a unphosphorylated state and as a monomer 
(ligands required to achieve the dimerization step).
17
 In contrast to previously 
mentioned the activation by ligands binding to the extracellular domain of receptor 
15 
 
tyrosine kinases generates the active conformation leading to the receptor homo or 
heterodimerization followed by autophosphorylation of a tyrosine residue in the 
activation loop of the catalytic domain. 
While the receptor tyrosine kinases are activated, a number of intracellular 
signalling pathways are launched such as SH2- or SH3-mediated which interact with 
others proteins located in the cytoplasm, in parallel signaling enzymes such as protein 
kinase C, phospholipase C, PI3K or mitogen-activated protein kinase are activated.
18
 
The receptor tyrosine kinases possess an auto-inhibitory domain at the surface of the 
cell in contrast to the non-receptor tyrosine kinases, which do not have, these kinases 
are generally in the inactive conformation due to inhibitory proteins performing an auto-
inhibition of the kinases. The activation of the non-receptor tyrosine kinases is possible 
due to intracellular signals which dissociate the inhibitory proteins, by attraction of 
existing receptors located at the cell transmembrane leading to a dimerization followed 
by autophosphorylation. The termination of this signaling cascade initiated by the non-
receptor tyrosine kinases signalling is observed by the action of tyrosine phosphatases 
which hydrolyse phosphate groups contained by the tyrosine residues and also by the 
formation of inhibitory molecules helping to the termination of this process.
19
 
The unregulated kinases can lead to aberrations in proliferation, cellular growth and 
survival pathways, such cases result in the formation and proliferation of tumored cells 
and generate cancer or diseases associated. Cancer and all related diseases represent one 
of the most challenging health problems of the 21
st
 century. In 2008, The American 
Cancer Society has estimated that more than one million cases of cancer were diagnosed 
in the USA alone and that over half a million people died from their disease.
20
 The 
National Institutes of Health has made an estimation that the additional cost of cancer, 
including direct medical costs, corresponded to more than $200 billion.  
The most common way for cancer to grow is the development of tumored cells in 
epithelial tissues, which after expansion become a tumor tissue or carcinoma. The other 
sources for non-epithelial cancers are the hematological malignancies, sarcomas, 
neutrally derived tumors and melanoma. At the beginning of the formation of a tumor, 
only signs of health problems and morbidity are observed but the lethality of cancer is 
generally linked to the invasion by a large amount of tumored cells and metastasis. 
16 
 
When tumored cells become malignant, they can migrate from their initial location of 
development to local and distal parts in the human in order to proliferate.
21
 
Knowing that protein kinases play a critical role in the control of several 
intracellular signaling pathways, the dysregulation of the kinase activity has been 
identified as common for most of the cancer and related diseases. This observation led 
to consider kinase inhibitors with a strong attention as targets for drug discovery 
projects.
22
 
The important attention attached to the development of kinases inhibitors was not 
only restricted to cancer but also extended towards other indications such as 
inflammatory diseases. In the last decade, the considerable efforts put in this field have 
been rewarded by a number of candidates for clinical trials and successful drugs on the 
market such as Gefitinib.
23
 Several kinase inhibitors compiling a large structural variety 
have been approved for the treatment of tumoral diseases, a large number of putative 
kinase inhibitors are submitted every year to clinical evaluation. The development of 
kinase inhibitors by the screening of large library of compounds and the study of 
structure-activity relationship, in addition to X-ray crystal structures and computational 
studies, have led to significant improvements in the understanding of the catalytic 
domain structure. Resulting from this research, the exploration of small molecule as 
kinase inhibitors has been better directed and the design of selective or potent inhibitors 
can be allowed. As discussed for the classification of the protein kinases, it is also 
possible to classify the kinase inhibitors into two classes, the first class corresponding to 
the inhibitors targeting the active form or "DFG-in" conformation of the kinase (type I 
inhibitors). The second class corresponds to the inhibitors of the inactive form or "DFG-
out" (type II inhibitors). The two classes of kinase inhibitor present advantages and 
inconvenient but none of them have proved to be a favorised strategy towards the 
development of a successful inhibitor for clinical trials. 
Due to the fact that kinases can be in an active or inactive conformation, many 
investigations have been performed to enhance the selectivity of the putative kinase 
inhibitor. It was stated that the possibility to target one of the two state of activation 
distinctly could lead to the design of kinase inhibitors more specific to a particular 
kinase. In fact, the active conformation possesses a high structural homology in 
comparison with the inactive conformation which displays a higher structural diversity. 
17 
 
These investigations led to the conclusion that the aim of selective kinase inhibitors will 
be achieved by selecting to target the inactive form of the kinase. 
The majority of the kinase inhibitors developed to date are ATP-competitive but few 
notable exceptions are known such as MEK inhibitors
24
 which are not competitive with 
ATP. The first strategy envisioned was to design kinase inhibitors in order to compete 
ATP because it was believed to be selective, in fact the high structural homology of the 
ATP binding site in the active conformation led to this misstatement. Moreover, the 
high concentration of ATP in the cells is known to be an important feature to overcome 
for ATP-competitive kinase inhibitors. Effective kinase inhibitors will display an 
important inhibition and potency in order to compete with ATP in catalytic domain.
25
 
The development of non-competitive kinase inhibitors are favorised due to no effect 
with the ATP concentration. Despite the fact that ATP concentration could have been a 
major issue for the development of kinase inhibitors, it was shown that it was not 
impossible. 
 
 
Figure 3. kinase inhibitors. 
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2. Aim of the thesis 
The aim of this PhD was to develop the synthesis of different scaffolds (mainly 
fused rings) and a library associated to each structure in order to evaluate the biological 
activity towards kinases. More than ten different scaffolds have been developed during 
this PhD research but with a view of clarity, only three families of scaffold will be 
discussed in details during the following chapters. 
In the first chapter, the synthesis of a series of compounds based on the 
pyrazolo[1,5-a]pyrimidine scaffold is discussed, the different routes investigated and the 
achievements are described, moreover, the development of new 3-fluoro pyrazolo[1,5-
a]pyrimidine derivatives are presented. The second chapter describes the development 
of short and convenient routes for the construction of pyridazine derivatives and the first 
synthesis of fused pyridazines associated such as dihydro-pyridazino[4,3-
e][1,4]diazepine. The third chapter of this study is focused on the synthesis of different 
triazolopyridine isomers and introduce the Dimroth rearrangement applied to the 
triazolo[4,3-a]pyridine. All the compounds synthesized during this PhD have been 
screened against specific kinase targets found in Galapagos projects. 
 
 
Figure 4. List of the scaffolds synthesized during the PhD. 
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During the last four years, the construction of 17 fused rings and 2 novel pyridazine 
derivatives have been developed, most of them led to a library synthesis of more than 
250 compounds to date. This report dealt in details mainly with the synthesis of 
pyrazolo[1,5-a]pyrimidine derivatives, the different triazolopyridine analogues, the 
simple approaches to novel pyridazines, the first synthesis of fused pyridazine 
derivatives and the elaboration of the first organophosphorus-catalyzed Diaza-Wittig 
reaction. 
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Chapter II. Synthesis and biological evaluation of a pyrazolo[1,5-a]pyrimidine 
library 
1. Introduction 
Over the past few decades, the pyrazolo[1,5-a]pyrimidine has surfaced in a variety 
of biologically active molecules
1
 such as the 122-selective ligand 2.1, the anti-
schistosomal agent 2.2,and the anti-inflammatory 2.3. 
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Figure 1. Biologically active pyrazolo[1,5-a]pyrimidine. 
 
Pyrazolo[1,5-a]pyrimidine has been studied in kinase inhibition and several 
compounds have been described such as Wyeth research potent B-Raf kinase inhibitor 
2.4 or a cyclin dependent kinase inhibitor 2.5 developed by Vernalis.
2
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Figure 2. Kinase inhibitors based on pyrazolo[1,5-a]pyrimidine. 
 
This core has shown inhibitory activity towards different kinases like B-Raf, CDK 
or Pim for example. Selectivity being an important factor in kinase inhibition, the 
substitution pattern and the kind of decoration used allowed the selectivity towards 
particular kinases with pyrazolo[1,5-a]pyrimidine that has itself interactions with the 
hinge region of the ATP binding site. 
This scaffold is extensively used and recently Array BioPharma and Genentech have 
described a novel series of ATP competitive B-Raf inhibitors
3
 with excellent cellular 
potency and selectivity towards the target with an IC50 = 43nM. In this study, the 
pyrazolo[1,5-a]pyrimidine 2.6 has been substituted by different heterocycles and it 
results with a decrease of the kinase inhibition while using pyridine 2.7, quinoline 2.8 
and especially with the isoster imidazo[1,2-a]pyrimidine 2.9. 
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Figure 3. Scaffold substitution of a B-Raf inhibitor. 
 
Teijin Pharma and BioFocus have discovered a novel class of selective mitogen-
activated protein kinase-activated protein kinase 2 (MAPKAP-K2) inhibitors
4
 using a 
focused library and structure-based approach to identify a series of pyrazolo[1,5-
a]pyrimidine derivatives. It was possible to determine the binding mode of the hit 2.10 
by binding the X-ray crystal structure of 2.10 to crystalline MAPKAP-K2, the hinge 
binding is performed by the scaffold as previously discussed and the selectivity 
obtained due to the substitutions of the pyrazolo[1,5-a]pyrimidine. 
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MAPKAP-K2 IC50 = 1.3 M
2.10  
Figure 4. MAPKAP-K2 inhibitor. 
 
 
Figure 5. Binding mode of 2.10. 
 
23 
 
In view of previous literature describing this structure as potential scaffold to 
develop kinase inhibitor, the synthesis of a library of pyrazolo[1,5-a]pyrimidine 2.11 
was set up in which substituents on the positions 3 and 7 were varied in a systematic 
way. 
N
N
N
1
2
3
4
5
6
7
2.11  
Figure 6. Scaffold explored 2.11. 
 
2. Results and discussion 
The synthesis of pyrazolo[1,5-a]pyrimidine started with a retrosynthetic study of the 
scaffold based on literature search. The ideal starting material for the synthesis is the 
commercially available 3-aminopyrazole 2.12, in fact it is necessary to use a 1,3-N,N-
bis-nucleophile to introduce the 3 nitrogens of the scaffold. One of the method used is 
the condensation of 2.12 with alkyl alkoxy acrylate or alkoxy acrylonitrile 2.13 which 
could lead to the 7-substituted pyrazolo[1,5-a]pyrimidine 2.14. 
 
N
N N NH2
NHN
R2
R1O
YH
R2= CN, COOMe
Y= OH, NH2
2.14 2.122.13
R1= Me, Et
 
Scheme 1. Retrosynthetic study of pyrazolo[1,5-a]pyrimidine. 
 
This method has been applied for the synthesis of the 7-hydroxy pyrazolo[1,5-
a]pyrimidine 2.14a, the 3-aminopyrazole has been condensed with methyl methoxy 
acrylate 2.13a in refluxing ethanol with a catalytic amount of acetic acid, this reaction 
has been monitored from 3 hours to 4 days but no conversion was observed and the 
starting material 2.12 was remaining. In order to fully assess this reaction, another 
attempt has been done in refluxing acetic acid for 2 days but 2.12 remained not 
converted. 
 
NH2
NHN
MeO OMe
O
X
N
N N
OH
Ethanol, Acetic acid
reflux, 4 days2.12
2.13a
2.14a  
Scheme 2. Condensation with methyl methoxy acrylate 2.13a. 
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A different condensation reagent has been envisioned, 2.13a was replaced by the 
ethoxy acrylonitrile 2.13b. This reagent was used to afford the 7-amino derivative 
2.14b, the condensation reagent was used also as a solvent due to its low boiling-point 
(83°C) combined to a catalytic amount of acetic acid to perform the cyclization. 
 
2.12
2.13b
2.14b
NH2
NHN
CN
EtO
N
N N
NH2
reflux, 16h
21%  
Scheme 3. Condensation with ethoxy acrylonitrile. 
 
2.14b was obtained as a white precipitate after 16 hours of reaction with a yield of 
21%, most of the starting material 2.12 was not converted. The reaction time has been 
extended up to 3 days but did not give better yields, a possible explanation is that the 
conversion depends on the reaction temperature and another solvent with higher boiling 
point could lead to an increase of the yield. 
Before attempting to improve the yield of the condensation reaction leading to 
2.14b, it was decided to pursue the synthesis towards the desired product. The second 
part of the synthesis was the introduction of a second point of substitution at the 
position 3 of the pyrazolo[1,5-a]pyrimidine, in order to get a key intermediate with 2 
functional groups which allow us to start a library synthesis. Following these principles, 
the introduction of a halide or a nitro group on the pyrazole ring may be of interest.  
The condensation with ethoxy acrylonitrile 2.13b could be applied to a 
functionalized aminopyrazole to lead directly to a versatile intermediate ready for a 
library synthesis. Our choice was directed to the commercially available pyrazole, 4-
nitro-pyrazole-3-carboxylic acid 2.15, this pyrazole contains a nitro group which can be 
the second functional group desired for the final scaffold. Prior to react with ethoxy 
acrylonitrile 2.13b, the carboxylic acid has to be converted into the corresponding 
amine 2.16, this transformation has been achieved by performing a Curtius 
rearrangement
5
 using DPPA (diphenylphosphorylazide) 2.17 as azide source. The first 
step of this rearrangement was the formation of the intermediate 2.18, then the azide 
group attacked 2.18 to generate an acyl azide 2.19. Under thermal conditions, 2.19 was 
rearranged into an isocyanate 2.20 and then the Boc protected amine 2.21 was obtained 
by the reaction between 2.20 and tert-butanol leading to the carbamate 2.21. 
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Scheme 4. Curtius rearrangement. 
 
The protected aminopyrazole 2.21 became available and the rest of the synthesis to 
obtain the desired 3,7-disubstituted pyrazolo[1,5-a]pyrimidine 2.22 was the cleavage of 
the protective group under acidic conditions and the condensation with 2.13b. 
 
NHN
H
N
NO2
O
O
2.21
a. HCl, dioxane, RT, 3h
N
N N
NH2
NO2
b. 2.13b, reflux, 16h
2.22
12%
 
Scheme 5. Synthesis of the 7-amino-3-nitro-pyrazolo[1,5-a]pyrimidine 2.22. 
 
The condensation of the aminopyrazole after cleavage led to the 7-amino-3-nitro-
pyrazolo[1,5-a]pyrimidine 2.22 as predicted but the yield was very low in our hands 
(12% after two steps). 
The derivatisation of the key intermediate 2.22 started with an attempt of acylation 
with benzoyl chloride of the amine using triethylamine in CH2Cl2 at room temperature 
but after 16 hours of reaction, no conversion of the starting material has been observed, 
harsher conditions have been applied to the compound 2.22 to perform the acylation in 
refluxing pyridine, but the starting material remained intact. Instead of the acylation, a 
reductive amination has been attempted with benzaldehyde and sodium 
cyanoborohydride as reducer in ethanol at room temperature, after 16 hours we did not 
observed any conversion of the amine 2.22. Finally, we decided to convert the amine 
into a halide to have access to another intermediate of interest, 2.22 has been treated 
with sodium nitrite in a mixture of water and hydrochloric acid at 0°C to obtain the 
corresponding diazonium salt and then by addition of CuCl to get the chloro derivative, 
but 2.22 was not reactive to the Sandmeyer reaction
6
 and only the starting material was 
recovered after 5 hours of reaction. 
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Scheme 6. Different reactions on 7-amino-3-nitro-pyrazolo[1,5-a]pyrimidine. 
 
One of the possible explanation is the presence of the electron withdrawing nitro 
group at the position 3 of 2.22 which makes the amine less reactive to further 
modification. It is possible also that the amine at the position 7 forms some hydrogen 
bonding which the nitrogen involved in the cyclization at the position 1, this hydrogen 
bond may prevent anymore derivatisation. Due to the unreactivity of the 7-amino-3-
nitro-pyrazolo[1,5-a]pyrimidine 2.22, another approach has been studied. 
The introduction of a hydroxy group instead of an amine at the position 7 could be 
more interesting for further modifications on the scaffold and avoid the problem of 
reactivity associated to the amine, from this statement many efforts have been made to 
achieve the synthesis of the 7-hydroxy-pyrazolo[1,5-a]pyrimidine using a different 
method than a condensation with methyl methoxy acrylate 2.13a discussed previously. 
In 2006, Gavrin et al. from Wyeth Research
7
 described several methodology for the 
synthesis of the two pyrazolo[1,5-a]pyrimidine regioisomers 2.14b and 2.14c. 
 
N
N
H
N
O
N
N
H
N
O
2.14a 2.14c  
Figure 7. Pyrazolo[1,5-a]pyrimidine regioisomers. 
 
The 7-hydroxy derivative 2.14a has been synthesized in three steps starting from the 
3-aminopyrazole 2.12. The first step was the condensation of 2.12 with diethyl 
ethoxymethylene malonate 2.23 in refluxing acetic acid to obtain the desired 
pyrazolo[1,5-a]pyrimidine 2.24 containing the hydroxy group at the position 7 but also 
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an ester group at the position 6, then it was necessary to do a saponification with sodium 
hydroxide to lead to the corresponding carboxylic acid 2.25. A final decarboxylation 
with Dowtherm A at 230°C for 5 hours was performed to deliver the expected scaffold 
2.14a. 
N
N N
OH
EtO
O
N
N N
OH
HO
O
N
N N
OH
N
N
H
NH2 EtO
O
OEt
O
OEt NaOH
EtOH/H2O
85°C, 3h
Dowtherm A
230°C, 5h
83%2.24 2.25 2.14a
AcOH, 100°C, 10h
2.12
2.23
62% 87%
 
Scheme 7. Synthesis of the 7-hydroxy-pyrazolo[1,5-a]pyrimidine 2.14a. 
 
Compound 2.14a has been subjected to chlorination in refluxing phosphorus 
oxychloride to assess the reactivity of the functional group, and the chlorinated 
derivative 2.26 was obtained in good yields. Hence, the introduction of second point of 
substitution has been applied directly to compound 2.26 instead of to repeat the 
synthesis with a functionalized pyrazole compared to previously discussed attempts. 
The iodination of 2.26 was the first choice for a palladium cross-coupling strategy 
on the pyrazole moiety, the chlorinated derivative has been treated with N-iodo 
succinimide in dichloromethane at room temperature to afford the 7-chloro-3-iodo-
pyrazolo[1,5-a]pyrimidine 2.27, an intermediate ready to be used for the synthesis of a 
library. 
N
N N
OH
N
N N
Cl
POCl3
95°C, 4h
88%
CH2Cl2, RT, 5h
N
N N
Cl
I
83%
2.14a 2.26 2.27
NIS
 
Scheme 8. Synthesis of the 7-chloro-3-iodo-pyrazolo[1,5-a]pyrimidine 2.27. 
 
The first strategy explored started with a nucleophilic substitution of 2.27, different 
amines have been used such as aliphatic amine, cycloalkyl amine, aromatic amine and 
also an example of aliphatic alcohol. The substitution of the chloride at the position 7 of 
2.27 led to 5 examples of amino (or alkoxy) substituted pyrazolo[1,5-a]pyrimidines 2.28 
with good yield by refluxing the nucleophile, 2.27 and triethylamine in ethanol for 16 
hours. 
2.27
N
N N
Cl
I
R1NH2, Et3N
EtOH, reflux, 16h
N
N N
NH
I
R1
2.28
43-79%
 
Scheme 9. Nucleophilic substitution. 
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Table 1. Substrate scope of the nucleophilic substitution.
a
 
entry 
starting 
material 
nucleophile pyrazolo[1,5-a]pyrimidine  yield (%)
b
 
1 2.27 NH2  
N
N N
NH
I  
2.28a 79 
2 2.27 
NH
O  
N
N N
N
I
O
 
2.28b 68 
3 2.27 
F
NH2
 N
N N
NH
I
F
 
2.28c 61 
4 2.27 
MeO
NH2
 
N
N N
NH
I
MeO
 
2.28d 43 
5 2.27 ONa  
N
N N
O
I  
2.28e 57 
a
All reactions were performed using 1 mmol of 2.27, 1.1 mmol of amine and 181 L of triethylamine in 
refluxing ethanol until completion of the reaction monitored by TLC. 
b
Isolated yield. 
 
A set of 5 amino substituted derivatives 2.28 became available and the second part 
of the synthesis was based on a Suzuki
8
 palladium cross-coupling strategy, in fact a 
numbers of boronic acids or esters have been chosen to react with 2.28 under two 
different conditions either thermal conditions or microwave conditions. Another 
difference between the two methods used was the nature of the base, for the coupling 
under conventional heating, K3PO4 has been chosen and while the reaction was 
performed under microwave irradiation, triethylamine was the base. The same catalyst 
1,1’-bis(diphenylphosphino)ferrocene dichloro palladium has been selected for all the 
Suzuki coupling with 2.28 as starting material. A series of novel pyrazolo[1,5-
a]pyrimidine derivatives 2.29 has been obtained with this strategy. 
 
R2B(OH)2, Pd(dppf)Cl2, base
N
N N
NH
I
R1
solvent, conditions
N
N N
NH
R2
R1
2.28 2.29
40-60%
 
Scheme 10. Suzuki cross-coupling reaction. 
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Table 2. Substrate scope of the Suzuki coupling.
a
 
entry 
starting 
material 
organoboron 
reagent 
pyrazolo[1,5-a]pyrimidine  yield (%)
b
 
1 2.28a 
B(OH)2
F  
N
N N
NH
F  
2.29a 60
c
 
2 2.28a 
B(OH)2
O NH2  
N
N N
NH
NH2
O  
2.29b 43
d
 
3 2.28a 
N
B(OH)2
 
N
N N
NH
N
 
2.29c 45
d
 
4 2.28b 
B(OH)2
F  
N
N N
N
O
F  
2.29d 58
c
 
5 2.28b 
B(OH)2
O NH2  
N
N N
N
O
NH2
O  
2.29
e
 42
d
 
6 2.28b 
N
B(OH)2
 N
N N
N
O
N
 
2.29f 51
d
 
7 2.28b 
HN
N
Bpin
 N
N N
N
O
N
H
N
 
2.29g 40
d
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8 2.28c 
N
B(OH)2
 
N
N N
NH
F
N
 
2.29h 43
d
 
9 2.28d 
N
BpinMeO
 N
N N
NH
MeO
N
MeO  
2.29i 50
d
 
10 2.28d 
NF
B(OH)2
 
N
N N
NH
MeO
N
F  
2.29j 40
d
 
11 2.28e 
B(OH)2
F  
N
N N
O
F  
2.29k 57
c
 
a
Two methods of Suzuki coupling were used. 
b
Isolated yield. 
 c
Reactions were performed using 1 mmol of 
2.28, 1.1 mmol of organoboron reagent, 41 mg of Pd(dppf)Cl2 and 467 mg of K3PO4 in refluxing dioxane 
using conventional heating conditions for 16 hours. 
d
Reactions were performed using 1 mmol of 2.28, 1.1 
mmol of organoboron reagent, 41 mg of Pd(dppf)Cl2 and 278 L of triethylamine in 5 mL of  water and 
dioxane (1/4), the vial was irradiated by microwaves at 105°C for 30minutes. 
 
The development of a 11-members library of pyrazolo[1,5-a]pyrimidine derivatives 
2.29 has been elaborated based on this first pathway, the first point of substitution on 
the pyrimidine side has been linked to various groups by nucleophilic substitution and 
then the introduction of a number of (hetero)aromatic rings has been attached by 
performing a Suzuki cross-coupling on the pyrazole moiety. In order to cover others 
palladium cross-coupling, the derivative 2.28b has been coupled with styrene by a Heck 
reaction
9
 to obtain an analogue containing an olefin bond 2.30a and with phenyl 
acetylene leading to a derivative containing an alkyne bond 2.30b by a Sonogashira 
coupling.
10
 For these two coupling reactions, the catalysts used were identical, in fact 
tetrakis(triphenylphosphine) palladium was used alone for the Heck reaction and in 
combination with copper iodide for the Sonogashira reaction. The yields obtained were 
low but no further optimization has been done to improve the results.  
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Pd(PPh3)4, Et3N
toluene, 80°C, 16h
28%
Pd(PPh3)4, CuI, Et3N
toluene, 80°C, 16h
35%
2.28b2.28b
Phstyrene
2.30a 2.30b
 
Scheme 11. Heck and Sonogashira coupling reactions. 
 
A second strategy has been explored, instead of to introduce a substituent by 
nucleophilic substitution at the position 7 of pyrazolo[1,5-a]pyrimidine 2.27, a pathway 
based on a palladium cross-coupling strategy on the two halides could be of interest. 
The iodine on the pyrazole ring of the scaffold should be the most reactive halide for 
a Suzuki reaction, but the high reactivity
11
 of the chloride at the position 4 of the 
pyrimidine ring towards nucleophilic substitution or coupling directed us to search for 
another strategy to avoid possible problems of competition between the two halides 
during the reaction. In fact, the derivative 2.26 was more appropriate for the synthesis of 
library based on palladium cross coupling strategy, the 7-chloro-pyrazolo[1,5-
a]pyrimidine 2.26 was subjected to a Suzuki coupling with p-fluorophenyl boronic acid 
under conventional heating to afford the derivative 2.31 in 87% yield after 16 hours. 
2.31 was converted into the iodo derivative 2.32 to perform another Suzuki coupling 
under microwaves irradiation to obtain the product 2.33. 
 
N
N N
Cl
CH2Cl2, RT, 5h
N
N N
I81%
2.26 2.32
NISPd(dppf)Cl2, K3PO4
dioxane, reflux, 16h
87%
B(OH)2
F
boronic acid, Pd(dppf)Cl2, Et3N
dioxane, MW, 105°C, 30min
N
N N
2.33
42%
F
N
N N
F
2.31
N
F
HN N O
 
Scheme 12. Synthesis of pyrazolo[1,5-a]pyrimidine 2.33. 
 
Most of the derivatives prepared so far were containing (hetero)aryl rings introduced 
by a Suzuki coupling on the pyrazole moiety of the pyrazolo[1,5-a]pyrimidine, some 
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efforts have been made to be able to introduce a nitrogen linker at the position 3 of the 
scaffold. The method envisioned to attach such linker was the nitration,
12
 the 
application of this reaction to the compound 2.26 has been attempted but 2.34 was not 
observed, instead the derivative 2.35 was obtained as a green precipitate in 61% yield 
after work-up. A possible explanation could be that the introduction of a strong electron 
withdrawing group such as nitro group made the chloride at the position 7 of the 
scaffold more reactive towards nucleophilic substitution and has been substituted by 
water during the work-up leading to the 2.35 instead of the expected derivative 2.34.  
 
N
N N
Cl
N
N N
Cl
NO22.34
HNO3, H2SO4
30 min, 0°C
2.26
and
N
N N
OH
NO22.35
61%0%  
Scheme 13. Synthesis of 7-hydroxy-3-nitro-pyrazolo[1,5-a]pyrimidine. 
 
Following this possible explanation, compound 2.35 could prove the formation of 
2.34 prior to work-up but while monitoring the reaction by LC/MS, only 2.35 has been 
observed. Milder conditions of nitration have been investigated using nitronium 
tetrafluoroborate
13
 from 0°C to room temperature but the starting material 2.26 
remained not converted after 16 hours of reaction. In parallel, 2.35 has been treated in 
refluxing phosphorus oxychloride during 16 hours to perform a chlorination of the 
hydroxy group, unfortunately 2.35 was not converted into 2.34. The chlorination has 
been repeated with a catalytic amount of triethylamine
14
 added to phosphorus 
oxychloride but the same results were obtained. These results led us to the same 
explanation previously discussed concerning the electron withdrawing nitro group 
attached to this scaffold. 
 
N
N N
OH
NO22.35
N
N N
Cl
N
N N
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NO22.34
0°C-RT, 16h
2.26
X
BF4NO2
CH3CN
POCl3
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N N
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NO22.34
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Scheme 14. Attempts to synthesize 7-chloro-3-nitro-pyrazolo[1,5-a]pyrimidine 2.34. 
 
The aim of this methodology was to obtain two nitrogen linkers at the positions 3 
and 7 of the pyrazolo[1,5-a]pyrimidine, but in view of our results, it was necessary to 
adapt the pathway. Compound 2.26 has been subjected to a nucleophilic substitution 
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prior to a nitration step with nitric acid in sulfuric acid to afford 2.37. We were able to 
introduce aliphatic amine and cycloalkyl amine by SNar with this strategy. 
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Scheme 15. Synthesis of 3-nitro-pyrazolo[1,5-a]pyrimidine derivatives 2.37. 
 
The introduction of (hetero)aryl or benzyl groups was not possible due to possible 
over nitration, in fact while attempting the nitration of 2.36c, we observed by LC/MS 
the introduction of two nitro groups on the structure 2.37c, one on the pyrazolo[1,5-
a]pyrimidine at the position 3 and another one on the benzyl group of the substituent at 
the position 7, we believed that the second nitro was not attached to the scaffold itself 
due to the deactivation towards electrophilic aromatic substitution
15
 after the 
introduction of the first nitro group.  
HNO3, H2SO4
30 min, 0°C
2.26
N
N N
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amine, Et3N
EtOH, reflux, 16h
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Scheme 16. Over nitration of the pyrazolo[1,5-a]pyrimidine derivatives 2.37c. 
 
The substituted 3-nitro-pyrazolo[1,5-a]pyrimidine analogue 2.37 was then reduced 
with zinc
16
 and a catalytic amount of acetic acid in methanol to the corresponding amine 
which was used directly without further purification, the amine was subjected to 
different reactions in order to build a library of pyrazolo[1,5-a]pyrimidine derivatives 
2.38. 
N
N N
N
NO2
R1
2.37
R2
a. Zn, cat. AcOH, MeOH, RT, 5h
b. different reactions
N
N N
N
NHR3
R1
2.38-2.42
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Scheme 17. Synthesis of pyrazolo[1,5-a]pyrimidine derivatives 2.38-2.42. 
 
The amino derivative has been modified following five different reactions, the first 
one was the acylation
17
 with acid chloride and triethylamine in dichloromethane for 16 
hours leading to the amide derivatives 2.38. Using the same conditions than the 
acylation with a sulfonyl chloride reagent led to a sulfonamide
18
 derivative 2.39. In 
order to synthesize some urea analogues
19
 2.40, the amino derivative was treated with 
isocyanate species in dichloromethane for 2 hours. The synthesis of carbamates 2.41 has 
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been achieved by reacting substituted chloroformates and the 3-amino-pyrazolo[1,5-
a]pyrimidine. The last reaction used to develop this library was the reductive 
amination
20
 to afford substituted amines 2.42. 
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Scheme 18. Synthesis of pyrazolo[1,5-a]pyrimidine derivatives 2.38-2.42. 
 
Table 3. Synthesis of pyrazolo[1,5-a]pyrimidine derivatives 2.38-2.42.
a
 
entry 
starting 
material 
reagent pyrazolo[1,5-a]pyrimidine  yield (%)
b
 
1 2.37a 
O
Cl  N
N N
NH
HN
O
 
2.38a 32 
2 2.37a S
O
Cl
O  
N
N N
NH
HN S
O
O  
2.39a 27 
3 2.37b 
O
Cl  
N
N N
N
HN
O
O
 
2.38b 29 
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4 2.37b 
C
N
O
 
N
N N
N
HN
H
N
O
O
 
2.40a 12 
5 2.37b 
O
O
Cl  N
N N
N
HN
O
O
O
 
2.41a 21 
6 2.37b 
N
H
O
 
N
N N
N
N
O
N
N  
2.42a 23 
7 2.37b 
O
Cl
 
N
N N
N
HN
O
O
 
2.38c 31 
8 2.37b 
CN O  
N
N N
N
HN
H
N
O
O
 
2.40b 26 
a
See the experimental section for details. 
b
Isolated yield. 
 
A last part was devoted to the synthesis of new analogues by Mannich reaction,
21
 in 
fact the position 3 of the scaffold is very reactive towards electrophilic substitution. 
Hence, it was necessary to form an electrophilic reagent, with the Mannich reaction, the 
generation of such intermediates was possible by reacting a solution of formaldehyde 
and an amine to obtain an imine which was attacked by the pyrazolo[1,5-a]pyrimidine 
leading to 2.43, this reaction was a one-pot procedure. 
CH2O, R3NH2
AcOH, 65°C, 16hN
N N
N
2.36 2.43
R1
N
N N
N
R1R2 R2
N
H
R3
23-35%
 
Scheme 19. Mannich reaction. 
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Table 4. Synthesis of pyrazolo[1,5-a]pyrimidine derivatives 2.43 by Mannich reaction.
a
 
entry 
starting 
material 
amine pyrazolo[1,5-a]pyrimidine  yield (%)
b
 
1 2.36b 
NH2
 
N
N N
N
N
H
O
 
2.43a 35 
2 2.36c 
NH2
CF3  
N
N N
NH
N
H
F
F3C
 
2.43b 29 
3 2.36c 
NH2
 N
N N
NH
N
H
F
 
2.43c 33 
4 2.36c 
HN
N
O
NH
N  
N
N N
NH
N
F
N
O
NH
N  
2.43d 23 
a
All reactions were performed using 1 mmol of 2.36, 1.5 mmol of amine and 245 L of 37% aqueous 
solution of formaldehyde in acetic acid at 65°C until completion of the reaction monitored by TLC. 
b
Isolated yield. 
  
Teijin pharma,
22
 a Japanese pharmaceutical company described in 2004, some 
pyrazolo[1,5-a]pyrimidine derivatives as putative kinase inhibitors. Most of the 
analogues were containing fluorine at the position 3 of the pyrazole moiety. All the 
examples were substituted at the positions 5 and 7 by various amines affording 
compound such as 2.44. Inspired by the work done by Teijin Pharma, we decided to 
direct our strategy into the synthesis of fluorinated pyrazolo[1,5-a]pyrimidine 2.45. 
 
N
N N
NH
F
2.44
R1
N
R2
R3
N
N N
NH
F
2.45
R1
 
Figure 8. Fluorinated pyrazolo[1,5-a]pyrimidine derivatives. 
 
One of the most common methods for the synthesis of fluorinated pyrazolo[1,5-
a]pyrimidine is the fluorination of the scaffold directly by electrophilic fluorination,
23
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using a reagent like 1-chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane 
bis(tetrafluoroborate) also known as Selectfluor 2.46.  
 
2BF4+
+
-N
N
Cl
F
2.46  
Figure 9. Selectfluor, electrophilic fluorinating reagent. 
 
However, such fluorination method is generally low yielding and has never worked 
in the case of the 7-chloro pyrazolo[1,5-a]pyrimidine 2.26 in our hands, in contrast to 
other halogenations such as iodination discussed previously. An alternative procedure 
was envisioned to avoid this problem, the introduction of the fluorine at an earlier stage 
of synthesis. In fact, the synthesis of an intermediate containing a fluorine could be of 
value for the development of a simple approach to the synthesis of pyrazolo[1,5-
a]pyrimidine derivatives. 
2BF4
+
+
-
N
N
Cl
F
2.46
N
N N
Cl
F
N
N N
Cl
X
2.26  
Scheme 20. Fluorination of pyrazolo[1,5-a]pyrimidine. 
 
The replacement of 3-amino-pyrazole 2.12 by 3-amino-4-fluoro-pyrazole 2.47 for 
the synthesis of the scaffold was first envisioned, some efforts have been made to 
synthesize the fluorinated pyrazole 2.47 but none of the methods attempted led to the 
desired target. 
H2N
N NH
F
2.47
H2N
N NH
2.12  
Figure 10. Pyrazole derivatives. 
 
Finally, we decided to synthesize a fluorinated pyrazole substituted at the position 5 
in contrast to 2.47. It was possible to obtain the pyrazole 2.50 by using the method 
developed by Cocconcelli et al.,
24
 this method allowed the synthesis of the fluoro 
derivative 2.50 through the intermediate -fluoro--ketonitrile 2.49. 
The substitution at the position 5 of the pyrazole ring was introduced with an acid 
chloride, in order to assess this strategy the benzoyl chloride was selected as model. The 
starting material of this pathway was the fluoro acetonitrile 2.48, an acylation reaction 
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was first performed at -78°C with LiHMDS as the base and benzoyl chloride for 5 hours 
to afford the intermediate -fluoro--ketonitrile 2.49 which was used without further 
purification in the next step. The hydrazinolysis of 2.49 in refluxing ethanol for 16 
hours leading to the 3-amino-4-fluoro-5-phenyl-pyrazole 2.50 was straightforward with 
50% yield over two steps. 
Cl
O
F CN
LiHMDS
THF, 5h, -78°C
O
CN
F
H
N
F
N
NH2
2.48 2.49 2.50
NH2NH2
EtOH, 16h, reflux
50% over two steps
 
Scheme 21. Synthesis of 3-amino-4-fluoro-5-phenyl-pyrazole 2.50. 
 
The formation of the fluorinated pyrazolo[1,5-a]pyrimidine scaffold was then 
realized by condensation of 2.50 with diethyl ethoxymethylene malonate in acetic acid 
at 100°C for 10h to afford the pyrazolo[1,5-a]pyrimidine 2.51 in good yield, which after 
saponification with sodium hydroxide gave the carbolylic acid 2.52. A final 
decarboxylation with Dowtherm A at 230°C for 5h, led to the desired intermediate 2.53. 
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Scheme 22. Synthesis of the 3-fluoro-7-hydroxy-2-phenyl-pyrazolo[1,5-a]pyrimidine 2.53. 
 
Intermediate 2.53 was treated in refluxing phosphorus oxychloride to give the 
chlorinated derivative 2.54 which was subjected to nucleophilic substitution with 
different amines to obtain compound 2.55. The versatility of this approach was 
demonstrated by the synthesis of a small-size library. 
 
N
N N
OH
N
N N
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POCl3
reflux, 4h
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N
N N
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F
2.53 2.54 2.55
F F
R1
55-70%
R1NH2, Et3N
EtOH, reflux, 16h
 
Scheme 23. Synthesis of 3-fluoro-pyrazolo[1,5-a]pyrimidine derivatives 2.55. 
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The amines used during the last step varied from aliphatic amines, cycloalkyl 
amines, benzyl amines to heteroaryl amines. In order to cover other substitutions at the 
position 7, another method has been used to obtain pyrazolo[1,5-a]pyrimidine 
derivatives directly attached to (hetero)aryl groups without a nitrogen linker. The 3-
amino-4-fluoro-5-phenyl-pyrazole 2.50 has been condensed with (hetero)aryl 
dimethylamino propenone 2.57 (obtained from acetophenone derivatives 2.56) in 
refluxing acetic acid to obtain 3-fluoro-7-(hetero)aryl-2-phenyl-pyrazolo[1,5-
a]pyrimidine derivatives 2.58. 
 
N
N N
R
F
R
O
2.56a, R= phenyl
2.56b, R= 2-thienyl
DMF-DMA
DMF, 115°C, 16h R
O
N
AcOH, reflux, 16h
70%
64%
2.57
2.50
2.58
50%
42%  
Scheme 24. Synthesis of 3-fluoro-pyrazolo[1,5-a]pyrimidine derivatives 2.58. 
 
Table 5. Synthesis of 3-fluoro-2-phenyl-pyrazolo[1,5-a]pyrimidine derivatives. 
entry 
starting 
material 
reagent pyrazolo[1,5-a]pyrimidine  yield (%)
a
 
1 2.54 NH2  
N
N N
NH
F  
2.55a 70
b
 
2 2.54 
NH
O  
N
N N
N
F
O
 
2.55b 63
b
 
3 2.54 
NH2
NO
O
 
N
N N
NH
F
NO
O
 
2.55c 69
b
 
4 2.55c 
TFA/CH2Cl2 
(1/4) 
N
N N
NH
F
HN
 
2.55d 65
c
 
5 2.55d 
Cl
S
O
O
 
N
N N
NH
F
N
S
O
O
 
2.55e 60
d
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6 2.55d Cl
O
 
N
N N
NH
F
N
O
 
2.55f 58
d
 
7 2.54 
NH2
 
N
N N
NH
F  
2.55g 68
b
 
8 2.54 
N
NH2
 N
N N
NH
F
N
 
2.55h 58
b
 
9 2.54 
NH2
N
H
N
 N
N N
NH
F
HN
N
 
2.55i 55
b
 
10 2.50 
O
N
 N
N N
F  
2.58a 50
e
 
11 2.50 
O
N
S
 N
N N
F
S
 
2.58b 42
e
 
a
Isolated yield. 
 b
All reactions were performed using 1 mmol of 2.54, 1.1 mmol of amine and 181 L of 
triethylamine in refluxing ethanol until completion of the reaction monitored by TLC. 
c
Cleavage of Boc 
group has been done by stirring 1 mmol of 2.55c in 5 mL of TFA/CH2Cl2 (1/4) from 0°C to room 
temperature for 2 hours. 
d
All reactions were performed using 1 mmol of 2.55c, 1.05 mmol of acid 
chloride or sulfonyl chloride and 181 L of triethylamine in CH2Cl2 at room temperature for 16 hours. 
e
All reactions were performed using 1 mmol of 2.50 and 1.1 mmol of condensation reagent in refluxing 
acetic acid for 16 hours. 
 
3. Biological evaluation 
The library of pyrazolo[1,5-a]pyrimidine derivatives described during this chapter 
has been screened towards selected kinases of ongoing projects of Galapagos. The 
compounds were first tested in an enzymatic assay at constant concentration and for the 
analogues displaying an interesting percentage of inhibition for a specified kinase, a 
further assay was performed at different concentrations in order to obtain the half 
maximal inhibitory concentration IC50.    
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Table 6. Biological evaluation of pyrazolo[1,5-a]pyrimidine derivatives (N/A not active). 
entry compounds 
LRRK2 
(% inhibition 
at 10 M) 
IC50 (nM) 
MAP4K4 
(% inhibition 
at 10 M) 
IC50 (nM) 
1 2.29a 81 ˃4000 78 ˃4000 
2 2.29b 91 2180 98 859 
3 2.29c 65 ˃4000 54 ˃4000 
4 2.29d N/A N/A N/A N/A 
5 2.29e N/A N/A N/A N/A 
6 2.29f N/A N/A N/A N/A 
7 2.29g N/A N/A N/A N/A 
8 2.29h N/A N/A N/A N/A 
9 2.29i N/A N/A N/A N/A 
10 2.29j N/A N/A 65 ˃4000 
11 2.29k N/A N/A N/A N/A 
12 2.30a 78 ˃4000 84 ˃4000 
13 2.30b N/A N/A N/A N/A 
14 2.33 N/A N/A N/A N/A 
15 2.38a 53 ˃4000 N/A N/A 
16 2.38b N/A N/A N/A N/A 
17 2.38c N/A N/A N/A N/A 
18 2.39a N/A N/A N/A N/A 
19 2.40a N/A N/A N/A N/A 
20 2.40b N/A N/A N/A N/A 
21 2.41a N/A N/A 56 ˃4000 
22 2.42a N/A N/A N/A N/A 
23 2.43a N/A N/A N/A N/A 
24 2.43b N/A N/A N/A N/A 
25 2.43c N/A N/A N/A N/A 
26 2.43d N/A N/A N/A N/A 
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entry compounds 
CDK9 
(% inhibition 
at 10 M) 
IC50 (nM) 
TGF- II 
(% inhibition 
at 10 M) 
IC50 (nM) 
27 2.55a 8 N/A 14 N/A 
28 2.55b 7 N/A 13 N/A 
29 2.55c N/A N/A N/A N/A 
30 2.55d 6 N/A 7 N/A 
31 2.55e N/A N/A N/A N/A 
32 2.55f N/A N/A N/A N/A 
33 2.55g 18 N/A 32 N/A 
34 2.55h 6 N/A 26 N/A 
35 2.55i 7 N/A 71 N/A 
36 2.58a N/A N/A N/A N/A 
37 2.58b N/A N/A 18 N/A 
 
The screening of the derivatives based on the pyrazolo[1,5-a]pyrimidine scaffold led 
to the discovery of one analogue 2.29b displaying a half maximal inhibitory 
concentration IC50 of 859 nM towards MAP4K4. The compounds containing a 
cycloalkylamine such as morpholine did not show significant inhibition, in fact it seems 
better to introduce a small aliphatic group such as ethyl at the position 7 of the scaffold 
to be able to inhibit the kinase (Table 6, entry 1-3). While varying the linker, the O-
linked scaffold 2.29k was not active compared to the N-linked analogues. The 
introduction of a fluoride on the pyrazolo[1,5-a]pyrimidine was expected to improve the 
biological activity of the synthesized analogues. The compounds were screened towards 
CDK9 and TGF- II to evaluate the percentage of inhibition but only the compound 
2.55i showed 71 % of inhibition at a concentration of 10 M against TGF- II receptor. 
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4. Conclusion 
In summary, we have first synthesized the 7-hydroxy-pyrazolo[1,5-a]pyrimidine 
following the method developed by Gavrin et al., hence the elaboration of a key 
intermediate allowing the synthesis of a library has been done by introducing two 
halides at the positions 3 and 7 of the scaffold. Then a first strategy based on a sequence 
of nucleophilic substitution/Suzuki coupling gave a 11-member library, two examples 
have been added to cover others palladium cross-coupling reactions such as Heck and 
Sonogashira reactions. 
A second part was devoted to the development of a pyrazolo[1,5-a]pyrimidine 
library with a nitrogen linker at the positions 3 and 7, different attempts of nitration 
have been done on the chloro derivative but we never obtained the expected derivative. 
A nucleophilic substitution has been done before the nitration of the scaffold, two 
examples of 3-nitro-pyrazolo[1,5-a]pyrimidine analogues have been synthesized. This 
method had limitations because it was not possible to perform a mono nitration while 
the scaffold was substituted by aryl or benzyl amines, in fact overnitration was 
observed. The derivatives with the nitro group were reduced to the corresponding 
amines with zinc prior to build a library by using various reactions such as acylation or 
reductive amination. 
The pyrazolo[1,5-a]pyrimidine is known to be a good substrate for electrophilic 
aromatic substitution, 4 analogues have been synthesized by performing a Mannich 
reaction with formaldehyde and different amines. 
In the last part, we have elaborated a simple approach for the synthesis of 
fluorinated pyrazolo[1,5-a]pyrimidine derivatives by introducing the fluorine at an 
earlier stage of the synthesis instead of using a direct electrophilic fluorination on the 
scaffold such as Selectfluor. The method could be employed to the development of a 
small-size library of “drug-like” compounds with different amines. 
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5. Experimental section 
For all reactions, analytical grade solvents were used. All moisture-sensitive reactions were carried 
out in oven-dried glassware (135 ºC) under a nitrogen or argon atmosphere. Reaction temperatures are 
reported as bath temperature. Precoated aluminum sheets (Fluka Silica gel/TLC-cards, 254 nm) were used 
for TLC. Compounds were visualized with UV light (λ = 254 nm). Products were purified by flash 
chromatography on ICN silica gel 63-200, 60 Å. Melting points were obtained on a melting point 
apparatus Electrothermal IA9200 with open capillary tubes. 
1
H and 
13
C NMR spectra were recorded on 
300 MHz, 500 MHz and 600 MHz spectrometer using CDCl3 and DMSO-d6 as the solvent. The 
1
H and 
13
C chemical shifts were referenced to residual solvent signals at δ H/C 7.26/77.00 (CDCl3), 3.31/49.10 
and 2.50/39.50 (DMSO-d6) relative to TMS as internal standard. Coupling constants J [Hz] were directly 
taken from the spectra. Splitting patterns are designated as s (singlet), d (doublet), t (triplet), q (quartet), 
m (multiplet) and br (broad). High resolution mass spectra were acquired on a quadrupole orthogonal 
acceleration time-of-flight mass spectrometer (Synapt G2 HDMS, Waters, Milford, MA). Samples were 
infused at 3 µL/min and spectra were obtained in positive (or negative) ionization mode with a resolution 
of 15000 (FWHM) using leucine enkephalin as lock mass. Electrospray MS spectra were obtained on a 
Micromass platform LC/MS spectrometer. Column used for all LC/MS analysis: Waters Acquity UPLC 
BEH C18 1.7 m, 2.1 mm ID x 50 mm L. All the methods are using MeCN/H2O gradients. Water 
contains either 0.1 % TFA or 0.1 % NH3. 
 
Pyrazolo[1,5-a]pyrimidin-7-amine (2.14b) 
A solution of compound 2.12 (3 g, 36.11 mmol) in 15 mL of ethoxy acrylonitrile 2.13b was refluxed for 
16 hours, after which was allowed to cool to room temperature and the formation of a precipitate was 
observed. The precipitate was filtered and washed with Et2O to afford the desired compound 2.14 in 21% 
yield as beige solid. Data for 2.14b: 
1
H NMR (300 MHz, DMSO-d6) δ 7.83-7.87 (m, 2H), 6.37 (d, J = 5.9 
Hz, 1H), 5.65 (d, J = 5.6 Hz, 1H); 
13
C NMR (75 MHz, DMSO-d6) δ 153.7, 141.4, 138.1, 136.7, 93.4, 
87.1. 
 
Tert-butyl 4-nitro-1H-pyrazol-3-ylcarbamate (2.21) 
A solution of compound 2.15 (2 g, 12.73 mmol) in 15 mL of acetonitrile under argon was successively 
added triethylamine (4.4 mL, 31.83 mmol), DPPA 2.17 (3 mL, 14.00 mmol) and tert-butanol (1.3 mL, 
14.00 mmol) at room temperature. The reaction mixture was refluxed for 16 hours and after completion 
of the reaction, was allowed to cool to room temperature. 15 mL of saturated aqueous NaHCO3 was added 
to the reaction mixture followed by an extraction with 2x15 mL of CH2Cl2. The combined organic layers 
were dried over Na2SO4 and concentrated in vacuo. The product was purified by flash column 
chromatography on silica gel (EtOAc/n-Hexane = 1:2) to afford the protected pyrazole 2.21 in 63% yield 
as white solid. Data for 2.21: 
1
H NMR (300 MHz, DMSO-d6) δ 13.65 (br. s, 1H), 7.44 (s, 1H), 4.41 (br. s, 
1H), 1.38 (s, 9H); 
13
C NMR (75 MHz, DMSO-d6) δ 164.2, 147.4, 133.7, 125.2, 82.5, 26.9. 
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3-Nitropyrazolo[1,5-a]pyrimidin-7-amine (2.22) 
To a solution of 2.21 (5 g, 43.06 mmol) in 15 mL of dioxane under argon at 0 °C was added 500 L of 
concentrated hydrochloric acid and the reaction was stirred at room temperature for 3 hours. Addition of 
10 mL of water and 15 mL of CH2Cl2 to the reaction mixture and the pH was adjusted to 8 with K2CO3. 
The organic layer was dried over Na2SO4 and concentrated in vacuo to obtain the amino pyrazole 
intermediate as an oily solid which was used directly without further purification for the next step. 
A solution of the previously prepared pyrazole in 15 mL of ethoxy acrylonitrile 2.13b was refluxed for 16 
hours, after which was allowed to cool to room temperature and the formation of a precipitate was 
observed. The precipitate was filtered and washed with Et2O to afford the desired compound 2.22 in 12% 
yield as beige solid. Data for 2.22: 
1
H NMR (300 MHz, DMSO-d6) δ 8.06 (s, 1H), 7.12 (d, J = 7.8 Hz, 
1H), 5.96 (d, J = 7.8 Hz, 1H); 
13
C NMR (75 MHz, DMSO-d6) δ 156.8, 149.3, 147.2, 139.9, 101.4. 
 
Ethyl 7-Oxo-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxylate (2.24) 
To a solution of pyrazol-3-ylamine 2.12 (4.15 g, 50 mmol) in 25 mL of acetic acid under argon at room 
temperature was added diethyl ethoxymethylenemalonate 2.23 (11.89 g, 55 mmol). The mixture was 
heated at 100 °C for 10 hours. The suspension was filtered warm, then washed several times with EtOH, 
and dried to yield 2.24 in 62% yield as white solid. Data for 2.24: 
1
H NMR (300 MHz, DMSO-d6) δ 
13.10 (s, 1 H), 8.59 (s, 1 H), 7.93 (d, J=2.0 Hz, 1 H), 6.31 (d, J=2.0 Hz, 1 H), 4.23 (q, J=7.1 Hz, 2 H), 
1.28 (t, J=7.1 Hz, 3 H); 
13
C NMR (75 MHz, DMSO-d6) δ 163.6, 157.2, 145.3, 143.4, 140.9, 98.5, 91.2, 
60.0, 14.3. 
 
7-Oxo-4,7-dihydropyrazolo[1,5-α]pyrimidine-6-carboxylic acid (2.25) 
To a suspension of 2.24 (2.07 g, 10 mmol) in 30 mL of ethanol and water (1/1) under argon at room 
temperature was added 2.5 N NaOH (10 mL). The resulting suspension was heated to 85 °C for 3 hours. 
The suspension was cooled to room temperature and diluted with water (100 mL) and concentrated 
hydrochlorhydric acid until the formation of a suspension (pH=1). The white suspension was stirred an 
additional 30 min, filtered, washed with water, and dried to yield 2.25 in 83% yield as white solid. Data 
for 2.25: 
1
H NMR (300 MHz, DMSO-d6) δ 12.95 (s, 1 H), 8.72 (s, 1 H), 8.05 (d, J=2.0 Hz, 1 H), 6.41 (d, 
J=2.0 Hz, 1 H); 
13
C NMR (75 MHz, DMSO-d6) δ 164.7, 157.2, 145.7, 144.5, 141.0, 97.7, 91.9. 
 
Pyrazolo[1,5-a]pyrimidin-7-ol (2.14a) 
To the carboxylic acid 2.25 (1 g, 5.58 mmol) was added 10 mL of Dowtherm A. The suspension was 
heated to 230 °C for 5h. The reaction mixture was cooled to room temperature, then diluted with 30 mL 
of hexanes, stirred vigorously, filtered and dried to obtain the desired product 2.14a in 87% yield as a 
light brown solid. Data for 2.14a: 
1
H NMR (300 MHz, DMSO-d6) δ 12.36 (s, 1 H), 7.86-7.89 (m, 2 H), 
6.18 (dd, J=1.8, 0.6 Hz, 1 H), 5.68 (d, J=7.3 Hz, 1 H); 
13
C NMR (75 MHz, DMSO-d6) δ 154.5, 140.5, 
139.8, 137.5, 93.1, 86.9. 
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7-Chloropyrazolo[1,5-a]pyrimidine (2.26) 
2.14a (1 g, 7.40 mmol) was dissolved in 10 mL of phosphorus oxychloride at room temperature. The 
reaction mixture was heated at 95 °C for 4 hours after which the color of the solution became brown. The 
flask was allowed to cool to room temperature and the excess of phosphorus oxychloride was 
concentrated in vacuo to a brown oil. The oil was dissolved in 15 mL of EtOAc and washed 2 times with 
20 mL of saturated aqueous NaHCO3, the organic layer was dried over Na2SO4 and concentrated to afford 
crude 2.26 as brown oil used directly without further purification. 
 
7-Chloro-3-iodopyrazolo[1,5-a]pyrimidine (2.27) 
To a solution of chlorinated derivative 2.26 (1 g, 6.51 mmol) in 15 mL of CH2Cl2 under argon at room 
temperature was added NIS (1.61 g, 7.16 mmol). The mixture was stirred at ambient temperature for 5 
hours. After completion of the reaction monitored by TLC, 10 mL of saturated aqueous NaHCO3 was 
added. The organic layer was separated, dried over Na2SO4 and concentrated in vacuo. The product was 
purified by flash column chromatography on silica gel (EtOAc/n-Hexane = 1:2) to afford the 
pyrazolo[1,5-a]pyrimidine 2.27 in 83% yield as beige solid. Data for 2.27: 
1
H NMR (300 MHz, DMSO-
d6) δ 8.57 (d, J = 5.6 Hz, 1H), 8.32 (s, 1H), 6.28 (d, J = 5.8 Hz, 1H); 
13
C NMR (75 MHz, DMSO-d6) δ 
159.1, 150.7, 149.0, 146.5, 143.4, 95.9. 
 
General procedure for the preparation of pyrazolo[1,5-a]pyrimidine derivatives 2.28: 
 
To a solution of 2.27 (280 mg, 1 mmol) in 5 mL of EtOH under argon was added an amine (1.1 mmol), 
followed by triethylamine (181 L, 1.3 mmol) at room temperature. The reaction mixture was refluxed 
until the completion of the reaction (16 hours monitored by TLC) and was allowed to cool to room 
temperature. 15 mL of saturated aqueous NaHCO3 was added to the reaction mixture followed by an 
extraction with 2x15 mL of CH2Cl2. The combined organic layers were dried over Na2SO4 and 
concentrated in vacuo. The product was purified by flash column chromatography on silica gel (EtOAc/n-
Hexane = 7:3) to afford the amino substituted pyrazolo[1,5-a]pyrimidine 2.28. 
 
N-ethyl-3-iodopyrazolo[1,5-a]pyrimidin-7-amine (2.28a) 
Beige solid, 79% yield; Data for 2.28a: 
1
H NMR (500 MHz, DMSO-d6)  8.15-8.17 (m, 2H), 8.05 (t, J = 
5.9 Hz, NH), 6.21 (d, J = 5.4 Hz, 1H), 3.40 (m, 2H), 1.19 (t, J = 7.2 Hz, 3H); 
13
C NMR (125 MHz, 
DMSO-d6) 151.4, 141.7, 146.2, 143.7, 86.5, 81.4, 37.1, 14.5. 
 
3-Iodo-7-morpholinopyrazolo[1,5-a]pyrimidine (2.28b) 
Orange solid, 68% yield; Data for 2.28b: 
1
H NMR (500 MHz, DMSO-d6)  8.34 (d, J = 5.1 Hz, 1H), 8.23 
(s, 1H), 6.46 (d, J = 5.2 Hz, 1H), 3.79-3.81 (m, 4H), 3.72-3.74 (m, 4H); 
13
C NMR (125 MHz, DMSO-d6) 
158.4, 151.0, 150.2, 149.7, 147.2, 93.5, 65.7, 48.1. 
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N-(4-fluorobenzyl)-3-iodopyrazolo[1,5-a]pyrimidin-7-amine (2.28c) 
Yellow solid, 61% yield; Data for 2.28c: 
1
H NMR (500 MHz, DMSO-d6)  8.58 (t, J = 6.4 Hz, 1H), 8.37 
(s, 1H), 7.94 (d, J = 5.0 Hz, 1H), 7.39-7.43 (m, 2H), 7.15-7.18 (m, 2H), 6.11 (d, J = 5.1 Hz, 1H), 4.63 (d, 
J = 6.7 Hz, 2H); 
13
C NMR (125 MHz, DMSO-d6) 159.7, 161.0, 149.7, 148.9, 146.1, 139.9, 133.7, 
122.0, 116.8, 93.3, 84.6, 46.5. 
 
7-Ethoxy-3-iodopyrazolo[1,5-a]pyrimidine (2.28e) 
Beige solid, 57% yield; Data for 2.28e: 
1
H NMR (500 MHz, DMSO-d6)  8.48 (d, J = 5.1 Hz, 1H), 8.23 
(s, 1H), 6.67 (d, J = 5.1 Hz, 1H), 4.51 (q, J = 7.0 Hz, 2H), 1.48 (t, J = 7.1 Hz, 3H); 
13
C NMR (125 MHz, 
DMSO-d6) 155.1, 152.4, 149.5, 148.4, 88.6, 67.0, 49.7, 14.0. 
 
General procedure for the preparation of pyrazolo[1,5-a]pyrimidine derivatives 2.29: 
 
Method using conventional heating 
To a solution of 2.28 (1.0 mmol) in 5 mL of dioxane under argon was added a boronic acid (1.3 mmol), 
K3PO4 (467 mg, 2.2 mmol) and 1,1’-bis(diphenylphosphino)ferrocenedichloro palladium (82 mg, 0.1 
mmol) at room temperature. The reaction mixture was refluxed until the completion of the reaction for 16 
hours and then was allowed to cool to room temperature. 15 mL of saturated aqueous NaHCO3 was added 
to the reaction mixture followed by an extraction with 2x15 mL of CH2Cl2. The combined organic layers 
were dried over Na2SO4 and concentrated in vacuo. The product was purified by preparative HPLC to 
afford the aryl substituted pyrazolo[1,5-a]pyrimidine 2.29. 
 
Method using microwaves irradiation 
To a solution of 2.28 (1.0 mmol) in 5 mL of water and dioxane (1/4) under argon was added a boronic 
acid (1.3 mmol), triethylamine (348 L, 2.5 mmol) and 1,1’-bis(diphenylphosphino)ferrocenedichloro 
palladium (82 mg, 0.1 mmol) at room temperature. The reaction mixture was irradiated by microwaves at 
105°C for 30minutes and then was allowed to cool to room temperature. 15 mL of saturated aqueous 
NaHCO3 was added to the reaction mixture followed by an extraction with 2x15 mL of CH2Cl2. The 
combined organic layers were dried over Na2SO4 and concentrated in vacuo. The product was purified by 
preparative HPLC to afford the aryl substituted pyrazolo[1,5-a]pyrimidine 2.29. 
 
N-ethyl-3-(4-fluorophenyl)pyrazolo[1,5-a]pyrimidin-7-amine (2.29a) 
Brown solid, 60% yield; Data for 2.29a: 
1
H NMR (600 MHz, DMSO-d6)  8.54 (s, 1H), 8.22 (d, J = 5.3 
Hz, 1H), 8.11-8.13 (m, 2H), 8.00 (t, J = 5.9 Hz, NH), 7.20 (t, J = 8.9 Hz, 2H), 6.22 (d, J = 5.3 Hz, 1H), 
3.40-3.45 (m, 2H), 1.22 (t, J = 7.1 Hz, 3H); 
13
C NMR (150 MHz, DMSO-d6) 164.4, 162.8, 153.6, 150.3, 
148.6, 144.5, 132.6, 130.4, 118.7, 109.9, 89.2, 39.7, 17.4. 
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3-(7-(Ethylamino)pyrazolo[1,5-a]pyrimidin-3-yl)benzamide (2.29b) 
Beige solid, 43% yield; Data for 2.29b: 
1
H NMR (600 MHz, DMSO-d6)  8.69 (s, 1H), 8.55-8.56 (m, 
1H), 8.39 (d, J = 7.9 Hz, 1H), 8.28 (d, J = 5.3 Hz, 1H), 8.17 (t, J = 6.1 Hz, NH), 8.00 (s, 1H), 7.88-7.90 
(m, 1H), 7.66 (d, J = 7.8 Hz, 1H), 7.39 (s, 1H), 6.27 (d, J = 5.4 Hz, 1H), 3.43-3.47 (m, 2H), 1.24 (t, J = 
7.2 Hz, 3H); 
13
C NMR (150 MHz, DMSO-d6) 171.7, 153.7, 150.4, 149.0, 144.7, 138.1, 136.4, 131.8, 
131.3, 129.3, 127.6, 110.3, 89.3, 39.7, 17.5. 
 
N-ethyl-3-(pyridin-3-yl)pyrazolo[1,5-a]pyrimidin-7-amine (2.29c) 
Beige solid, 45% yield; Data for 2.29c: 
1
H NMR (600 MHz, DMSO-d6)  9.33-9.34 (m, 1H), 8.74 (s, 
1H), 8.52-8.53 (m, 1H), 8.36-8.37 (m, 1H), 8.28 (d, J = 5.5 Hz, 1H), 8.22 (t, J = 5.9 Hz, NH), 7.40-7.42 
(m, 1H), 6.29 (d, J = 5.4 Hz, 1H), 3.44-3.47 (m, 2H), 1.24 (t, J = 7.1 Hz, 3H); 
13
C NMR (150 MHz, 
DMSO-d6) 150.6, 147.1, 146.4, 146.1, 146.0, 141.3, 131.9, 129.1, 123.7, 104.2, 86.2, 36.4, 14.2. 
 
3-(4-Fluorophenyl)-7-morpholinopyrazolo[1,5-a]pyrimidine (2.29d) 
Brown solid, 58% yield; Data for 2.29d: 
1
H NMR (500 MHz, DMSO-d6)  8.6 (s, 1H), 8.39 (d, J = 5.0 
Hz, 1H), 8.17-8.20 (m, 2H), 7.25 (t, J = 8.9 Hz, 2H), 6.47 (d, J = 5.1 Hz, 1H), 3.82-3.84 (m, 3H), 3.76-
3.78 (m, 4H); 
13
C NMR (125 MHz, DMSO-d6) 161.5, 159.6, 150.3, 150.2, 146.8, 141.3, 129.0, 127.4, 
115.4, 106.9, 93.4, 65.7, 48.2. 
 
3-(7-Morpholinopyrazolo[1,5-a]pyrimidin-3-yl)benzamide (2.29e) 
Brown solid, 42% yield; Data for 2.29e: 
1
H NMR (600 MHz, CDCl3)  8.53 (s, 1H), 8.43 (s, 1H), 8.41 (d, 
J = 5.0 Hz, 1H), 8.24 (d, J = 7.7 Hz, 1H), 7.70 (d, J = 8.3 Hz, 1H), 7.53 (t, J = 7.9 Hz, 1H), 6.19 (d, J = 
5.0 Hz, 1H), 3.99-4.00 (m, 4H), 3.78-3.80 (m, 4H); 
13
C NMR (150 MHz, CDCl3) 153.8, 152.9, 144.5, 
132.6, 132.0, 128.0, 127.8, 96.1, 69.3, 51.5. 
 
7-Morpholino-3-(pyridin-3-yl)pyrazolo[1,5-a]pyrimidine (2.29f) 
White solid, 51% yield; Data for 2.29f: 
1
H NMR (500 MHz, CDCl3)  9.20 (s, 1H), 8.45-8.49 (m, 2H), 
8.40-8.41 (m, 2H), 7.36-7.39 (m, 1H), 6.20 (d, J = 5.0 Hz, 1H), 3.99-4.01 (m, 4H), 3.78-3.80 (m, 4H); 
13
C 
NMR (125 MHz, CDCl3) 150.8, 150.1, 147.2, 146.8, 141.1, 133.5, 128.7, 123.6, 106.3, 93.2, 66.3, 48.5. 
 
7-Morpholino-3-(1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine (2.29g) 
Brown solid, 40% yield; Data for 2.29g: 
1
H NMR (600 MHz, DMSO-d6)  8.43 (s, 1H), 8.33 (d, J = 5.1 
Hz, 1H), 8.07-8.11 (m, 2H), 6.39 (d, J = 5.1 Hz, 1H), 3.81-3.83 (m, 4H), 3.73-3.75 (m, 4H); 
13
C NMR 
(150 MHz, DMSO-d6) 165.6, 150.1, 149.5, 146.2, 140.6, 111.9, 102.2, 92.8, 65.8, 48.1. 
 
N-(4-fluorobenzyl)-3-(pyridin-3-yl)pyrazolo[1,5-a]pyrimidin-7-amine (2.29h) 
Beige solid, 43% yield; Data for 2.29h: 
1
H NMR (600 MHz, DMSO-d6)  9.32-9.33 (m, 1H), 8.89 (t, J = 
6.5 Hz, NH), 8.78 (s, 1H), 8.50-8.52 (m, 1H), 8.37-8.38 (m, 1H), 8.23 (d, J = 5.3 Hz, 1H), 7.46-7.49 (m, 
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2H), 7.40-7.42 (m, 1H), 7.17 (t, J = 8.9 Hz, 2H), 6.24 (d, J = 5.3 Hz, 1H), 4.64 (d, J = 6.5 Hz, 2H); 
13
C 
NMR (150 MHz, DMSO-d6) 165.6, 164.0, 153.9, 150.5, 149.8, 149.6, 149.2, 144.8, 137.6, 135.4, 
132.6, 132.3, 127.1, 118.7, 107.8, 90.2, 47.3. 
 
3-(2-Fluoropyridin-4-yl)-N-(4-methoxyphenyl)pyrazolo[1,5-a]pyrimidin-7-amine (2.29j) 
Brown solid, 40% yield; Data for 2.29j: 
1
H NMR (600 MHz, DMSO-d6)  10.31 (s, 1H), 9.02 (s, 1H), 
8.38 (d, J = 5.4 Hz, 1H), 8.21 (d, J = 5.3 Hz, 1H), 8.15-8.16 (m, 1H), 7.95 (s, 1H), 7.39 (t, J = 8.1 Hz, 
1H), 7.07-7.08 (m, 2H), 6.88-6.90 (m, 1H), 6.53 (d, J = 5.4 Hz, 1H), 3.78 (s, 3H); 
13
C NMR (150 MHz, 
DMSO-d6) 165.1, 163.5, 160.2, 151.9, 147.8, 147.1, 146.2, 146.1, 143.1, 138.2, 130.5, 117.7, 116.5, 
111.9, 110.4, 104.5, 103.7, 89.3, 55.5. 
 
7-Ethoxy-3-(3-fluorophenyl)pyrazolo[1,5-a]pyrimidine (2.29k) 
Beige solid, 57% yield; Data for 2.29k: 
1
H NMR (600 MHz, DMSO-d6)  8.79 (s, 1H), 8.58 (d, J = 5.0 
Hz, 1H), 8.05-8.08 (m, 1H), 8.02-8.03 (m, 1H), 7.46 (q, J = 7.9 Hz, 1H), 7.03-7.06 (m, 1H), 6.73 (d, J = 
5.1 Hz, 1H), 4.55 (q, J = 7.0 Hz, 2H), 1.51 (t, J = 7.0 Hz, 3H); 
13
C NMR (150 MHz, DMSO-d6) 163.5, 
161.9, 155.2, 152.2, 146.7, 142.9, 134.7, 130.6, 121.4, 112.3, 111.8, 107.3, 89.0, 66.9, 14.2. 
 
7-Morpholino-3-styrylpyrazolo[1,5-a]pyrimidine (2.30a) 
To a solution of 2.28b (330 mg, 1.0 mmol) in 5 mL of toluene under argon was added styrene (229 mg, 
2.0 mmol), tetrakis(triphenylphosphine) palladium (116 mg, 0.1 mmol) and triethylamine (236 L, 1.7 
mmol) at room temperature. The reaction mixture was heated at 80 °C for 16 hours and then was allowed 
to cool to room temperature. 15 mL of saturated aqueous NaHCO3 was added to the reaction mixture 
followed by an extraction with 2x15 mL of CH2Cl2. The combined organic layers were dried over Na2SO4 
and concentrated in vacuo. The product was purified by preparative HPLC to afford the pyrazolo[1,5-
a]pyrimidine 2.30a in 28% yield as beige solid. Data for 2.30a: 
1
H NMR (500 MHz, DMSO-d6)  8.38 (d, 
J = 5.2 Hz, 1H), 8.18 (s, 1H), 7.49-7.53 (m, 2H), 7.31-7.36 (m, 3H), 6.78-6.86 (m, 2H), 6.35 (d, J = 5.0 
Hz, 1H), 3.93-3.96 (m, 4H), 3.68-3.73 (m, 4H); 
13
C NMR (125 MHz, DMSO-d6) 152.4, 150.7, 149.6, 
145.3, 139.9, 132.1, 128.3, 128.0, 123.6, 117.0, 96.4, 66.7, 47.3. 
 
7-Morpholino-3-(2-phenylethynyl)pyrazolo[1,5-a]pyrimidine (2.30b) 
To a solution of 2.28b (330 mg, 1.0 mmol) in 5 mL of toluene under argon was added phenyl acetylene 
(165 mg, 1.5 mmol), tetrakis(triphenylphosphine) palladium (116 mg, 0.1 mmol), copper iodide (19 mg, 
0.1 mmol) and triethylamine (236 L, 1.7 mmol) at room temperature. The reaction mixture was heated at 
80 °C for 16 hours and then was allowed to cool to room temperature. 15 mL of saturated aqueous 
NaHCO3 was added to the reaction mixture followed by an extraction with 2x15 mL of CH2Cl2. The 
combined organic layers were dried over Na2SO4 and concentrated in vacuo. The product was purified by 
preparative HPLC to afford the pyrazolo[1,5-a]pyrimidine 2.30b in 35% yield as brown solid. Data for 
2.30b: 
1
H NMR (500 MHz, CDCl3)  8.40 (d, J = 5.0 Hz, 1H), 8.22 (s, 1H), 7.57-7.59 (m, 2H), 7.30-7.35 
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(m, 3H), 6.17 (d, J = 5.1 Hz, 1H), 3.96-3.98 (m, 4H), 3.77-3.79 (m, 4H); 
13
C NMR (125 MHz, CDCl3) 
151.0, 150.9, 150.7, 145.8, 131.5, 128.2, 127.8, 123.7, 93.4, 93.1, 93.0, 79.6, 66.2, 48.5. 
 
7-(4-Fluorophenyl)pyrazolo[1,5-a]pyrimidine (2.31) 
To a solution of 2.26 (154 mg, 1.0 mmol) in 5 mL of dioxane under argon was added p-fluorophenyl 
boronic acid (182 mg, 1.3 mmol), K3PO4 (467 mg, 2.2 mmol) and 1,1’-
bis(diphenylphosphino)ferrocenedichloro palladium (82 mg, 0.1 mmol) at room temperature. The reaction 
mixture was refluxed until the completion of the reaction for 16 hours and then was allowed to cool to 
room temperature. 15 mL of saturated aqueous NaHCO3 was added to the reaction mixture followed by 
an extraction with 2x15 mL of CH2Cl2. The combined organic layers were dried over Na2SO4 and 
concentrated in vacuo. The product was purified by flash column chromatography on silica gel (EtOAc/n-
Hexane = 1:2) to afford the pyrazolo[1,5-a]pyrimidine 2.31 in 87% yield as beige solid. Data for 2.31: 
1
H 
NMR (300 MHz, DMSO-d6)  8.62 (d, J = 4.4 Hz, 1H), 8.21-8.29 (m, 3H), 7.44-7.50 (m, 2H), 7.26 (d, J 
= 4.4 Hz, 1H), 6.84 (d, J = 2.4 Hz, 1H); 
13
C NMR (75 MHz, DMSO-d6) 165.2, 149.7, 149.5, 144.6, 
132.3, 132.1, 115.8, 115.6, 107.7, 96.7. 
 
7-(4-Fluorophenyl)-3-iodopyrazolo[1,5-a]pyrimidine (2.32) 
To a solution of 2.31 (213 mg, 1.0 mmol) in 15 mL of CH2Cl2 under argon at room temperature was 
added NIS (270 mg, 1.2 mmol). The mixture was stirred at ambient temperature for 5 hours. After 
completion of the reaction monitored by TLC, 10 mL of saturated aqueous NaHCO3 was added. The 
organic layer was separated, dried over Na2SO4 and concentrated in vacuo. The product was purified by 
flash column chromatography on silica gel (EtOAc/n-Hexane = 1:3) to afford the pyrazolo[1,5-
a]pyrimidine 2.32 in 81% yield as beige solid. Data for 2.32: 
1
H NMR (300 MHz, CDCl3) δ 8.36 (d, J = 
4.3 Hz, 1H), 7.92 (s, 1H), 7.82-7.86 (m, 2H), 6.99-7.05 (m, 2H), 6.77 (d, J = 4.3 Hz, 1H); 
13
C NMR (75 
MHz, CDCl3) δ 167.0, 150.8, 147.2, 141.9, 133.4, 130.9, 110.9, 107.3, 102.1, 94.9. 
 
5-(7-(4-Fluorophenyl)pyrazolo[1,5-a]pyrimidin-3-yl)-N-(2-morpholinoethyl)pyridin-2-amine (2.33) 
To a solution of 2.32 (339 mg, 1.0 mmol) in 5 mL of water and dioxane (1/4) under argon was added 
boronic acid (1.3 mmol), triethylamine (347 L, 2.5 mmol) and 1,1’-
bis(diphenylphosphino)ferrocenedichloro palladium (82 mg, 0.1 mmol) at room temperature. The reaction 
mixture was irradiated by microwaves at 105°C for 30minutes and then was allowed to cool to room 
temperature. 15 mL of saturated aqueous NaHCO3 was added to the reaction mixture followed by an 
extraction with 2x15 mL of CH2Cl2. The combined organic layers were dried over Na2SO4 and 
concentrated in vacuo. The product was purified by preparative HPLC to afford the aryl substituted 
pyrazolo[1,5-a]pyrimidine 2.33 in 42% yield as brown solid. Data for 2.33: 
1
H NMR (300 MHz, DMSO-
d6) δ 8.43 (d, J = 4.1 Hz, 1H), 7.87 (s, 1H), 7.79-7.85 (m, 2H), 7.43-7.56 (m, 3H), 7.01-7.11 (m, 3H), 6.59 
(d, J = 4.2 Hz, 1H), 3.64-3.72 (m, 4H), 3.45-3.53 (m, 4H), 2.89 (t, J = 6.9 Hz, 2H), 2.41 (t, J = 6.8 Hz, 
2H); 
13
C NMR (75 MHz, DMSO-d6) δ 162.8, 151.3, 147.5, 142.6, 136.1, 134.7, 130.1, 128.7, 123.6, 
118.2, 111.0, 108.4, 100.7, 97.6, 66.3, 58.4, 47.9, 41.5. 
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N-Ethylpyrazolo[1,5-a]pyrimidin-7-amine (2.36a) 
To a solution of 2.26 (154 mg, 1.0 mmol) in 5 mL of EtOH under argon was added ethylamine (70% 
aqueous) (104 L, 1.3 mmol), followed by triethylamine (181 L, 1.3 mmol) at room temperature. The 
reaction mixture was refluxed until the completion of the reaction (16 hours monitored by TLC) and was 
allowed to cool to room temperature. 15 mL of saturated aqueous NaHCO3 was added to the reaction 
mixture followed by an extraction with 2x15 mL of CH2Cl2. The combined organic layers were dried over 
Na2SO4 and concentrated in vacuo. The product was purified by flash column chromatography on silica 
gel (EtOAc/n-Hexane = 9:1) to afford the amino substituted pyrazolo[1,5-a]pyrimidine 2.36a in 68% 
yield as pale yellow solid. Data for 2.36a: 
1
H NMR (500 MHz, DMSO-d6)  8.21 (d, J = 5.4 Hz, 1H), 
8.17 (d, J = 2.2 Hz, 1H), 7.97 (t, J = 6.3 Hz, NH), 6.53 (d, J = 2.1 Hz, 1H), 6.21 (d, J = 5.4 Hz, 1H), 3.50-
3.54 (m, 2H), 1.19 (t, J = 7.3 Hz, 3H); 
13
C NMR (125 MHz, DMSO-d6) 150.6, 142.3, 141.8, 139.7, 
91.1, 82.0, 37.9, 14.4. 
 
7-Morpholinopyrazolo[1,5-a]pyrimidine (2.36b) 
To a solution of 2.26 (154 mg, 1.0 mmol) in 5 mL of EtOH under argon was added morpholine (113 L, 
1.3 mmol), followed by triethylamine (181 L, 1.3 mmol) at room temperature. The reaction mixture was 
refluxed until the completion of the reaction (16 hours monitored by TLC) and was allowed to cool to 
room temperature. 15 mL of saturated aqueous NaHCO3 was added to the reaction mixture followed by 
an extraction with 2x15 mL of CH2Cl2. The combined organic layers were dried over Na2SO4 and 
concentrated in vacuo. The product was purified by flash column chromatography on silica gel (EtOAc/n-
Hexane = 9:1) to afford the amino substituted pyrazolo[1,5-a]pyrimidine 2.36b in 65% yield as beige 
solid. Data for 2.36b: 
1
H NMR (300 MHz, DMSO-d6)  8.29 (d, J = 5.1 Hz, 1H), 8.14 (d, J = 2.3 Hz, 
1H), 6.57 (d, J = 2.3 Hz, 1H), 6.37 (d, J = 5.0 Hz, 1H), 3.80-3.83 (m, 4H), 3.71-3.74 (m, 4H); 
13
C NMR 
(75 MHz, DMSO-d6) 150.8, 150.0, 149.8, 143.4, 95.2, 92.7, 65.7, 48.0. 
 
General procedure for the preparation of 3-nitropyrazolo[1,5-a]pyrimidine derivatives 2.37: 
 
To a solution of 2.36 (1.0 mmol) in 3 mL of H2SO4 at 0 °C was added dropwise 1 mL of nitric acid. The 
reaction mixture was stirred for 30 minutes and 15 mL of water was carefully added to the reaction 
mixture and small portions of K2CO3 were added while stirring until basic pH was reached. An extraction 
with 2x15 mL of AcOEt was performed. The organic layer was dried over Na2SO4 and concentrated in 
vacuo. The product was directly used for the next step without further purification. 
 
N-Ethyl-3-nitropyrazolo[1,5-a]pyrimidin-7-amine (2.37a) 
Yellow solid, 50% yield; Data for 2.37a: 
1
H NMR (300 MHz, DMSO-d6)  8.72 (s, 1H), 8.37 (d, J = 5.3 
Hz, 1H), 8.09 (t, J = 5.9 Hz, NH), 6.32 (d, J = 5.4 Hz, 1H), 3.59-3.63 (m, 2H), 1.18 (t, J = 7.2 Hz, 3H); 
13
C NMR (75 MHz, DMSO-d6) 148.7, 139.1, 140.9, 137.2, 95.0, 87.4, 38.3, 14.6. 
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7-Morpholino-3-nitropyrazolo[1,5-a]pyrimidine (2.37b) 
Orange solid, 57% yield; Data for 2.37b: 
1
H NMR (500 MHz, CDCl3)  8.67 (s, 1H), 8.59 (d, J = 5.5 Hz, 
1H), 6.42 (d, J = 5.5 Hz, 1H), 3.95-3.98 (m, 4H), 3.89-3.92 (m, 4H); 
13
C NMR (125 MHz, CDCl3) 
154.5, 150.5, 145.4, 141.4, 96.1, 66.1, 49.0. 
 
N-(4-fluorobenzyl)pyrazolo[1,5-a]pyrimidin-7-amine (2.36c) 
To a solution of 2.26 (154 mg, 1.0 mmol) in 5 mL of EtOH under argon was added p-fluoro benzylamine 
(149 L, 1.3 mmol), followed by triethylamine (181 L, 1.3 mmol) at room temperature. The reaction 
mixture was refluxed until the completion of the reaction (16 hours monitored by TLC) and was allowed 
to cool to room temperature. 15 mL of saturated aqueous NaHCO3 was added to the reaction mixture 
followed by an extraction with 2x15 mL of CH2Cl2. The combined organic layers were dried over Na2SO4 
and concentrated in vacuo. The product was purified by flash column chromatography on silica gel 
(EtOAc/n-Hexane = 9:1) to afford the amino substituted pyrazolo[1,5-a]pyrimidine 2.36c in 58% yield as 
beige solid. Data for 2.36c: 
1
H NMR (600 MHz, DMSO-d6)  8.66 (t, J = 6.5 Hz, 1H), 8.10 (d, J = 2.3 
Hz, 1H), 8.08 (d, J = 5.2 Hz, 1H), 7.44-7.47 (m, 2H), 7.14-7.17 (m, 2H), 6.42 (d, J = 2.3 Hz, 1H), 6.08 (d, 
J = 5.3 Hz, 1H), 4.60 (d, J = 6.5 Hz, 2H); 
13
C NMR (150 MHz, DMSO-d6) 162.2, 160.6, 149.6, 149.1, 
146.8, 143.4, 134.4, 129.2, 115.3, 94.7, 85.5, 43.9. 
 
General procedure for the preparation of 2.38 derivatives: 
 
To a solution of 2.37 (1.0 mmol) in 5 mL of MeOH under argon was added a catalytic amount of acetic 
acid (6 L, 0.1 mmol) followed by zinc (327 mg, 5.0 mmol) at room temperature. The reaction mixture 
was stirred for 5 hours. 15 mL of saturated aqueous NaHCO3 was added to the reaction mixture followed 
by an extraction with 2x15 mL of CH2Cl2. The combined organic layers were dried over Na2SO4 and 
concentrated in vacuo. The reduced derivative was directly used for the next step without further 
purification. 
To a solution of the amine (1.0 mmol) in 5 mL of CH2Cl2 under argon was added an acid chloride (1.3 
mmol) followed by triethylamine (181 L, 1.3 mmol) at room temperature. The reaction mixture was 
stirred for 16 hours, after which 15 mL of saturated aqueous NaHCO3 was added to the reaction mixture 
followed by an extraction with 2x15 mL of CH2Cl2. The combined organic layers were dried over Na2SO4 
and concentrated in vacuo. The product was purified by preparative HPLC to afford the amino substituted 
pyrazolo[1,5-a]pyrimidine 2.38. 
 
General procedure for the preparation of 2.39 derivatives: 
 
To a solution of 2.37 (1.0 mmol) in 5 mL of MeOH under argon was added a catalytic amount of acetic 
acid (6 L, 0.1 mmol) followed by zinc (327 mg, 5.0 mmol) at room temperature. The reaction mixture 
was stirred for 5 hours. 15 mL of saturated aqueous NaHCO3 was added to the reaction mixture followed 
by an extraction with 2x15 mL of CH2Cl2. The combined organic layers were dried over Na2SO4 and 
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concentrated in vacuo. The reduced derivative was directly used for the next step without further 
purification. 
To a solution of the amine (1.0 mmol) in 5 mL of CH2Cl2 under argon was added an sulfonyl chloride 
(1.3 mmol) followed by triethylamine (181 L, 1.3 mmol) at room temperature. The reaction mixture was 
stirred for 16 hours, after which 15 mL of saturated aqueous NaHCO3 was added to the reaction mixture 
followed by an extraction with 2x15 mL of CH2Cl2. The combined organic layers were dried over Na2SO4 
and concentrated in vacuo. The product was purified by preparative HPLC to afford the amino substituted 
pyrazolo[1,5-a]pyrimidine 2.39. 
 
General procedure for the preparation of 2.40 derivatives: 
 
To a solution of 2.37 (1.0 mmol) in 5 mL of MeOH under argon was added a catalytic amount of acetic 
acid (6 L, 0.1 mmol) followed by zinc (327 mg, 5.0 mmol) at room temperature. The reaction mixture 
was stirred for 5 hours. 15 mL of saturated aqueous NaHCO3 was added to the reaction mixture followed 
by an extraction with 2x15 mL of CH2Cl2. The combined organic layers were dried over Na2SO4 and 
concentrated in vacuo. The reduced derivative was directly used for the next step without further 
purification. 
To a solution of the amine (1.0 mmol) in 5 mL of CH2Cl2 under argon was added an isocyanate (1.3 
mmol) at room temperature. The reaction mixture was stirred for 2 hours, after which 15 mL of saturated 
aqueous NaHCO3 was added to the reaction mixture followed by an extraction with 2x15 mL of CH2Cl2. 
The combined organic layers were dried over Na2SO4 and concentrated in vacuo. The product was 
purified by preparative HPLC to afford the amino substituted pyrazolo[1,5-a]pyrimidine 2.40. 
 
General procedure for the preparation of 2.41 derivatives: 
 
To a solution of 2.37 (1.0 mmol) in 5 mL of MeOH under argon was added a catalytic amount of acetic 
acid (6 L, 0.1 mmol) followed by zinc (327 mg, 5.0 mmol) at room temperature. The reaction mixture 
was stirred for 5 hours. 15 mL of saturated aqueous NaHCO3 was added to the reaction mixture followed 
by an extraction with 2x15 mL of CH2Cl2. The combined organic layers were dried over Na2SO4 and 
concentrated in vacuo. The reduced derivative was directly used for the next step without further 
purification. 
To a solution of the amine (1.0 mmol) in 5 mL of CH2Cl2 under argon was added a chloroformate (1.3 
mmol) followed by triethylamine (181 L, 1.3 mmol) at room temperature. The reaction mixture was 
stirred for 16 hours, after which 15 mL of saturated aqueous NaHCO3 was added to the reaction mixture 
followed by an extraction with 2x15 mL of CH2Cl2. The combined organic layers were dried over Na2SO4 
and concentrated in vacuo. The product was purified by preparative HPLC to afford the amino substituted 
pyrazolo[1,5-a]pyrimidine 2.41. 
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General procedure for the preparation of 2.42 derivatives: 
 
To a solution of 2.37 (1.0 mmol) in 5 mL of MeOH under argon was added a catalytic amount of acetic 
acid (6 L, 0.1 mmol) followed by zinc (327 mg, 5.0 mmol) at room temperature. The reaction mixture 
was stirred for 5 hours. 15 mL of saturated aqueous NaHCO3 was added to the reaction mixture followed 
by an extraction with 2x15 mL of CH2Cl2. The combined organic layers were dried over Na2SO4 and 
concentrated in vacuo. The reduced derivative was directly used for the next step without further 
purification. 
To a solution of the amine (1.0 mmol) in 5 mL of EtOH under argon was added an aldehyde (1.3 mmol) 
followed by sodium cyanoborohydride (126 mg, 2.0 mmol) at room temperature. The reaction mixture 
was stirred for 16 hours, after which 15 mL of saturated aqueous NaHCO3 was added to the reaction 
mixture followed by an extraction with 2x15 mL of CH2Cl2. The combined organic layers were dried over 
Na2SO4 and concentrated in vacuo. The product was purified by preparative HPLC to afford the amino 
substituted pyrazolo[1,5-a]pyrimidine 2.42. 
 
N-(7-(ethylamino)pyrazolo[1,5-a]pyrimidin-3-yl)acetamide (2.38a) 
Orange solid, 32% yield; Data for 2.38a: 
1
H NMR (500 MHz, DMSO-d6)  9.90 (br. s, NH), 8.41 (s, 1H), 
8.10 (d, J = 5.2 Hz, 1H), 8.03 (t, J = 5.9 Hz, NH), 6.12 (d, J = 5.2 Hz, 1H), 3.39-3.44 (m, 2H), 2.06 (s, 
3H), 1.22 (t, J = 7.1 Hz, 3H); 
13
C NMR (125 MHz, DMSO-d6) 171.2, 151.7, 149.8, 143.1, 139.7, 112.7, 
88.0, 39.6, 26.2, 17.5. 
 
N7-ethyl-N3-tosylpyrazolo[1,5-a]pyrimidine-3,7-diamine (2.39a) 
Brown solid, 27% yield; Data for 2.39a: 
1
H NMR (600 MHz, DMSO-d6)  9.71 (br. s, 1H), 8.00-8.02 (m, 
2H), 7.74 (s, 1H), 7.62 (d, J = 8.2 Hz, 2H), 7.28 (d, J = 8.2 Hz, 2H), 6.10 (d, J = 5.3 Hz, 1H), 3.36-3.40 
(m, 2H), 2.33 (s, 3H), 1.18 (t, J = 7.2 Hz, 3H); 
13
C NMR (150 MHz, DMSO-d6) 149.6, 146.6, 143.7, 
142.6, 140.5, 137.8, 129.4, 126.9, 105.8, 85.3, 36.3, 21.1, 14.1. 
 
Ethyl 7-morpholinopyrazolo[1,5-a]pyrimidin-3-ylcarbamate (2.41a) 
Beige solid, 21% yield; Data for 2.41a: 
1
H NMR (500 MHz, DMSO-d6)  9.05 (s, 1H), 8.24 (d, J = 5.0 
Hz, 1H), 6.36 (d, J = 5.0 Hz, 1H), 4.09-4.11 (m, 2H), 3.80-3.82 (m, 4H), 3.72-3.74 (m, 4H), 1.22-1.24 (m, 
3H); 
13
C NMR (125 MHz, DMSO-d6) 156.3, 149.7, 148.8, 138.4, 92.6, 65.7, 60.3, 47.9, 14.7. 
 
N-(7-morpholinopyrazolo[1,5-a]pyrimidin-3-yl)benzamide (2.38c) 
Brown solid, 31% yield; Data for 2.38c: 
1
H NMR (500 MHz, DMSO-d6)  10.18 (br. s, NH), 8.46 (s, 1H), 
8.29 (d, J = 5.0 Hz, 1H), 8.03 (d, J = 7.1 Hz, 2H), 7.58 (t, J = 7.3 Hz, 1H), 7.52 (t, J = 7.2 Hz, 2H), 6.41 
(d, J = 5.1 Hz, 1H), 3.81-3.84 (m, 4H), 3.75-3.78 (m, 4H); 
13
C NMR (125 MHz, DMSO-d6) 165.5, 
149.8, 149.0, 143.1, 138.7, 134.1, 131.6, 128.5, 127.8, 108.9, 92.8, 65.7, 48.0. 
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1-Isopropyl-3-(7-morpholinopyrazolo[1,5-a]pyrimidin-3-yl)urea (2.40b) 
Brown solid, 26% yield; Data for 2.40b: 
1
H NMR (500 MHz, DMSO-d6)  8.31 (s, 1H), 8.15-8.16 (m, 
1H), 7.89 (br. s, NH), 6.25-6.26 (m, 1H), 6.19-6.21 (m, 1H), 3.81-3.82 (m, 4H), 3.75-3.76 (m, 4H), 3.65-
3.67 (m, 1H), 1.10-1.11 (m, 6H); 
13
C NMR (125 MHz, DMSO-d6) 164.1, 154.8, 149.4, 147.3, 134.5, 
111.6, 92.0, 65.7, 47.8, 41.1, 23.2. 
 
General procedure for the preparation of 2.43 derivatives: 
 
To a solution of 2.36 (1.0 mmol) in 5 mL of AcOH under argon was added formaldehyde (37% aqueous 
solution) (97 L, 1.3 mmol) followed by an amine (1.3 mmol) at room temperature. The reaction mixture 
was heated at 65 °C for 16 hours, after completion of the reaction the reaction was allowed to col to room 
temperature. 15 mL of water was carefully added to the reaction mixture and small portions of K2CO3 
were added while stirring until basic pH was reached. An extraction with 2x15 mL of AcOEt was 
performed. The organic layer was dried over Na2SO4 and concentrated in vacuo.. The product was 
purified by preparative HPLC to afford the amino substituted pyrazolo[1,5-a]pyrimidine 2.43. 
 
N-((7-morpholinopyrazolo[1,5-a]pyrimidin-3-yl)methyl)benzenamine (2.43a) 
Beige solid, 35% yield; Data for 2.43a: 
1
H NMR (600 MHz, DMSO-d6)  8.26 (d, J = 4.9 Hz, 1H), 7.94 
(s, 1H), 6.90 (d, J = 8.4 Hz, 2H), 6.44-6.46 (m, 3H), 6.33 (d, J = 5.0 Hz, 1H), 4.80-4.81 (m, 1H), 3.85 (s, 
2H), 3.79-3.81 (m, 4H), 3.70-3.71 (m, 4H); 
13
C NMR (150 MHz, DMSO-d6) 153.2, 152.2, 151.3, 150.0, 
146.2, 132.4, 132.1, 131.9, 117.4, 112.4, 95.7, 69.1, 51.2, 31.1. 
 
N-(4-fluorobenzyl)-3-((cyclohexylamino)methyl)pyrazolo[1,5-a]pyrimidin-7-amine (2.43c) 
Brown solid, 33% yield; Data for 2.43c: 
1
H NMR (600 MHz, DMSO-d6)  8.61 (br. s, NH), 8.07 (s, 1H), 
8.05 (d, J = 5.2 Hz, 1H), 7.43-7.46 (m, 2H), 7.15 (t, J = 8.8 Hz, 2H), 6.05 (d, J = 5.2 Hz, 1H), 4.58-4.59 
(m, 2H), 3.84 (s, 2H), 2.38-2.43 (m, 1H), 1.84-1.85 (m, 2H), 1.63-1.66 (m, 2H), 1.51-1.53 (m, 1H), 1.00-
1.20 (m, 5H); 
13
C NMR (150 MHz, DMSO-d6) 162.3, 160.6, 148.9, 146.8, 143.0, 134.5, 129.3, 115.3, 
107.5, 85.3, 55.2, 43.9, 32.7, 26.0, 24.5. 
 
2-(4-((7-(4-fluorobenzylamino)pyrazolo[1,5-a]pyrimidin-3-yl)methyl)piperazin-1-yl)-N-(pyridin-3-
yl)acetamide (2.43d) 
Brown solid, 23% yield; Data for 2.43d: 
1
H NMR (600 MHz, DMSO-d6)  9.86 (br. s, NH), 8.75-8.76 
(m, 1H), 8.65 (t, J = 6.6 Hz, NH), 8.25-8.26 (m, 1H), 8.07 (d, J = 5.2 Hz, 1H), 8.03-8.05 (m, 2H), 7.44-
7.47 (m, 2H), 7.31-7.33 (m, 1H), 7.16 (t, J = 8.8 Hz, 2H), 6.06 (d, J = 5.3 Hz, 1H), 4.59 (d, J = 6.5 Hz, 
2H), 3.64 (s, 2H), 3.11 (s, 2H), 2.43-2.54 (m, 8H); 
13
C NMR (150 MHz, DMSO-d6) 169.1, 162.3, 160.7, 
149.3, 147.5, 146.8, 144.4, 141.5, 135.3, 134.5, 129.3, 126.8, 123.6, 115.3, 104.1, 85.4, 61.9, 52.9, 52.0, 
50.1, 43.9. 
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4-fluoro-5-phenyl-1H-pyrazol-3-amine (2.50) 
A 1M solution of LiHMDS in THF (29.4 mL, 29.4 mmol, 2.0 equiv) was added dropwise to a solution of 
benzoyl chloride (1.7 mL, 14.68 mmol, 1.0 equiv) and fluoroacetonitrile 2.48 (0.82 mL, 14.68 mmol, 1.0 
equiv) in dry THF (15 mL) cooled to -78 °C under nitrogen. The mixture was allowed to reach room 
temperature after 5h of reaction and quenched with a saturated solution of ammonium chloride. The 
mixture was concentrated under reduced pressure to afford the desired -fluoro--ketonitrile 2.49 in a 
form pure enough for the next step. 
Hydrazine hydrate (64% in water) (1.4 mL, 29.4 mmol, 2.0 equiv) was added to a solution of the -
fluoro--ketonitrile 2.49 (14.68 mmol) in ethanol (20 mL), and the reaction was heated at reflux for 16 h. 
The reaction mixture was allowed to cool to room temperature, and the solvent was evaporated under 
reduced pressure. The residue was dissolved in dichloromethane and washed with water. The organic 
phase was concentrated to give a crude product, flash column chromatography on silica gel (ethyl 
acetate/hexane 90:10) afforded the desired product 2.50 in 50% yield as beige solid. Data for 2.50: 
1
H 
NMR (500 MHz, DMSO-d6) 11.92 (br. s, 1H), 7.66 (d, J = 7.5 Hz, 2H), 7.45 (t, J = 7.4 Hz, 2H), 7.32 (t, 
J = 7.3 Hz, 1H), 4.77 (br. s, 2H); 
13
C NMR (125 MHz, DMSO-d6): 143.3, 135.9, 134.3, 129.0, 127.9, 
126.2, 124.7; 
19
F NMR (470 MHz, DMSO-d6) 186.5. 
 
Ethyl 3-fluoro-7-hydroxy-2-phenylpyrazolo[1,5-a]pyrimidine-6-carboxylate (2.51) 
To a solution of 2.50 (177 mg, 1.0 mmol) in 25 mL of acetic acid under argon at room temperature was 
added diethyl ethoxymethylenemalonate 2.23 (220 mg, 1.1 mmol). The mixture was heated at 100 °C for 
10 hours. The suspension was filtered warm, then washed several times with EtOH, and dried to yield 
2.51 in 57% yield as beige solid. Data for 2.51: 
1
H NMR (300 MHz, DMSO-d6) δ 8.53 (s, 1H), 7.93 (d, 
J=7.4 Hz, 2H), 7.46-7.58 (m, 3H), 4.25 (q, J=7.1 Hz, 2H), 1.30 (t, J=7.1 Hz, 3H); 
13
C NMR (75 MHz, 
DMSO-d6) δ 163.4, 152.4, 145.4, 140.3, 131.8, 129.8, 129.7, 129.6, 129.2, 128.5, 128.3, 126.6, 98.9, 60.2, 
14.4. 
 
3-Fluoro-7-hydroxy-2-phenylpyrazolo[1,5-a]pyrimidine-6-carboxylic acid (2.52) 
To a suspension of 2.51 (301 mg, 1.0 mmol) in 30 mL of ethanol and water (1/1) under argon at room 
temperature was added 2.5 N NaOH (10 mL). The resulting suspension was heated to 85 °C for 3 hours. 
The suspension was cooled to room temperature and diluted with water (100 mL) and concentrated 
hydrochlorhydric acid until the formation of a suspension (pH=1). The white suspension was stirred an 
additional 30 min, filtered, washed with water, and dried to yield 2.52 in 86% yield as white solid. Data 
for 2.52: 
1
H NMR (300 MHz, DMSO-d6) δ 8.46 (s, 1H), 7.96 (d, J=7.5 Hz, 2H), 7.54 (t, J=7.1 Hz, 2H), 
7.45 (t, J=7.2 Hz, 1H); 
13
C NMR (75 MHz, DMSO-d6) δ 167.0, 159.3, 150.6, 140.1, 135.1, 133.1, 130.7, 
129.1, 129.0, 126.5, 95.2. 
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3-fluoro-2-phenylpyrazolo[1,5-a]pyrimidin-7-ol (2.53) 
To the carboxylic acid 2.52 (1 g, 3.66 mmol) was added 10 mL of Dowtherm A. The suspension was 
heated to 230 °C for 5h. The reaction mixture was cooled to room temperature, then diluted with 30 mL 
of hexanes, stirred vigorously, filtered and dried to obtain the desired product 2.53 in 82% yield as light 
brown solid. Data for 2.53: 
1
H NMR (500 MHz, DMSO-d6)  7.97 (d, J = 7.6 Hz, 2H), 7.75 (d, J = 5.9 
Hz, 1H), 7.49 (t, J = 7.6 Hz, 2H), 7.39 (t, J = 7.5 Hz, 1H), 5.48 (d, J = 5.9 Hz, 1H); 
13
C NMR (125 MHz, 
DMSO-d6) 157.2, 148.0, 136.9, 131.8, 131.7, 128.8, 128.3, 126.5, 92.8. 
 
7-chloro-3-fluoro-2-phenylpyrazolo[1,5-a]pyrimidine (2.54) 
2.53 (229 mg, 1.0 mmol) was dissolved in 10 mL of phosphorus oxychloride at room temperature. The 
reaction mixture was heated at 95 °C for 4 hours after which the color of the solution became brown. The 
flask was allowed to cool to room temperature and the excess of phosphorus oxychloride was 
concentrated in vacuo to a brown oil. The oil was dissolved in 15 mL of EtOAc and washed 2 times with 
20 mL of saturated aqueous NaHCO3, the organic layer was dried over Na2SO4 and concentrated to afford 
crude 2.54 as brown oil used directly without further purification. 
 
General procedure for the preparation of pyrazolo[1,5-a]pyrimidine derivatives 2.55: 
 
To a solution of 2.54 (248 mg, 1.0 mmol) in 5 mL of EtOH under argon was added an amine (1.3 mmol), 
followed by triethylamine (181 L, 1.3 mmol) at room temperature. The reaction mixture was refluxed 
until the completion of the reaction (16 hours monitored by TLC) and was allowed to cool to room 
temperature. 15 mL of saturated aqueous NaHCO3 was added to the reaction mixture followed by an 
extraction with 2x15 mL of CH2Cl2. The combined organic layers were dried over Na2SO4 and 
concentrated in vacuo. The product was purified by flash column chromatography on silica gel (EtOAc/n-
Hexane = 9:1) to afford the amino substituted pyrazolo[1,5-a]pyrimidine 2.55. 
 
N-ethyl-3-fluoro-2-phenylpyrazolo[1,5-a]pyrimidin-7-amine (2.55a) 
White solid, 70% yield; mp 212-216°C; Data for 2.55a: 
1
H NMR (500 MHz, DMSO-d6)  8.16 (d, J = 
5.3 Hz, 1H), 8.13 (t, J = 5.8 Hz, 1H), 8.04 (d, J = 7.3 Hz, 2H), 7.55 (t, J = 7.6 Hz, 2H), 7.47 (t, J = 7.5 Hz, 
1H), 6.22 (d, J = 5.3 Hz, 1H), 3.48 (m, 2H), 1.26 (t, J = 7.3 Hz, 3H); 

C NMR (125 MHz, DMSO-d6) 
149.8, 146.0, 138.7, 136.9, 135.1, 133.5, 130.6, 129.1, 126.7, 85.5, 36.6, 14.2. 
 
3-Fluoro-7-morpholino-2-phenylpyrazolo[1,5-a]pyrimidine (2.55b) 
Beige solid, 63% yield; Data for 2.55b: 
1
H NMR (600 MHz, DMSO-d6)  8.30 (d, J = 5.0 Hz, 1H), 7.99 
(d, J = 7.5 Hz, 2H), 7.56 (t, J = 7.6 Hz, 2H), 7.47 (t, J = 7.3 Hz, 1H), 6.44 (d, J = 5.2 Hz, 1H), 3.82-3.86 
(m, 8H); 
13
C NMR (150 MHz, DMSO-d6) 149.8, 149.0, 138.5, 138.3, 135.5, 133.9, 130.2, 129.4, 129.2, 
93.4, 65.6, 48.1. 
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Tert-butyl 4-(3-fluoro-2-phenylpyrazolo[1,5-a]pyrimidin-7-ylamino)piperidine carboxylate (2.55c) 
Beige solid, 69% yield; Data for 2.55c: 
1
H NMR (300 MHz, CDCl3)  8.21 (d, J = 5.1 Hz, 1H), 8.09 (d, J 
= 7.2 Hz, 2H), 7.51 (t, J = 7.9 Hz, 2H), 7.43 (t, J = 7.6 Hz, 1H), 6.38 (d, J = 8.2 Hz, NH), 5.95 (d, J = 5.2 
Hz, 1H), 4.13-4.17 (m, 2H), 2.99-3.07 (m, 2H), 2.14-2.19 (m, 2H), 1.61-1.74 (m, 3H), 1.51 (s, 9H); 
13
C 
NMR (75 MHz, CDCl3) 149.4, 144.2, 139.7, 135.1, 132.0, 131.8, 131.3, 129.3, 125.5, 123.9, 123.6, 
121.8, 80.0, 74.9, 44.4, 26.6, 23.3. 
 
3-Fluoro-2-phenyl-N-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-7-amine (2.55d) 
White solid, 65% yield; Data for 2.55d: 
1
H NMR (500 MHz, DMSO-d6)  8.15 (d, J = 5.3 Hz, 1H), 8.06 
(d, J = 7.6 Hz, 2H), 7.73 (d, J = 8.5 Hz, NH), 7.55 (t, J = 7.5 Hz, 2H), 7.47 (t, J = 7.4 Hz, 1H), 6.31 (d, J 
= 5.4 Hz, 1H), 3.69-3.71 (m, 1H), 3.00-3.03 (m, 2H), 2.59-2.64 (m, 2H), 1.87-1.89 (m, 2H), 1.61-1.69 (m, 
2H); 
13
C NMR (125 MHz, DMSO-d6) 149.8, 145.2, 138.7, 137.1, 136.9, 135.3, 133.3, 130.5, 129.2, 
129.0, 126.8, 126.7, 86.0, 50.0, 45.05, 32.4. 
 
3-Fluoro-N-(1-(methylsulfonyl)piperidin-4-yl)-2-phenylpyrazolo[1,5-a]pyrimidin-7-amine (2.55e) 
White solid, 60% yield; Data for 2.55e: 
1
H NMR (600 MHz, DMSO-d6)  8.18 (d, J = 5.3 Hz, 1H), 8.06 
(d, J = 7.4 Hz, 2H), 7.91 (d, J = 8.9 Hz, NH), 7.56 (t, J = 7.8 Hz, 2H), 7.47 (t, J = 7.3 Hz, 1H), 6.36 (d, J 
= 5.3 Hz, 1H), 3.81-3.88 (m, 1H), 3.65-3.68 (m, 2H), 2.91-2.93 (m, 5H), 2.02-2.03 (m, 2H), 1.84-1.90 (m, 
2H); 
13
C NMR (150 MHz, DMSO-d6) 149.8, 145.4, 138.9, 135.1, 133.5, 130.5, 129.2, 129.0, 126.8, 
86.1, 48.6, 44.8, 34.8, 30.4. 
 
1-(4-(3-fluoro-2-phenylpyrazolo[1,5-a]pyrimidin-7-ylamino)piperidin-1-yl)ethanone (2.55f) 
White solid, 58% yield; Data for 2.55f: 
1
H NMR (600 MHz, CDCl3)  8.21 (d, J = 5.1 Hz, 1H), 8.07 (d, J 
= 7.5 Hz, 2H), 7.50 (t, J = 7.6 Hz, 2H), 7.43 (t, J = 7.5 Hz, 1H), 6.38 (d, J = 8.2 Hz, NH), 5.95 (d, J = 5.2 
Hz, 1H), 4.59-4.62 (m, 1H), 3.91-3.94 (m, 1H), 3.77-3.83 (m, 1H), 3.28-3.33 (m, 1H), 2.92-2.96 (m, 1H), 
2.19-2.24 (m, 2H), 2.16 (s, 3H), 1.66-1.74 (m, 2H); 
13
C NMR (150 MHz, CDCl3) 169.0, 149.3, 144.7, 
140.4, 137.0, 136.9, 136.2, 134.6, 130.5, 129.1, 128.8, 126.9, 85.2, 49.4, 44.8, 40.0, 32.3, 31.5, 21.5. 
 
N-benzyl-3-fluoro-2-phenylpyrazolo[1,5-a]pyrimidin-7-amine (2.55g) 
Beige solid, 68% yield; Data for 2.55g: 
1
H NMR (600 MHz, DMSO-d6)  8.80 (t, J = 6.5 Hz, NH), 8.10 
(d, J = 5.2 Hz, 1H), 8.05 (d, J = 7.3 Hz, 2H), 7.57 (t, J = 7.5 Hz, 2H), 7.48 (t, J = 7.6 Hz, 1H), 7.43 (d, J = 
7.3 Hz, 2H), 7.35 (t, J = 7.6 Hz, 2H), 7.27 (t, J = 7.3 Hz, 1H), 6.14 (d, J = 5.3 Hz, 1H), 4.68 (d, J = 6.4 
Hz, 2H); 
13
C NMR (150 MHz, DMSO-d6) 149.7, 146.2, 138.9, 138.0, 137.0, 136.8, 135.2, 133.6, 130.6, 
129.2, 129.0, 128.6, 127.4, 127.2, 126.7, 86.2, 44.7. 
 
3-Fluoro-2-phenyl-N-((pyridin-3-yl)methyl)pyrazolo[1,5-a]pyrimidin-7-amine (2.55h) 
Beige solid, 58% yield; Data for 2.55h: 
1
H NMR (600 MHz, CDCl3)  8.69 (s, 1H), 8.62 (d, J = 4.7 Hz, 
1H), 8.19 (d, J = 5.0 Hz, 1H), 8.07 (d, J = 7.6 Hz, 2H), 7.72 (d, J = 7.6 Hz, 1H), 7.49 (t, J = 7.5 Hz, 2H), 
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7.42 (t, J = 7.2 Hz, 1H), 7.33-7.35 (m, 1H), 6.90 (t, J = 5.6 Hz, NH), 5.92 (d, J = 5.2 Hz, 1H), 4.68 (d, J = 
6.0 Hz, 2H); 
13
C NMR (150 MHz, CDCl3) 149.8, 149.5, 148.9, 145.7, 140.5, 136.9, 136.8, 136.4, 134.9, 
134.7, 131.7, 130.5, 129.1, 128.8, 126.9, 123.9, 85.5, 43.7. 
 
3-Fluoro-2-phenyl-N-(1H-pyrazol-3-yl)pyrazolo[1,5-a]pyrimidin-7-amine (2.55i) 
White solid, 55% yield; Data for 2.55i: 
1
H NMR (600 MHz, DMSO-d6)  12.10 (br. s, NH), 10.25 (s, 
1H), 8.31 (d, J = 5.2 Hz, 1H), 8.13 (d, J = 7.6 Hz, 2H), 7.78-7.79 (s, 1H), 7.59 (t, J = 7.6 Hz, 2H), 7.50 (t, 
J = 7.2 Hz, 1H), 7.33 (d, J = 5.2 Hz, 1H), 6.39-6.40 (m, 1H); 
13
C NMR (150 MHz, DMSO-d6) 150.3, 
147.1, 142.6, 138.8, 137.1, 136.9, 135.4, 133.8, 130.5, 129.6, 129.3, 129.0, 126.8, 97.2, 89.9. 
 
General procedure for the preparation of pyrazolo[1,5-a]pyrimidine derivatives 2.58: 
 
To a solution of 2.50 (150 mg, 0.85 mmol) in 5 mL of AcOH under argon was added a (hetero)aryl 
dimethylamino propenone (1.3 mmol) at room temperature. The reaction mixture was refluxed for 16 
hours. The suspension was filtered warm, then washed several times with ethanol and dried to obtain the 
desired product 2.58. 
 
3-Fluoro-2,7-diphenylpyrazolo[1,5-a]pyrimidine (2.58a) 
Beige solid, 50% yield; Data for 2.58a: 
1
H NMR (500 MHz, DMSO-d6)  8.63 (d, J = 4.4 Hz, 1H), 8.19-
8.22 (m, 2H), 7.98 (d, J = 7.3 Hz, 2H), 7.65-7.67 (m, 3H), 7.55-7.58 (m, 2H), 7.47-7.50 (m, 1H), 7.30 (d, 
J = 4.3 Hz, 1H); 
13
C NMR (125 MHz, DMSO-d6) 149.8, 145.1, 139.5, 137.2, 136.3, 134.3, 131.4, 
130.1, 130.0, 129.7, 129.6, 129.5, 129.2, 128.7, 126.7, 108.6. 
 
3-Fluoro-2-phenyl-7-(thiophen-2-yl)pyrazolo[1,5-a]pyrimidine (2.58b) 
Yellow solid, 42% yield; mp 233-237°C; Data for 2.58b: 
1
H NMR (500 MHz, DMSO-d6)  8.61 (d, J = 
4.6 Hz, 1H), 8.59 (d, J = 3.8 Hz, 1H), 8.18 (d, J = 5.0 Hz, 1H), 8.13 (d, J = 7.7 Hz, 2H), 7.82 (d, J = 4.6 
Hz, 1H), 7.62 (t, J = 7.7 Hz, 2H), 7.52 (t, J = 7.5 Hz, 1H), 7.43 (t, J = 4.8 Hz, 1H); 
13
C NMR (125 MHz, 
DMSO-d6) 149.0, 139.2, 138.6, 136.2, 135.0, 134.2, 132.5, 130.0, 129.6, 129.3, 129.2, 127.8, 126.6, 
104.6. 
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Chapter III. Synthesis and biological evaluation of substituted pyridazine 
derivatives and novel fused pyridazine analogues   
1. Introduction 
The first synthesis of the pyridazine was described in 1895 by Taüber
1
 but was not 
considered as relevant by the medicinal chemistry community compared to other 
diazines such as pyrimidines and pyrazines. The interest raised from 1971 with the 
discovery of the naturally occurring hexahydropyridazine amino acids 3.1 reported by 
Hassall et al.
2
 followed in 1988 by the first natural product containing a pyridazine, 
pyridazomycin 3.2.
3
 After these discoveries, more attention has been directed towards 
the pyridazine ring and its application in medicinal chemistry. 
N
H
NH
Cl
COOH
N
H
NH
COOH
H
HO
H
N
NH2N
O
O
O
NH3H
Cl
Hexahydropyridazine amino acids Pyridazomycin
3.1 3.2
 
Figure 1. Naturally occurring pyridazine derivatives. 
 
Recently, pyridazines have been considered by GlaxoSmithKline as one of the 
“most developable” heteroaromatic rings for drug design.4 Pyridazine analogues proved 
to be useful ligands for different targets and have been proposed as “privileged 
structure” for drug discovery.5 Several compounds with pyridazine rings demonstrate 
biological activity and many examples of pyridazine structures are naturally occurring.
6 
Pyridazines were recognized as selective GABA-A receptor antagonists, such as 
minaprine 3.3.
7
 Volonterio et al. develop the synthesis of pyridazine-based scaffolds 
such as 3.4 to target protein/protein interaction as -helix mimetics.8 3-Amino-6-aryl-
pyridazines have been considered as an interesting pharmacophore in drug discovery. 
Some compounds show biological activitiy ranging from obesity
9
 or neurodegenerative 
diseases
10
 to inflammatory pain such as the selective CB2 agonist 3.5.
11
 Among kinase 
inhibitors, different compounds containing the diazine pyridazine have been identified. 
For example, compound 3.6 is based on a pyridazinone ring and has been identified as a 
potent p38 MAP inhibitor
12
 (Figure 1). 
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Figure 2. Biologically active pyridazine derivatives. 
 
The nitrogen containing heterocycle pyridazine is a key intermediate in the synthesis 
of several fused heterocycles used in drug discovery.
13
 Fused pyridazines can be 
distinguished into two classes. The first one having a bridgehead nitrogen atom. Some 
of them can be obtained from substituted 3-amino-pyridazine which is easily available 
from substituted 3-chloro-pyridazine, and further cyclized to a bi-heterocyclic structure. 
Generally rings fused to pyridazines are 5-membered rings. Triazolo[4,3-b]pyridazine 
such as PIM-1 inhibitor 3.7
14
 can be considered as an example of this class of fused 
pyridazines. These derivatives were obtained after hydrazinolysis and cyclization of 
substituted 3-chloro-pyridazines. Another example of this class of compounds is a 
VEGFR2 kinase inhibitor based on a imidazo[1,2-b]pyridazine 3.8 scaffold,
15
 which can 
be obtained by condensing substituted 3-amino-pyridazines with 2-chloro-acetaldehyde. 
The second class represents pyridazines fused to a 6- or 5-membered ring, without 
bridgehead nitrogen atom. Examples of this class of compounds are the 
phosphodiesterase 10A inhibitor 3.9
16
 and the melanin-concentrating hormone 1 
antagonist
17
 3.10 (Figure 2). 
A strategy for the synthesis of functionalized pyridazines has been developed, a 
versatile building block for further modification and especially on the position 4 of the 
ring. In order to extend the scope of this process, many efforts have been made to 
synthesize different novel fused pyridazines. 
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Figure 3. Biologically active fused pyridazine derivatives. 
 
2. Results and discussion 
The development of a library of pyridazine derivatives has been envisioned based on 
the methodology described by Neurogen in 2004.
18
 The starting material was the diethyl 
acetone dicarboxylate 3.11, which was subjected to a diazo transfer reagent to obtain 
3.12. The diazo derivative 3.12 was then converted to a phosphazine 3.13 with triphenyl 
phosphine (equilibrium) and directly heated in a mixture of acetic acid and water at 
105°C to afford the desired pyridazine 3.14 in moderate yield over two steps. A final 
chlorination with POCl3 led to the key intermediate 3.15, the pyridazine obtained can be 
modified in a site selective way, in fact three points of substitution became available, 
the ester group at position 3 and the two chlorides at position 4 and position 6.  
p-ABSA, Et3N
acetonitrile
2h, RT
EtO
O O
OEt
O
EtO
O O
OEt
O
N2
EtO
O O
OEt
O
N
N
PPh3
PPh3
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AcOH/H2O
24h, reflux
N
N
HO
OEt
OOH
POCl3
4h, reflux N
N
Cl
OEt
OCl
3.11 3.12 3.13
3.14 3.15
85%
30% 75%
 
Scheme 1. Synthesis of 4,6-dichloro-3-ethoxycarbonyl pyridazine. 
 
Some examples in literature have shown that the reactivity of the position 4 towards 
nucleophilic substitution is favorised compared to the position 6,
19
 thus a nucleophilic 
substitution has been chosen to be the first step, followed by a Suzuki palladium cross-
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coupling at the position 6 and finally the formation of an amide to get the desired 
product 3.16.  
N
N
Cl
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OCl
R1NH2
N
N
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R1
R2B(OH)2
SNAr Pd coupling
N
N
R2
OEt
ONH
R1
N
N
R2
N
H
ONH
R3
R1
a. Saponification
b. Amide coupling
3.163.15
Scheme 2. Synthesis of 3.16 from 4,6-dichloro-3-ethoxycarbonyl pyridazine 3.15. 
 
A first attempt of nucleophilic substitution with m-anisidine has been done but the 
LC/MS  analysis showed a mixture of two products with the same mass, the two 
isomers have been synthesized without selectivity. Unfortunately, no isolation of 3.17a 
and 3.17b was possible. 
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Scheme 3. Nucleophilic substitution with m-anisidine. 
 
From this observation, a methodology allowing the introduction of substituents in a 
site selective way was highly desirable. The synthesis of a pyridazine already 
substituted at one of the position (4 or 6) could be very interesting for the rest of the 
synthesis, with a short retrosynthetic study, we can see that it is easier to introduce a 
variation at the position 6 than 4 because C6 is involved in the final cyclization with the 
diazo group. 
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Scheme 4. Retrosynthetic study. 
 
In our search for operationally simple processes, we have investigated a new method 
to prepare pyridazines under mild conditions. It has been decided to replace one of the 
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ester groups of diethyl acetone dicarboxylate 3.11 by a ketone to facilitate the 
cyclization reaction. However, the diazo transfer reaction may then occur at two 
positions. One position can be privileged by the introduction of an alcohol group instead 
of an ester group or a ketone. Thus, the replacement of 3.14 by a novel intermediate 
3.18 could be of high value and in order to synthesize this pyridazine, it was necessary 
to modify the starting material 3.11. By using an aldol reaction developed by Weiler
20
 
based on the dianion of the methyl acetoacetate 3.19, it is possible to introduce a 
substituted alcohol instead of an ester group and to obtain a -hydroxy ketoester 3.20. 
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O O
25-60%
O
O O
R1
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a.NaH, THF
b.BuLi, THF
R1CHO, THF
Methyl acetoacetate
3.19 3.20
2h, -78°C
O
OM OM
Weiler dianion
5h, -78°C
 
Scheme 5. Weiler dianion chemistry. 
 
The formation of the dianion is generated from the treatment of the methyl 
acetoacetate with first one equivalent of sodium hydride followed by one equivalent of 
n-BuLi at -78°C, after 1 hour of reaction, an aldehyde was added to afford the -
hydroxy ketoester 3.20.  
Prompted by the need for a more reliable and versatile preparation of pyridazines 
allowing the introduction of various substituents such as alkyls, cycloalkyls, aryls, and 
heteroaryls, we envisioned a more convenient synthesis of 6-substituted-4-hydroxy-3-
methoxycarbonyl pyridazines starting from methyl acetoacetate 3.19. The synthesis of a 
new pyridazine derivative has been developed in four steps with moderate to good 
yields. To the best of our knowledge, the only existing procedure leading to 3-
alkoxycarbonyl-4-hydroxy-6-substituted pyridazines 3.18 is the one developed by 
Zelesov et al. starting from furan-4,5-dione.
21
 However, this method is limited to the 
synthesis of aryl substituted compounds at the C6 position, such as compound 3.21. 
Importantly, and of particular value for the development of a versatile method for the 
synthesis of pyridazine derivatives, is that the obtained compounds can be further 
modified in a site-selective way. For example, selective reaction of 4,6-dichloro 
pyridazine 3.15 at positions 4 and 6 was problematic as previously discussed.  
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Figure 4. Pyridazine derivatives. 
 
The synthesis starts with the reaction of Weiler dianion
22
 of methyl acetoacetate 
3.19 with an aldehyde, which led to the -hydroxy ketoester 3.20 in moderate yields. 
These aldol products are easily degraded (water elimination) to give the corresponding 
enone. After treatment of 3.20 with p-ABSA (p-acetamido benzene sulfonyl azide) in 
acetonitrile, the diazo derivative 3.22 was obtained in good yields.
23
 A mild oxidation of 
3.22 using IBX (1-hydroxy-1,2-benziodoxol-3(1H)-one 1-oxide)
24
 in acetonitrile for 2h 
under reflux led to the corresponding -diazo--ketoester 3.23 in good yields. The final 
stages of the synthesis (the formation of phosphazine and the subsequent diaza-Wittig 
reaction) occur as a tandem process to obtain the pyridazine 3.24 in moderate to good 
yields.  
This procedure allowed the introduction of different groups at the C6 position of the 
pyridazine ring, such as alkyls, cycloalkyls, aryls and heteroaryls by selecting the 
appropriate aldehyde as starting material. In this respect this procedure proved to be 
more selective than a strategy based on palladium cross-coupling. 
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Scheme 6. Synthesis of 6-substituted-4-hydroxy-3-methoxycarbonyl pyridazines. 
 
We observed that better yields were obtained with alkyl aldehydes or cycloalkyl 
aldehydes than with aryl aldehydes and heteroaryl aldehydes. In order to cover a wide 
variety of substitutions, different attempts using aryl aldehydes containing electron 
withdrawing groups like p-nitrobenzaldehyde have been explored but did not give the 
required -hydroxy ketoester 3.22 in our hands. 
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Table 1. Synthesis of 6-substituted-4-hydroxy-3-methoxycarbonyl pyridazines.
a
 
entry 
aldehyde  
derivative 
pyridazine  
yield of 3.24 
(%)
b
 
1 propionaldehyde  
N
N
OH
O
O
 
3.24a 68 
2 isobutyraldehyde  
N
N
OH
O
O
 
3.24b 75 
3 
cyclohexane 
carboxaldehyde  N N
OH
O
O
 
3.24c 62 
4 benzaldehyde 
N
N
OH
O
O
 
3.24d 60 
5 p-anisaldehyde 
N
N
OH
O
O
O  
3.24e 45 
6 2-furfural 
N
N
OH
O
O
O  
3.24f 27 
7 
thiophene-2-
carboxaldehyde N N
OH
O
O
S  
3.24g 33 
a
All reactions were performed using 1 mmol of 3.22 and 364 mg of IBX in refluxing acetonitrile for 2 
hours, followed by a filtration to obtain the corresponding -diazo--ketoester. The crude compound was 
stirred with 183 L of HMPT in dichloromethane for 16 hours. bIsolated yield. 
 
Due to the low yields of the first step of the procedure and the toxicity of the 
HMPT
25
 used for the Diaza Wittig reaction, an improvement of the method to 
synthesize versatile pyridazines has been investigated. Calter et al.
26
 described an aldol 
reaction from -diazo--ketoester 3.25 using titanium chloride to afford the diazo 
derivative 3.22 directly in good yields. In fact, while the diazo transfer reaction was 
done directly on 3.19 followed by the titanium aldol reaction with appropriate aldehyde, 
3.22 was obtained in better yields than the initial method. 
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Scheme 7. Synthesis of 3.22 with the Calter’s method. 
 
The replacement of the HMPT by a safer reagent was then the most important 
modification to do, different phosphines have been screened to convert the derivative 
3.22d into the pyridazine 3.24d after oxidation with IBX. A first attempt to replace 
HMPT by triphenyl phosphine was not successful. In fact, after two days of reaction in 
diethyl ether at room temperature, no -diazo--ketoester 3.23d was converted into the 
corresponding pyridazine (Table 2, entry 2). An increase of the temperature to 60°C by 
using tetrahydrofuran as a solvent led to the same result (Table 2, entry 3). By using 
triethyl phosphite, the pyridazine was obtained in a lower yield than with HMPT (Table 
2, entry 4). Triethyl phosphine allowed the formation of the pyridazine in 5 hours in 
dichloromethane (Table 2, entry 5). Due to the toxicity and facile oxidation of triethyl 
phosphine,
27
 the tributyl phosphine was explored and the pyridazine was obtained in 
less than 1 hour at room temperature (Table 2, entry 6) in good yields. Diisopropyl ether 
(i-Pr2O) proved to be the best solvent for this reaction, allowing to obtain the pyridazine 
3.24d as precipitate in less than 30 minutes in high yields (Table 2, entry 8). This 
modification represents an improved and safe method for the synthesis of the pyridazine 
derivatives 3.24. 
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Table 2. Influence of phosphines and solvents on the Diaza-Wittig reaction.
a
 
O
O O OH
N2 N
N
O
OOH
3.22d 3.24d
a.IBX, acetonitrile, 2h, reflux
b.Phosphine, solvent, time, temperature
 
entry phosphine solvent conditions yield of 3.24d (%)
b
 
1 HMPT CH2Cl2 16 h, RT 60
 c
 
2 P(Ph)3 Et2O 48 h, RT -
 d
 
3 P(Ph)3 THF 16 h, 60°C -
 d
 
4 P(OEt)3 CH2Cl2 16 h, RT 37
 c
 
5 P(Et)3 CH2Cl2 5 h, RT 52
 c
 
6 P(n-Bu)3 CH2Cl2 1 h, RT 58
 c
 
7 P(n-Bu)3 Et2O 30 min, RT 53
 c
 
8 P(n-Bu)3 i-Pr2O 30 min, RT 70
 e
 
a
All reactions were performed using 1 mmol of 3.22d and 364 mg of IBX in refluxing acetonitrile for 2 
hours, followed by a filtration to obtain the -diazo--ketoester. The crude compound was stirred with 
183 L of phosphine following the conditions described above. bIsolated yield. cPurification by flash 
column chromatography on silica gel. 
d-diazo--ketoester 3.23d recovered. ePrecipitation of 3.24d. 
 
These two modifications led to an improved and safe method for the synthesis of 
pyridazine derivatives. 
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Scheme 8. Improved method for the synthesis of pyridazine derivatives. 
 
Invariable, the use of P(n-Bu)3 gives higher yields of pyridazines than while using 
HMPT. Most of the derivatives were obtained as precipitate (Table 3, entry 1-3) in less 
than 30 minutes of reaction. 
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Table 3. Synthesis of 6-substituted-4-hydroxy-3-methoxycarbonyl pyridazines.
a
 
entry 
aldehyde  
derivative 
pyridazine  
yield of 12 (%)
b
 
(HMPT 
method) 
yield of 12 (%)
b
 
(P(n-Bu)3 
method) 
1 propionaldehyde 
N
N
OH
O
O
 
3.24a 68
 c
 85
 d
 
2 
cyclohexane 
 carboxaldehyde N N
OH
O
O
 
3.24c 62
 c
 72
 d
 
3 benzaldehyde 
N
N
OH
O
O
 
3.24d 60
 c
 70
 d
 
4 2-furfural 
N
N
OH
O
O
O  
3.24f 27
 c
 35
 c
 
a
All reactions were performed using 1 mmol of 3.22 and 364 mg of IBX in refluxing acetonitrile for 2 
hours, followed by a filtration to obtain the corresponding -diazo--ketoester. The crude compound was 
stirred with 183 L of HMPT in dichloromethane for 16 hours (HMPT method) or with 250 L of P(n-
Bu)3 in i-Pr2O for 30 minutes (P(n-Bu)3 method). 
b
Isolated yield. 
c
Purification by flash column 
chromatography on silica gel. 
d
Precipitation of 3.24. 
 
Pyridazine 3.24 was subjected to chlorination to get 3.26 followed by a nucleophilic 
substitution to afford compound 3.27. Different amines have been used for the 
nucleophilic substitution from aliphatic amines and cycloalkyl amines introduced in a 
couple of hours to aromatic amines which needed more than 16 hours of reaction, both 
of the introduction have been done in refluxing dioxane with triethylamine as base. 
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80-90%
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N
N
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3.24
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50-85%
POCl3
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O
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Scheme 9. Nucleophilic substitution on pyridazines. 
 
 The yields obtained were better with aliphatic and cyclalkyl amines than 
aromatic amines. 
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Table 4. Substrate scope of the nucleophilic substitution on pyridazine derivatives.
a
 
entry 
starting 
material 
amine pyridazine  yield (%)
b
 
1 3.24d NH2  
N
N
O
ONH
 
3.27a 85 
2 3.24
e
 NH2  
N
N
O
ONH
MeO  
3.27b 83 
3 3.24d 
NH
O  
N
N
O
ON
O
 
3.27c 83 
4 3.24f 
NH2  
N
N
O
ONH
O  
3.27d 75 
5 3.24b 
NH2
NO
O
 
N
N
O
ONH
NO
O
 
3.27e 68 
6 3.24d 
NH2
 N
N
O
ONH
 
3.27f 52 
7 3.24c 
NH2
 N
N
O
ONH
 
3.27g 57 
8 3.24g 
NH2
 N
N
O
ONH
S  
3.27h 50 
9 3.24a 
OMe
OMe
MeO
NH2
 
N
N
O
ONH
OMe
MeO
MeO
 
3.27i 62 
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10 3.24d 
OMe
OMe
MeO
NH2
 N
N
O
ONH
OMe
MeO
MeO
 
3.27j 56 
a
All reactions were performed using 1 mmol of 3.24, 1.1 mmol of amine and 181 L of triethylamine in 
refluxing dioxane until completion of the reaction monitored by TLC. 
b
Isolated yield. 
 
The last part of the synthesis was the formation of an amide bond, two different 
methods have been attempted. First, 3.27 has been converted to the corresponding 
carboxylic acid 3.28 by saponification and then coupled with various amines with an 
amide coupling reagent to get 3.29.  
 
 
Scheme 10. Saponification and amide coupling. 
 
Unfortunately the saponification was low yielding and the work has been directed 
towards a method converting directly the ester group into amides. The most convenient 
way was the use of DABAL-Me3 developed by the Woodward group,
28
 this reagent is a 
safe alternative to the dangerous trimethyl aluminium. DABAL-Me3 is an adduct of 
trimethylaluminum and DABCO that is a free-flowing solid that can be manipulated 
without the need for an inert atmosphere. 
 
N
N
AlMe3
AlMe3
DABAL-Me3  
Figure 5. DABAL-Me3, direct amide formation reagent. 
 
Novak et al. described a good yielding direct amide formation
29
 from unactivated 
esters and amines, this method has been applied to derivative 3.27 to obtain amide 3.29, 
different amines were used such as aliphatic amines, cycloalkyl amines and 
(hetero)aromatic amines. 
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3.27
30-50%N
N
R1
O
ONH
R2
THF, 24h-96h, reflux
R3NH2, DABAL-Me3
N
N
R1
N
H
ONH
R3
R2
3.29  
Scheme 11. Amide formation with Dabal-Me3. 
 
The synthesis of a library of novel pyridazine derivatives 3.29 has been built with 
three different points of substitution.  
 
Table 5. Substrate scope of the amide formation.
a
 
entry 
starting 
material 
amine pyridazine  yield (%)
b
 
1
c
 3.27a 
OMe
OMe
MeO
NH2
 
N
N
N
H
ONH
OMe
OMe
OMe
 
3.29a 37 
2
c
 3.27b 
NH
O  N
N
N
ONH
MeO
O
 
3.29b 43 
3
c
 3.27b 
NH2
F  
N
N
N
H
ONH
MeO
F
 
3.29c 38 
4
c
 3.27b N
NH2
 
N
N
N
H
ONH
MeO
N
 
3.29d 32 
5
c
 3.27d 
NH2
F  N
N
N
H
ONH
O
F
 
3.29e 35 
6
c
 3.27e 
NH2
F  
N
N
N
H
ONH
NO
O
F
 
3.29f 41 
7
c
 3.27e N
NH2
 
N
N
N
H
ONH
NO
O
N
 
3.29g 30 
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8
c
 3.27f 
NH2  
N
N
N
H
ONH
 
3.29h 47 
9
c
 3.27f 
NH
O  
N
N
N
ONH
O
 
3.29i 50 
10
c
 3.27f 
NH2
F  N
N
N
H
ONH
F
 
3.29j 47 
11
c
 3.27f N
NH2
 N
N
N
H
ONH
N
 
3.29k 33 
12
c
 3.27g 
H2N  
N
N
N
H
ONH
 
3.29l 48 
13
c
 3.27g 
NH
O  
N
N
N
ONH
O
 
3.29m 44 
14
c
 3.27g 
NH2
F  N
N
N
H
ONH
F
 
3.29n 39 
15
c
 3.27g N
NH2
 N
N
N
H
ONH
N
 
3.29o 31 
16
d
 3.27i H2N  
N
N
N
H
ONH
OMe
MeO
MeO
 
3.29p 60 
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17
d
 3.27i 
NH
O  
N
N
N
ONH
OMe
MeO
MeO
O
 
3.29q 56 
18
d
 3.27j 
NH
O  
N
N
N
ONH
OMe
MeO
MeO
O
 
3.29r 51 
19
d
 3.27j 
NH2
F  N
N
N
H
ONH
OMe
MeO
MeO
F
 
3.29s 35 
a
Two methods have been used for the synthesis of amides. 
b
Isolated yield. 
c
1.5 mmol of amine and 385 
mg of Dabal-Me3 were stirred at 40 °C for 1 hour, after which 0.5 mmol of 3.27 was added. The reaction 
mixture was refluxed in THF until completion of the reaction monitored by TLC. 
d
To a solution of 0.5 
mmol of 3.27 in MeOH/water was added 200 mg of sodium hydroxyde dissolved in water, the reaction 
was heated at 80 °C for 16 hours. After an acidic workup and evaporation to the carbolylic acid derivative 
3.28, the crude was used directly without further purification. To a solution of 3.28 in THF was added 83 
L of triethylamine, followed by 209 mg of TBTU and 0.75 mmol of amine. The reaction was stirred at 
room temperature until completion of the reaction monitored by TLC. 
 
4-aryl pyridazines are known to be biologically active compounds towards different 
receptors,
30
 in order to expand the library, a Suzuki palladium cross-coupling has been 
done between 3.26b and phenyl boronic acid. The yield obtained for 3.30 was low and 
no optimization was attempted, 3.30 was directly used for the formation of amides with 
Dabal-Me3 to afford 3.31. 
3.26b
88%
3.30
N
N
O
OOH
3.24b
Dioxane, 48h, reflux
34%
POCl3
4h 95°C N
N
O
OCl
PhB(OH)2
N
N
O
O
38%
THF, 24h-96h, reflux
R3NH2, DABAL-Me3
N
N
N
H
O
3.31a
N
N
N
H
O
3.31b
N
F
Pd(dppf)Cl2, K3PO4
33%  
Scheme 12. Synthesis of 4-aryl pyridazine derivatives 3.31. 
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Based on this novel methodology developed for the synthesis of pyridazine 
derivatives bearing an ester group, a different starting material has been chosen to 
deliver a pyridazine bearing a ketone group, an interesting intermediate to access novel 
fused pyridazines. 
For the building of pyridazines bearing a 3-keto group, starting material of type 3.32 
is needed. This approach will, likewise, allow us to obtain pyridazine derivatives, useful 
for the formation of new bicyclic heterocycles. 
 
O
O O
3.25
R1
O O
3.32
Replaced by
N2 N2
R1= aryl, heteroaryl  
Figure 6. Diazo derivatives. 
 
The reaction scheme starts with the synthesis of -hydroxy ketone. In order to avoid 
any side reaction during the synthetic route, R1 has been chosen to be an aryl or 
heteroaryl group. Different methods for the synthesis of 1,3-diketone have been 
described in the past.
31
 We have followed two different approaches. The first one is 
based on L-proline organocatalysis discovered by List et al..
32
 This strategy was applied 
on aldehydes bearing an electron withdrawing group (nitro group and cyano group) 3.33 
to afford -hydroxy ketone 3.34. The final -diazo-1,3-diketone 3.35 was obtained by 
mild oxidation with IBX, followed by a diazo transfer reaction with p-ABSA. However, 
when using other aldehydes, the reaction becomes slow and at least one day of reaction 
is required to afford the corresponding -hydroxy ketone.33 
Therefore, for the other -diazo-1,3-diketone derivatives, a strategy based on the 
Mukaiyama aldol reaction
34
 has been used. The acetophenone derivative 3.36 was 
converted to the corresponding silyl enol ether at -78 °C with LiHMDS and 
trimethylsilyl chloride. The silyl enol ether from 3.36 reacted with acetaldehyde or 
propionaldehyde in the presence of titanium tetrachloride to afford 3.37. The desired 
diazo compound 3.38 was obtained after oxidation with IBX and diazo transfer reaction 
with p-ABSA. 
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H
O
R
OH
R
O
L-proline 25%
DMSO/acetone (4/1)
3.33a, R= NO2
3.33b, R= CN
5h, RT
O
R
O
N2
a.IBX, CH3CN, 2h, reflux
b.p-ABSA, Et3N, CH3CN, 2h, RT
3.35a, R= NO2
3.35b, R= CN
3.34a, R= NO2
3.34b, R= CN
R= NO2, 57%
R= CN, 55%
R= NO2, 85%
R= CN, 77%
O O OH
3.36a 3.37a
O O
3.38a
S S Sa.LiHMDS, TMSCl, THF, 2h, -78°C
b.TiCl4, acetaldehyde, THF, 5h, -78°C
a.IBX, CH3CN, 2h, reflux
b.p-ABSA, Et3N, CH3CN, 2h, RT N2
63% 87%
O O OH
3.36b 3.37b
O O
3.38b
a.LiHMDS, TMSCl, THF, 2h, -78°C
b.TiCl4, propionaldehyde, THF, 5h, -78°C
a.IBX, CH3CN, 2h, reflux
b.p-ABSA, Et3N, CH3CN, 2h, RT N2
68% 81%Cl ClCl
O O
89%
p-ABSA, Et3N
2h, RT
O O
N2
3.39 3.40
CH3CN
 
Scheme 13. Synthesis of -diazo-1,3-diketone. 
 
A commercially available reagent 3.39 was used to synthesize the -diazo-1,3-
diketone 3.40 by a Regitz reaction with p-ABSA. Five different -diazo-1,3-diketones 
3.35a, 3.35b, 3.38a, 3.38b and 3.40 became available in this way. 
 
The -diazo-1,3-diketone derivatives were used for the synthesis of pyridazines. 
The first step was the titanium aldol reaction to afford the -hydroxy--diazo diketone 
3.41. Derivative 3.41 was oxidized with IBX in refluxing acetonitrile. The crude 
product was used without further purification in the Diaza-Wittig reaction. Treatment 
with tributyl phosphine in diisopropyl ether for 30 minutes led to the desired pyridazine 
3.42 bearing a ketone group at position 3. 
 
R1
O O
N2
R1
O O
N2
R3
OH
N
N
OH
R3
O
R1R2
R2
R2a.TiCl4, Et3N
b.R3CHO
THF, 5h, -78°C
50-85%
R1= aryl, heteroaryl
R2= H, methyl
R3= alkyl, cycloalkyl, aryl, heteroaryl
a.IBX, CH3CN, 2h, reflux
45-60%
b.PBu3, i-Pr2O, 30min, RT
3.41a-i 3.42a-i3.35a, 3.35b, 3.38a, 
3.38b, 3.40
 
Scheme 14. Synthesis of pyridazine derivatives bearing a ketone group. 
 
This strategy led to the synthesis of nine novel pyridazine derivatives covering 
different substitutions, such as several aryl ketones (Table 3, entry 1-3, 5-9) and a 
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heteroaryl ketone (Table 3, entry 4). On the pyridazine ring, it was possible to introduce 
various R3 groups such as alkyl (Table 3, entry 1, 2, 4, 5, 9), cycloalkyl (Table 3, entry 
8), aryl (Table 3, entry 3, 7) and heteroaryl (Table 3, entry 6). The use of 3.38b allowed 
the synthesis of a tetrasubstituted pyridazine (Table 3, entry 5) with R2 being a methyl 
group. 
 
Table 6. Synthesis of pyridazine derivatives bearing a ketone group at position 3.
a
 
entry -diazo-1,3-diketone 
 aldehyde 
derivative 
pyridazine 
 yield 
(%)
b
 
1 
O
O2N
O
N2
 
3.35a 
O
H  
N
N
OH O
NO2  
3.42a 60
 c
 
2 
O
NC
O
N2
 
3.35b 
O
H  
N
N
OH O
CN  
3.42b 57
 c
 
3 
O
NC
O
N2
 
3.35b 
O
H
F
 
N
N
OH O
CN
F  
3.42c 45
 d
 
4 
O O
S
N2  
3.38a 
O
H  
N
N
OH O
S
 
3.42d 55
 c
 
5 
O O
N2
Cl  
3.38b 
O
H  
N
N
OH O
Cl  
3.42e 57
 c
 
6 
O O
N2  
3.40 
O
H
S  N
N
OH O
S  
3.42f 53
 d
 
7 
O O
N2  
3.40 
O
H
 
N
N
OH O
 
3.42g 48
 d
 
8 
O O
N2  
3.40 
O
H
 
N
N
OH O
 
3.42h 52
 d
 
9 
O O
N2  
3.40 
O
H
 N
N
OH O
 
3.42i 55
 c
 
a
All reactions were performed using 1 mmol of 3.41 and 364 mg of IBX in refluxing acetonitrile for 2h, 
followed by a filtration to obtain the corresponding -diazo--ketoester. The crude compound was stirred 
with 250 L of P(n-Bu)3 in i-Pr2O for 30min at room temperature. 
b
Isolated yield. 
c
Precipitation of 3.42. 
 
d
Purification by flash column chromatography on silica gel. 
 
79 
 
It should be noted that these aldol products 3.41 are easily degraded (water 
elimination) to give the corresponding enone 3.43 (complete degradation of the crude 
product 3.41j, obtained from the titanium aldol reaction between 3.38a and p-methoxy 
benzaldehyde, into the enone 3.43 during the purification by flash chromatography on 
silica gel). 
O O
S
N2
OH
O
Crude 3.41j
Flash
chromatography
O O
S
N2
O
3.43
on silica gel
 
Scheme 15. Degradation of aldol into enone. 
 
The pyridazine analogues 3.42a-i have been subjected to different cyclization 
methods to obtain various fused pyridazines. 
 
N
N
OH
R3
O
R1
R2
R1= aryl, heteroaryl
R2= H, methyl
R3= alkyl, cycloalkyl, aryl, heteroaryl
R4= methyl, ethyl
3.42a-i
a.POCl3, 4h, 95°C
75-87%
b.Hydrazine hydrate 64%, EtOH, 4h, reflux N
N
HN
R3
N
R1R2
3.44a-f
Method A
N
N
OH
R3
O
R1
R2
3.42a-i
a.POCl3, 4h, 95°C
33-52%
b.Methyl thioglycolate, EtOH, 16h, reflux N
N
S
R3
R1R2
3.45a-d
Method B
O
O R4
N
N
OH
R3
O
R1
R2
3.42a-i
a.POCl3, 4h, 95°C
77-82%
b.Ethylene diamine, EtOH, 16h, reflux N
N
R3
R2
3.46a-h
Method C
NHN
R1
N
N
OH
R3
O
R1
R2
3.42a-i
a.POCl3, 4h, 95°C
46-61%
b.NH2OH-HCl, EtOH/pyridine (5/1), 16h, reflux N
N
R3
R2
3.47a-b
Method D
NO
R1
c.NaH, THF, 2h, 40°C
 
Scheme 16. Synthesis of fused pyridazines by 4 different methods (A, B, C, D). 
 
The first scaffold investigated was the pyrazolo[4,3-c]pyridazine 3.44. After 
chlorination of 3.42 with phosphorous oxychloride, the crude product was refluxed with 
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hydrazine hydrate in ethanol for 4 hours to lead to the desired product 3.44 (method A). 
A condensation of the methyl thioglycolate on the chlorinated pyridazine in refluxing 
ethanol for 16 hours led to the thieno[3,2-c]pyridazine 3.45 (method B). 
In our search for novel scaffolds, we described the first synthesis of 6,7-dihydro-5H-
pyridazino[4,3-e][1,4]diazepine 3.46. Treatment of 3.42 with POCl3, followed by a 
cyclization with ethylene diamine in refluxing ethanol for 16 hours, led to the fused 
pyridazine 3.46 (method C). Another novel scaffold that was synthesized with this 
strategy, is isoxazolo[4,5-c]pyridazine 3.47. The ketone of the chlorinated pyridazine 
was converted into an oxime with hydroxylamine hydrochloride and finally cyclized by 
heating at 40 °C for 2 hours with sodium hydride in tetrahydrofuran to afford 3.47 
(method D). 
 
Table 7. Synthesis of fused pyridazine analogues. 
entry pyridazine  method 
fused  
pyridazine 
 
yield 
(%)
a
 
1 
N
N
OH O
NO2  
3.42a B
 b
 
N
N
S
NO2
O
O
 
3.45a 52 
2 
N
N
OH O
NO2  
3.42a C
 c
 
N
N
NO2
NHN
 
3.46a 77 
3 
N
N
OH O
CN  
3.42b A
 d
 
N
N
HN N
CN
 
3.44a 83 
4 
N
N
OH O
CN
F  
3.42c A
 d
 
N
N
HN N
CN
F  
3.44b 79 
5 
N
N
OH O
CN
F  
3.42c C
 c
 
N
N
CN
NHN
F  
3.46b 79 
6 
N
N
OH O
S
 
3.42d B
 b
 
N
N
S S
O
O
 
3.45b 38 
7 
N
N
OH O
S
 
3.42d C
 c
 
N
N
N
S
HN
 
3.46c 81 
81 
 
8 
N
N
OH O
Cl  
3.42e A
 d
 
N
N
HN N
Cl
 
3.44c 87 
9 
N
N
OH O
Cl  
3.42e C
 c
 
N
N
Cl
NHN
 
3.46d 82 
10 
N
N
OH O
Cl  
3.42e D
 e
 
N
N
O N
Cl
 
3.47a 61 
11 
N
N
OH O
S  
3.42f A
 d
 
N
N
HN N
S  
3.44d 81 
12 
N
N
OH O
S  
3.42f B
 b
 
N
N
S
S
O
O
 
3.45c 33 
13 
N
N
OH O
S  
3.42f C
 c
 
N
N
S
NHN
 
3.46e 79 
14 
N
N
OH O
S  
3.42f D
 e
 
N
N
O N
S  
3.47b 46 
15 
N
N
OH O
 
3.42g A
 d
 
N
N
HN N
 
3.44e 79 
16 
N
N
OH O
 
3.42g B
 b
 
N
N
S
O
O
 
3.45d 41 
17 
N
N
OH O
 
3.42g C
 d
 
N
N
NHN
 
3.46f 77 
18 
N
N
OH O
 
3.42h C
 c
 
N
N
NHN
 
3.46g 79 
19 
N
N
OH O
 
3.42i A
 d
 
N
N
HN N
 
3.44f 75 
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20 
N
N
OH O
 
3.42i C
 c
 
N
N
NHN
 
3.46h 78 
a
Isolated yield. 
b
Synthesis of thieno[3,2-c]pyridazine 3.45 with method B, see the experimental section 
for details.
 c
Synthesis of 6,7-dihydro-5H-pyridazino[4,3-e][1,4]diazepine 3.46 with method C, see the 
experimental section for details.
 d
Synthesis of pyrazolo[4,3-c]pyridazine 3.44 with method A, see the 
experimental section for details. 
e
Synthesis of isoxazolo[4,5-c]pyridazine 3.47 with method D, see the 
experimental section for details. 
 
During the previous paragraphs, the synthesis of new pyridazine derivatives bearing 
an ester group then a ketone group have been discussed, in order to cover different 
functional groups at the position 3 of the pyridazine, some efforts have been done to 
synthesize a pyridazine bearing a sulfonyl group. The first idea was the use of a sulfonyl 
acetone 3.47 containing an aryl substituent and the application of the strategy previously 
described. 
S
O O
3.47
O
Ar
sulfonyl acetone
Ar= aryl group  
Figure 7. Sulfonyl acetone containing an aryl group. 
 
Some sulfonyl acetone derivatives are commercially available but a strategy 
covering the synthesis of 3.47 could be more convenient in case of particular aryl 
groups. The method privileged for the synthesis involved the use of sodium salt of the 
sulfinic acid obtained from the corresponding sulfonyl chloride. 
The first step was the reduction of sulfonyl chloride 3.48 into the sulfinic acid 
sodium salt 3.49 with sodium sulfite and sodium hydrogenocarbonate in refluxing 
water.
35
 The intermediate 3.49 was treated with chloro acetone 3.50 in DMF at room 
temperature for 16 hours to afford the sulfonyl acetone 3.51, then a similar chemistry 
than the Weiler dianion previously discussed was applied to 3.51. The dianion 
chemistry was used to perform an aldol reaction with an aldehyde but instead of using 
sodium hydride then butyl lithium to generate the dianion, two equivalents of lithium 
diisopropyl amide
36
 were necessary before the addition of aldehyde to obtain the -
hydroxy ketone 3.52. A diazo transfer reaction has been applied on 3.52 to get the -
hydroxy--diazo ketone 3.53, followed by an oxidation with IBX in acetonitrile and the 
diaza Wittig reaction leading to novel sulfonyl pyridazine derivatives 3.54. 
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Scheme 17. Synthesis of sulfonyl pyridazine derivatives. 
 
Table 8. Synthesis of sulfonyl pyridazine derivatives.
a
 
entry sulfonyl acetone 
 aldehyde 
derivative 
pyridazine 
 yield 
(%)
b
 
1 
S
O
O
O
 
3.51 
O
H  
N
N
S
OH O
O
 
3.54a 40 
2 
S
O
O
O
 
3.51 
O
H
MeO  
N
N
S
OH O
O
MeO  
3.54b 29 
3 
S
O
O
O
 
3.51 
O
H
S  N
N
S
OH O
O
S  
3.54c 20 
a
All reactions were performed using 1 mmol of 3.53 and 364 mg of IBX in refluxing acetonitrile for 2h, 
followed by a filtration to obtain the corresponding -diazo--ketoester. The crude compound was stirred 
with 250 L of P(n-Bu)3 in i-Pr2O for 30min at room temperature. 
b
Isolated yield. 
 
The second part of the synthesis was the introduction of different groups at the 
position 4 of the pyridazine like the previous work by doing a chlorination of 3.54 and a 
nucleophilic substitution to have compound like 3.56 to start a library of sulfonyl 
pyridazines. Unfortunately, the chlorination attempts did not give the desired compound 
and instead of expected chlorinated derivative 3.55, different side products appeared on 
TLC, but no separation has been done due to the complexity of the mixture.  
One possible explanation is that the sulfonyl group itself is a leaving group, and 
could have been involved during the chlorination step, moreover the position of the 
sulfonyl group on the pyridazine (position 3) could have played a detrimental role due 
the high reactivity of leaving group on this position. In fact, in pyridazine chemistry it is 
known that nucleophilic substitution is favorised at position 4, then position 3 and 
finally position 6, all these assumptions led us to think about other ways of introducing 
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variations on the sulfonyl pyridazine derivatives, and many efforts are currently under 
investigation to solve this problem. 
 
N
N
S
OH
R2
O
O
R1
3.54
POCl3
2h, 95°C
X
N
N
S
Cl
R2
O
O
R1
3.55
N
N
S
NH
R2
O
O
R1
3.56
Solvent, conditions
R3NH2
R3
 
Scheme 18. Attempt of chlorination on sulfonyl pyridazine derivatives. 
 
The most important reaction described during this chapter was the Diaza-Wittig 
reaction, at the beginning the HMPT was the reagent chosen to perform the cyclization 
to afford the pyridazine ring. A first improvement has been done to substitute this 
organophosphorus specie by a less toxic reagent, after a screening of different 
phosphines, P(n-Bu)3 led to the synthesis of pyridazine derivatives in shorter reaction 
time. By choosing the adequate solvent for the Diaza-Wittig reaction, it was possible to 
obtain the product as a precipitate in most of the cases. 
 
 
Scheme 19. Catalytic Diaza-Wittig reaction. 
 
In our search for innovative and safe pathways, the elaboration of a catalytic Diaza-
Wittig reaction became highly desirable. The first example of the synthesis of a 
heterocycle by using a catalytic amount of organophosphorus reagent was reported  in 
2008 by Marsden et al..
37
 An isocyanate group was needed to regenerate the phosphine 
oxide following a mechanism of activation, described by Campbell et al.,
38
 for the 
production of carbodiimides. 
Several important reactions are using organophosphorus reagents such as Appel 
reaction,
39
 Mitsunobu reaction
40
 or Wittig olefination,
41
 and numerous groups have been 
focused on the development of a catalytic approach of these reactions. Denton et al. 
reported the first example of catalytic phosphorus mediated dichlorination of epoxides 
under Appel reaction conditions.
42
 The group of O’Brien43 made a breakthrough in this 
field by introducing a mild reduction of phosphine oxide into the corresponding 
phosphine by using silane as reducing reagent in contrast to previously described harsh 
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conditions
44
 using lithium aluminium hydride, not compatible with all substrates. This 
reduction led to the first catalytic olefination reaction. A recent study
45
 has 
demonstrated that the choice of the phosphine oxide is critical to achieve the reduction 
by silane reagent. In fact, it was shown that cyclic phosphine oxide is effectively 
reduced compared to acyclic phosphine oxide such as triphenyl phosphine oxide. 5-
Membered phospholane gave better results and directed our work towards the use of the 
commercially available phospholene oxide 3.57 as catalyst. 
The development of a catalytic Diaza-Wittig reaction can be divided in a four-step 
catalytic process. The first step is the reduction of the phospholene oxide 3.57 into the 
corresponding phospholene 3.59 with a silane reagent 3.58. The second step is the 
formation of a phosphazine intermediate 3.60 from the reaction between 3.59 and a 
diazo derivative 3.22. Then the phosphazine 3.60 is converted into an oxazaphosphetane 
intermediate 3.61 prior to the last step leading to the desired pyridazine 3.24 and 
regeneration of the phospholene oxide 3.57. 
 
 
Scheme 20. Proposed catalytic cycle for the Diaza-Wittig reaction. 
 
The reduction of phosphine oxide into the corresponding phosphine with silane 
reagent has proved to be chemoselective in the presence of aldehyde or ketone but it is 
the first report of this reduction in the presence of a diazo group. The reduction of the 
phosphine oxide did not affect the diazo group and the cyclization leading to the 
pyridazine could be achieved. A study on the effect of the phosphine, silane, solvent, 
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temperature and reaction time has been performed on the conversion of 3.22a into 
3.24a.  
In order to prove that the original reaction with stoichiometric amount of HMPT 
(Table 9, entry 1) cannot be catalytic, the same reaction with 25% of phosphine has 
been run for 48 hours, never exceeding a yield of 15% (Table 9, entry 2). A reaction 
with a stoichiometric amount of HMPA demonstrated that phosphine oxide alone is not 
enough to obtain the pyridazine (Table 9, entry 3). Likewise, using catalytic amount of 
triphenyl phosphine oxide or HMPA with diphenylsilane led to no formation of 
pyridazine 3.24a (Table 9, entry 4-5). While varying the silane reagent and using a 
catalytic amount of phospholene oxide 3.57, the use of phenylsilane led to the formation 
of the desired product 3.24a in moderate yield (Table 9, entry 6). By using 
diphenylsilane, the pyridazine 3.24a was obtained in excellent yields and no purification 
was necessary due to the precipitation of the desired pyridazine after cooling down the 
reaction (Table 9, entry 11-12). As a control reaction, no formation of pyridazine 3.24a 
was observed in the absence of the silane reagent.  
The temperature seems to be an important parameter. When the reaction was 
performed in DCM at room temperature, like the reaction with HMPT, 3.24a was not 
formed (Table 9, entry 7). An increase of the temperature to 65 °C with acetonitrile as 
solvent did not give better results (Table 9, entry 8). A high temperature (100 °C) was 
needed to perform the first step of the catalytic process i.e. the reduction of 3.57 by the 
silane reagent. In DMF at 100 °C, it was possible to obtain 3.24a in moderate yield and 
purification by flash chromatography on silica gel was necessary (Table 9, entry 9). 
Toluene is the only solvent which gives 3.24a in excellent yields and without 
purification. A sealed tube was used to perform the reaction at 115 °C in toluene in 
order to reduce the reaction time but the product 3.24a was obtain in lower yield (Table 
9, entry 10). 
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Table 9. Evaluation of the phosphine, silane, solvent, temperature and reaction time on the catalytic 
Diaza-Wittig reaction.
a
 
O
OOOH
N2
b. Phosphine oxide, silane
solvent, time, temperature N
N
O
OOH
a.IBX, acetonitrile, 2h, reflux
3.22a 3.24a  
entry 
organophosphorus 
reagent 
silane solvent 
temperature 
(°C)
 b
 
time 
(hours) 
yield 
(%)
c
 
1 HMPT
d
 - CH2Cl2 RT 16 68
e
 
2 HMPT
f
 - CH2Cl2 RT 48 13
e
 
3 HMPA
d
 - CH2Cl2 RT 16 0 
4 O=PPh3
f
 Ph2SiH2 toluene 100 16 0 
5 HMPA
f
 Ph2SiH2 toluene 100 16 0 
6 3.57
g
 PhSiH3 toluene 100 16 46
e
 
7 3.57
g
 Ph2SiH2 CH2Cl2 RT 16 0 
8 3.57
g
 Ph2SiH2 CH3CN 65 16 0 
9 3.57
g
 Ph2SiH2 DMF 100 16 71
e
 
10 3.57
g
 Ph2SiH2 toluene 115
h
 16 64
i
 
11 3.57
g
 Ph2SiH2 toluene 100 16 92
i
 
12 3.57
g
 Ph2SiH2 toluene 100 48 95
i,j
 
13 3.57
g
 -
k
 toluene 100 16 0 
a
See experimental section. 
b
Temperature of the oil bath. 
c
Yield of isolated product is quoted as an average 
over at least two experiments. 
d
Stoichiometric amounts of organophosphorus reagent were used. 
e
Purification by flash chromatography on silica gel. 
f
Catalytic amounts (25 mol %) were used. 
g
Catalytic 
amounts (10 mol %) were used. 
h
Reaction was performed in a sealed tube at 115 °C. 
i
Precipitation of 2a. 
j
Addition of 10 mol % of 3 to the initial amount after 24 h of reaction. 
k
Control reaction without silane. 
 
The optimum conditions for the catalytic Diaza-Wittig reaction is the use of 10 mol 
% of 3.57 with diphenylsilane as reducing reagent in toluene at 100 °C for 16 hours. 
The amount of catalyst used so far was always 10 mol % of 3.57. To assess this novel 
method further, it was necessary to vary the loading of the phospholene oxide 3.57. The 
conversion of 3.22d into 3.24d was used for this optimization process. 
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Table 10. Optimization of the catalytic Diaza-Wittig reaction by varying the loading of the catalyst 3.57.
a
 
O
OOOH
N2
b. Catalytic Diaza-Wittig
N
N
O
OOH
a.IBX, acetonitrile, 2h, reflux
3.22d 3.24d  
entry loading of 3.57 (mol %) time (hours) yield (%)
b
 
1 1 36 51 
2 3 36 55 
3 5 36 69 
4 10 16 75 
5 25 16 78 
a
See experimental section for details. 
b
Yield of isolated product is quoted as an average over at least two 
experiments. 
 
The catalytic Diaza-Wittig reaction was performed following the optimum 
conditions previously discussed and the amount of catalyst 3.57 was varied. The use of 
3.22d as starting material led to the desired product 3.24d in 75% yield with 10 mol % 
of 3.57 (Table 10, entry 4). Increasing the amount of 3.57 to 25 mol % gave almost 
similar results (Table 10, entry 5), and a decrease below 10 mol % of the phospholene 
oxide 3.57 (Table 10, entry 2-3), likewise, led to product formation but in longer 
reaction time. The use of 1 mol % of catalyst 3.57 afforded 3.57 in 51% after 36 hours 
(Table 10, entry 1). 
We then focused on the synthesis of a small library of pyridazine derivatives 3.24 
and 3.42 to evaluate the catalytic Diaza-Wittig reaction with different substrates. 
 
Table 11. Substrate scope of the catalytic Diaza-Wittig reaction.
a
 
R3 R1
OOOH
N2
b. Catalytic Diaza-Wittig
N
N
R1
OOH
R3
a.IBX, acetonitrile, 2h, reflux
3.22, 3.41 3.24, 3.42
R2
R2
 
entry R1 R2 R3 product yield (%)
b
 
1 OMe H Et 3.24a 92
c
 
2 OMe H Ph 3.24d 75
c
 
3 OMe H Cyclohexyl 3.24c 79
d
 
4 OMe H 4-MeOC6H4 3.24e 78
c
 
5 OMe H 2-FC6H4 3.24h 82
c
 
6 OMe Me Et 3.24i 81
c
 
7 OMe Me Ph 3.24j 63
c
 
8 OMe Me Cyclohexyl 3.24k 75
d
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9 OMe Me 4-MeOC6H4 3.24l 70
c
 
10 OMe Me 2-FC6H4 3.24m 78
c
 
11 Ph H Ph 3.42g 53
c
 
12 Ph H i-Pr 3.42i 74
c
 
a
See supporting information for details. 
b
Yield of isolated product is quoted as an average over at 
least two experiments. 
c
Precipitation of the pyridazine. 
d
Purification by flash chromatography on silica 
gel. 
 
Most of the pyridazines were obtained as precipitate in good (Table 11, entry 11) to 
excellent yields (Table 11, entry 1). Only compounds 3.24c and 3.24k needed to be 
purified by flash chromatography on silica gel. The catalytic Diaza-Wittig reaction was 
compatible with different substitutions R3, from alkyl (3.24a, 3.42i), cycloalkyl (3.24c, 
3.24k) to aryl (3.24e, 3.24m). It was also possible to perform the reaction in the 
presence of different functional groups such as ester (3.24l) or ketone (3.42g). Finally, 
the cyclization gave access to trisubstituted (3.24h) and tetrasubstituted (3.24i) 
pyridazines by varying R2.  
In order to extend this novel catalytic method to other substrates, our work was 
directed to the synthesis of 1,4-benzodiazepine.
46
 The Diaza-Wittig reaction is based on 
the reaction between a diazo derivative and a carbonyl group to generate substituted 
hydrazone. The Aza-Wittig
47
 reaction leads to substituted imines from azido derivatives 
and carbonyl groups. In both cases the key reagent is the organophosphorus specie. 
From this observation, we decided to apply similar conditions as previously discussed, 
to perform a novel catalytic Aza-Wittig reaction to synthesize 1,4-benzodiazepine and 
especially the Diazepam
48
 used to treat anxiety or insomnia. 
The synthesis started with the EDCI amide coupling of 2-amino-5-chloro 
benzophenone 3.62 and azido acetic acid 3.63 at room temperature to lead to the azido 
acetamido derivative 3.64 in 88% yield. The next step is the intramolecular catalytic 
Aza-Wittig between the azide and the ketone. The 1,4-benzodiazepine 3.65 was 
obtained after purification by flash chromatography on silica gel in 77% yield. The final 
methylation of 3.65 with iodomethane afforded the Diazepam 3.66. 
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77%
MeI, NaH
3.62
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3.64
3.65 3.66
THF
16h, RT
52%
 
Scheme 21. Synthesis of Diazepam by a catalytic Aza-Wittig reaction. 
 
3. Biological evaluation 
The different libraries of pyridazine derivatives and related fused heterocycles 
developed in this chapter have been screened towards selected kinases of ongoing 
projects of Galapagos. The compounds were first tested in an enzymatic assay at 
constant concentration and for the analogues displaying an interesting percentage of 
inhibition for a specified kinase, a further assay was performed at different 
concentrations in order to obtain the half maximal inhibitory concentration IC50.    
Table 12. Biological evaluation of pyridazine derivatives (N/A not active). 
entry compounds 
CDK9 
(% inhibition 
at 10 M) 
IC50 (nM) 
TGF- II 
(% inhibition 
at 10 M) 
IC50 (nM) 
1 3.29a 5 N/A 16 N/A 
2 3.29b N/A N/A 4 N/A 
3 3.29c 27 N/A 10 N/A 
4 3.29d 94 290 9 N/A 
5 3.29e 9 N/A 13 N/A 
6 3.29f 53 N/A 16 N/A 
7 3.29g 14 N/A 21 N/A 
8 3.29h N/A N/A N/A N/A 
9 3.29i N/A N/A N/A N/A 
10 3.29j 15 N/A 9 N/A 
11 3.29k N/A N/A N/A N/A 
12 3.29l N/A N/A 5 N/A 
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13 3.29m 11 N/A 23 N/A 
14 3.29n N/A N/A N/A N/A 
15 3.29o 23 N/A 8 N/A 
16 3.29p 4 N/A 16 N/A 
17 3.29q N/A N/A 4 N/A 
18 3.29r N/A N/A N/A N/A 
19 3.29s N/A N/A 21 N/A 
20 3.31a 52 N/A 5 N/A 
21 3.31b 16 N/A N/A N/A 
 
entry compounds 
GSK3 
(% inhibition 
at 20 M) 
IC50 (nM) 
IRAK4 
(% inhibition 
at 20 M) 
IC50 (nM) 
22 3.44a 78 ˃4000 55 ˃20000 
23 3.44b 92 783 76 ˃20000 
24 3.44c 87 ˃4000 95 3932 
25 3.44d 75 ˃4000 94 2150 
26 3.44e 83 ˃4000 97 1829 
27 3.44f 17 ˃20000 9 ˃20000 
28 3.45a 28 ˃20000 7 ˃20000 
29 3.45b N/A N/A N/A N/A 
30 3.45c 40 ˃20000 7 ˃20000 
31 3.45d 16 ˃20000 10 ˃20000 
32 3.46a 12 ˃20000 7 ˃20000 
33 3.46b 13 ˃20000 12 ˃20000 
34 3.46c N/A N/A N/A N/A 
35 3.46d 20 ˃20000 4 ˃20000 
36 3.46e 6 ˃20000 13 ˃20000 
37 3.46f 16 ˃20000 10 ˃20000 
38 3.46g 22 ˃20000 13 ˃20000 
39 3.46h 15 ˃20000 30 ˃20000 
40 3.47a 12 ˃20000 8 ˃20000 
41 3.47b 21 ˃20000 8 ˃20000 
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42 3.54a 30 ˃20000 13 ˃20000 
43 3.54b 39 ˃20000 10 ˃20000 
44 3.54c 22 ˃20000 9 ˃20000 
 
The first screening concerned the derivatives of pyridazine containing a substituted 
amide group 3.29. These analogues have been assayed towards CDK9 and TGF- II 
receptor and only the compound 3.29d displayed an interesting half maximal inhibitory 
concentration IC50 = 290 nM. Most of the other pyridazines did not lead to a percentage 
of inhibition higher than 50 % and thus have not been screened at different 
concentrations but it can be observed from 3.29d that an aliphatic amine substitutiuon 
such as ethylamine at the position 4 gave better response compared to cyccloalkyl or 
aryl amines. Moreover, the replacement of a N-linker at the position 4 of the pyridazine 
by an aryl directly connected without linker 3.31 did not improve the characteristic of 
the analogues. A series of fused pyridazine has been towards two different kinases the 
GSK3 and IRAK4, amongst them only the derivatives based on the pyrazolo[4,3-
c]pyridazine scaffold 3.44 have led to more than 70 % of inhibition at 20 M. Of 
particular interest, the compound 3.44b gave an IC50 value of 783 nM against GSK3 
and the compound 3.44e with an IC50 of 1829 nM towards IRAK4. The other libraries 
of fused rings 3.45, 3.46, 3.47 did not display significant biological activity. The three 
examples of sulfonyl pyridazine derivatives 3.54 did not give inhibition above 50 % for 
the two targeted receptors. 
4. Conclusion 
In conclusion, we have first developed a concise and convenient procedure for the 
synthesis of 6-substituted-4-hydroxy-3-methoxycarbonyl pyridazines 3.24 involving a 
Diaza-Wittig reaction as key-step, allowing the introduction of a variety of substitutions 
from alkyl, cycloalkyl to aryl and heteroaryl at the C6 position. This method, likewise, 
allows the synthesis of pyridazines with different substitutions at C4 and C6 positions, 
and a library has been synthesized varying three different points of substitutions to 
obtain pyridazine analogues 3.29 and 3.31.  
Then, the method has been improved by using the Calter method for the formation 
of the aldol intermediate 3.22 and 3.41, the second improvement was the replacement of 
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the toxic HMPT by P(n-Bu)3 to perform the Diaza-Wittig reaction in a shorter reaction 
time and with better yields.  
In a second part, based on the methodology developed and starting from 1,3-
diketones instead of methyl acetoacetate, it was possible to synthesize novel pyridazines 
bearing a ketone group 3.42 with different substituents at position 6. These pyridazine 
analogues were used for the development of a 20-member library of novel 
biheterocyclic compounds such as pyrazolo[4,3-c]pyridazine 3.44 and thieno[3,2-
c]pyridazine 3.45. It is also the first report dealing with the synthesis of 6,7-dihydro-5H-
pyridazino[4,3-e][1,4]diazepine 3.46 and isoxazolo[4,5-c]pyridazine 3.47. 
The synthesis of pyridazine bearing a sulfonyl group at the position 3 has also been 
elaborated following the same strategy and using sulfonyl acetone 3.51 as starting 
material but the synthesis of library was not possible due to the non-chlorination of the 
hydroxyl group of the pyridazine derivative 3.54. 
Finally, we reported the first catalytic Diaza-Wittig reaction and its application for 
the synthesis of pyridazine analogues 3.24 and 3.42. The reaction tolerated various 
substituents and functional groups and delivered most of the derivatives without 
purification. This methodology also led to a novel catalytic Aza-Wittig reaction and was 
applied to the synthesis of the 1,4-benzodiazepine Diazepam 3.66. These two methods 
represent new catalytic approaches to relevant heterocycles known as “privileged 
structures” for the pharmaceutical industry. 
 
5. Experimental section 
For all reactions, analytical grade solvents were used. All moisture-sensitive reactions were carried 
out in oven-dried glassware (135 ºC) under a nitrogen or argon atmosphere. Reaction temperatures are 
reported as bath temperature. Precoated aluminum sheets (Fluka Silica gel/TLC-cards, 254 nm) were used 
for TLC. Compounds were visualized with UV light (λ = 254 nm). Products were purified by flash 
chromatography on ICN silica gel 63-200, 60 Å. Melting points were obtained on a melting point 
apparatus Electrothermal IA9200 with open capillary tubes. 
1
H and 
13
C NMR spectra were recorded on 
300 MHz, 500 MHz and 600 MHz spectrometer using CDCl3 and DMSO-d6 as the solvent. The 
1
H and 
13C chemical shifts were referenced to residual solvent signals at δ H/C 7.26/77.00 (CDCl3), 3.31/49.10 
and 2.50/39.50 (DMSO-d6) relative to TMS as internal standard. Coupling constants J [Hz] were directly 
taken from the spectra. Splitting patterns are designated as s (singlet), d (doublet), t (triplet), q (quartet), 
m (multiplet) and br (broad). High resolution mass spectra were acquired on a quadrupole orthogonal 
acceleration time-of-flight mass spectrometer (Synapt G2 HDMS, Waters, Milford, MA). Samples were 
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infused at 3 µL/min and spectra were obtained in positive (or negative) ionization mode with a resolution 
of 15000 (FWHM) using leucine enkephalin as lock mass. Electrospray MS spectra were obtained on a 
Micromass platform LC/MS spectrometer. Column used for all LC/MS analysis: Waters Acquity UPLC 
BEH C18 1.7 m, 2.1 mm ID x 50 mm L. All the methods are using MeCN/H2O gradients. Water 
contains either 0.1 % TFA or 0.1 % NH3. 
 
Diethyl 2-diazo-3-oxopentanedioate (3.12) 
To a solution of compound 3.11 (1 g, 4.95 mmol) in 20 mL of acetonitrile under argon at 0 °C was added 
successively triethylamine (895 L, 6.44 mmol) and p-acetamido benzene sulfonyl azide (p-ABSA) (1.2 
g, 4.95 mmol). The reaction mixture was stirred for 2 hours and was allowed to warm to room 
temperature and was diluted with 100 mL of Et2O/n-Hexane (1:1) and then filtered. The filtrate was 
concentrated and the residue purified by flash column chromatography on silica gel (EtOAc/n-Hexane = 
1:2) to afford the desired compound 3.12 in 85% yield as yellow oil. Data for 3.12: 
1
H NMR (300 MHz, 
DMSO-d6) δ 4.24 (q, J = 7.4 Hz, 2H), 4.16 (q, J = 7.3 Hz, 2H), 3.78 (s, 2H), 1.32 (t, J = 7.3 Hz, 3H), 1.24 
(t, J = 7.5 Hz, 3H); 
13
C NMR (75 MHz, DMSO-d6) δ 183.2, 164.3, 159.0, 62.1, 61.7, 60.9, 45.2, 15.1, 
14.8. 
 
Ethyl 4,6-dihydroxypyridazine-3-carboxylate (3.14) 
To a solution of 3.12 (1 g, 4.38 mmol) in 15 mL of Et2O under argon was added PPh3 (1.7 g, 6.44 mmol) 
at room temperature. The reaction mixture was stirred for 24 hours and concentrated in vacuo to an 
orange oil, which was dissolved in AcOH/H2O (4:1) and refluxed for further 24 hours. The reaction was 
allowed to cool to room temperature and the solvent were evaporated to obtain a yellow oil purified by 
flash column chromatography on silica gel (CHCl3/MeOH = 9:1) to afford the desired compound 3.14 in 
30% yield as pale yellow solid. Data for 3.14: 
1
H NMR (300 MHz, DMSO-d6) δ 13.02 (br. s, 1H), 11.59 
(br. s, 1H), 6.02 (s, 1H), 4.28 (q, J = 7.1 Hz, 2H), 1.28 (t, J = 7.1 Hz, 3H); 
13
C NMR (75 MHz, DMSO-d6) 
δ 170.5, 162.6, 158.5, 135.8, 105.7, 61.8, 14.1. 
 
Ethyl 4,6-dichloropyridazine-3-carboxylate (3.15) 
3.14 (184 mg, 1 mmol) was dissolved in 5 mL of phosphorus oxychloride at room temperature. The 
reaction mixture was refluxed for 4 hours after which the color of the solution became brown. The flask 
was allowed to cool to room temperature and the excess of phosphorus oxychloride was concentrated in 
vacuo to a brown oil. The oil was dissolved in 15 mL of EtOAc and washed 2 times with 20 mL of 
saturated aqueous NaHCO3, the organic layer was dried over Na2SO4 and concentrated to afford crude 
3.15 in 75% yield as brown oil used directly without further purification. Data for 3.15: 
1
H NMR (300 
MHz, DMSO-d6) δ 8.58 (s, 1H), 4.47 (q, J = 7.1 Hz, 2H), 1.36 (t, J = 7.1 Hz, 3H); 
13
C NMR (75 MHz, 
DMSO-d6) δ 166.7, 159.3, 147.2, 141.0, 109.8, 62.3, 14.1. 
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General procedure for preparation of 5-hydroxy-5-substituted-3-oxo-pentanoates 3.20: 
 
To a suspension of 60% sodium hydride (48 mg, 1.2 mmol) in 60 mL of dry THF under argon at 0°C was 
slowly added methyl acetoacetate 3.19 (108 L, 1.0 mmol). After hydrogen evolution had ceased (30 
minutes), the reaction mixture was cooled to -78°C and 2.5 M butyllithium (480 L, 1.2 mmol). The 
mixture was stirred for 30 minutes, after which time aldehyde was added and the mixture stirred for 5 
hours. The reaction was allowed to warm to room temperature and was diluted with 100 mL of saturated 
aqueous NH4Cl and extracted 2 times with 100 mL of ethyl acetate. The organic layer was dried over 
Na2SO4, concentrated in vacuo, and purified by flash column chromatography on silica gel (EtOAc/n-
Hexane = 1:3) to afford the desired compound 3.20. 
 
Methyl 5-hydroxy-3-oxoheptanoate (3.20a) 
Yellow oil, 60% yield; Data for 3.20a: 
1
H NMR (500 MHz, CDCl3) -4.07 (m, 1H), 3.75 (s, 3H), 
3.50 (s, 2H), 2.62-2.76 (m, 2H), 1.48-1.55 (m, 2H), 0.94-0.97 (m, 3H); 
13
C NMR (125 MHz, CDCl3) 
203.6, 167.3, 68.9, 52.4, 49.7, 49.2, 29.3, 11.7. HRMS calcd for C8H14O4 [M+Na]
+
 197.0785, found 
197.0791. 
 
Methyl 5-hydroxy-6-methyl-3-oxoheptanoate (3.20b) 
Yellow oil, 51% yield; Data for 3.20b: 
1
H NMR (500 MHz, CDCl3) 3.85-3.87 (m, 1H), 3.75 (s, 3H), 
3.53 (s, 2H), 2.73 (dd, J = 17.2, 2.6 Hz, 1H), 2.65 (dd, J = 17.3, 9.4 Hz, 1H), 1.69-1.72 (m, 1H), 0.92-0.95 
(m, 6H); 
13
C NMR (125 MHz, CDCl3) 204.0, 167.4, 72.1, 52.4, 49.7, 46.7, 33.0, 18.3, 17.6. HRMS 
calcd for C9H16O4 [M+Na]
+
 211.0941, found 211.0940. 
 
Methyl 5-cyclohexyl-5-hydroxy-3-oxopentanoate (3.20c) 
Yellow oil, 37% yield; Data for 3.20c: 
1
H NMR (500 MHz, CDCl3) 3.85 (m, 1H), 3.75 (s, 3H), 3.52 (s, 
2H), 2.73 (dd, J = 17.3, 2.6 Hz, 1H), 2.67 (dd, J = 17.4, 9.6 Hz, 1H), 1.82-1.85 (m, 1H), 1.75-1.77 (m, 
3H), 1.64-1.68 (m, 2H), 1.33-1.39 (m, 1H), 1.11-1.27 (m, 4H), 1.07-0.97 (m, 2H); 
13
C NMR (125 MHz, 
CDCl3) 204.1, 167.4, 71.6, 52.4, 49.7, 46.8, 42.9, 28.8, 28.1, 26.3, 26.1, 25.9. HRMS calcd for 
C12H20O4 [M+Na]
+
 251.1254, found 251.1249. 
 
Methyl 5-hydroxy-3-oxo-5-phenylpentanoate (3.20d) 
Yellow oil, 55% yield; Data for 3.20d: 
1
H NMR (500 MHz, CDCl3) 7.35-7.36 (m, 4H), 7.28-7.30 (m, 
1H), 5.19 (dd, J = 9.4, 2.6 Hz, 1H), 3.74 (s, 3H), 3.51 (s, 2H), 3.00 (dd, J = 17.5, 9.4 Hz, 1H), 2.91 (dd, J 
= 17.3, 3.0 Hz, 1H); 
13
C NMR (125 MHz, CDCl3) 202.8, 167.3, 142.4, 128.6, 127.8, 125.6, 69.8, 52.5, 
51.5, 49.6. HRMS calcd for C12H14O4 [M+Na]
+
 245.0785, found 245.0778. 
 
Methyl 5-hydroxy-5-(4-methoxyphenyl)-3-oxopentanoate (3.20e) 
Yellow oil, 40% yield; Data for 3.20e: 
1
H NMR (500 MHz, CDCl3) 7.27-7.29 (m, 2H), 6.87-6.89 (m, 
2H), 5.15 (dd, J = 9.4, 3.2 Hz, 1H), 3.80 (s, 3H), 3.73 (s, 3H), 3.50 (s, 2H), 3.00 (dd, J = 17.2, 9.3 Hz, 
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1H), 2.88 (dd, J = 17.2, 3.2 Hz, 1H); 
13
C NMR (125 MHz, CDCl3) 202.7, 167.3, 159.2, 134.6, 126.9, 
114.0, 69.5, 55.3, 52.4, 51.5, 49.7. HRMS calcd for C13H16O5 [M+Na]
+
 275.0890, found 275.0885. 
 
Methyl 5-(furan-2-yl)-5-hydroxy-3-oxopentanoate (3.20f) 
Yellow oil, 25% yield; Data for 3.20f: 
1
H NMR (500 MHz, CDCl3) 7.37-7.38 (m, 1H), 6.33 (dd, J = 
3.2, 1.8 Hz, 1H), 6.28 (d, J = 3.3 Hz, 1H), 5.20 (dd, J = 8.9, 3.3 Hz, 1H), 3.75 (s, 3H), 3.54 (s, 2H), 3.18 
(dd, J = 17.6, 8.9 Hz, 1H), 3.04 (dd, J = 17.6, 3.5 Hz, 1H); 
13
C NMR (125 MHz, CDCl3) 167.2, 
154.4, 142.2, 110.3, 106.5, 63.5, 52.5, 49.5, 47.7. HRMS calcd for C10H12O5 [M+Na]
+
 235.0577, found 
235.0576. 
 
Methyl 5-hydroxy-3-oxo-5-(thiophen-2-yl)-pentanoate (3.20g) 
Yellow oil, 30% yield; Data for 3.20g: 
1
H NMR (500 MHz, CDCl3) 7.25-7.27 (m, 1H), 6.96-6.98 (m, 
2H), 5.44 (dd, J = 8.9, 3.1 Hz, 1H), 3.75 (s, 3H), 3.53 (s, 2H), 3.13 (dd, J = 17.6, 8.9 Hz, 1H), 3.05 (dd, J 
= 17.5, 3.4 Hz, 1H); 
13
C NMR (125 MHz, CDCl3) 202.2, 167.1, 146.1, 126.7, 124.9, 123.7, 66.0, 52.5, 
51.3, 49.6. HRMS calcd for C10H12O4S1 [M+Na]
+
 251.0349, found 251.0344. 
 
General procedure for preparation of 3.22 by diazo transfer : 
 
To a solution of compound 3.20 (1 mmol) in 30 mL of acetonitrile under argon at 0°C was added 
successively triethylamine (181 L, 1.3 mmol) and p-acetamido benzene sulfonyl azide (p-ABSA) (240 
mg, 1 mmol). The mixture was stirred for 2 hours and was allowed to warm to room temperature and was 
diluted with 50 mL of Et2O/n-Hexane (1:1) and then filtered. The filtrate was concentrated and the 
residue purified by flash column chromatography on silica gel (EtOAc/n-Hexane = 1:2) to afford the 
desired compound 3.22. 
 
Methyl 2-diazo-5-hydroxy-3-oxoheptanoate (3.22a) 
Yellow oil, 90% yield; Data for 3.22a: 
1
H NMR (500 MHz, CDCl3) 4.01-4.02 (m, 1H), 3.85 (s, 3H), 
3.10 (dd, J = 17.1, 2.4 Hz, 1H), 3.04 (d, J = 3.3 Hz, 1H), 2.91 (dd, J = 17.1, 9.4 Hz, 1H), 1.50-1.61 (m, 
2H), 0.98 (t, 3H); 
13
C NMR (125 MHz, CDCl3) 161.7, 69.4, 52.3, 46.3, 29.5, 9.8. HRMS calcd 
for C8H12N2O4 [M+Na]
+
 223.0690, found 223.0690. 
 
Methyl 2-diazo-5-hydroxy-6-methyl-3-oxoheptanoate (3.22b) 
Yellow oil, 90% yield; Data for 3.22b: 
1
H NMR (500 MHz, CDCl3) 3.80-3.85 (m, 4H), 3.08 (dd, J = 
17.0, 2.3 Hz, 1H), 2.90-2.95 (m, 2H), 1.72-1.78 (m, 1H), 0.95-0.98 (m, 6H); 
13
C NMR (125 MHz, CDCl3) 
. HRMS calcd for C9H14N2O4 [M+Na]
+
 237.0846, found 
237.0847. 
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Methyl 2-diazo-5-cyclohexyl-5-hydroxy-3-oxopentanoate (3.22c) 
Yellow oil, 87% yield; Data for 3.22c: 
1
H NMR (500 MHz, CDCl3) 3.85 (m, 4H), 3.09 (dd, J = 16.8, 
2.3 Hz, 1H), 2.94 (dd, J = 16.9, 9.9 Hz, 2H), 1.87-1.89 (m, 1H), 1.75-1.78 (m, 2H), 1.65-1.71 (m, 2H), 
1.38-1.44 (m, 1H), 1.00-1.28 (m, 5H); 
13
C NMR (125 MHz, CDCl3) 
. HRMS calcd for C12H18N2O4 [M+Na]
+
 
277.1159, found 277.1159. 
 
Methyl 2-diazo-5-hydroxy-3-oxo-5-phenylpentanoate (3.22d) 
Yellow oil, 90% yield; Data for 3.22d: 
1
H NMR (500 MHz, CDCl3) 7.39-7.41 (m, 2H), 7.34-7.37 (m, 
2H), 7.26-7.29 (m, 1H), 5.20-5.22 (m, 1H), 3.83 (s, 3H), 3.39 (d, J = 3.1 Hz, 1H), 3.27-3.29 (m, 2H); 
13
C 
NMR (125 MHz, CDCl3) . HRMS calcd for 
C12H12N2O4 [M+Na]
+
 271.0690, found 271.0687. 
 
Methyl 2-diazo-5-hydroxy-5-(4-methoxyphenyl)-3-oxopentanoate (3.22e) 
Yellow oil, 80% yield; Data for 3.22e: 
1
H NMR (500 MHz, CDCl3) 7.31-7.33 (m, 2H), 6.87-6.89 (m, 
2H), 5.13-5.17 (m, 1H), 3.83 (s, 3H), 3.80 (s, 3H), 3.22-3.32 (m, 2H); 
13
C NMR (125 MHz, CDCl3) 
. HRMS calcd for C13H14N2O5 [M+Na]
+
 
301.0795, found 301.0795. 
 
Methyl 2-diazo-5-(furan-2-yl)-5-hydroxy-3-oxopentanoate (3.22f) 
Yellow oil, 62% yield; Data for 3.22f: 
1
H NMR (500 MHz, CDCl3) 7.37-7.38 (m, 1H), 6.33 (dd, J = 
3.4, 1.8 Hz, 1H), 6.30 (d, J = 3.5 Hz, 1H), 5.23 (dd, J = 9.2, 2.9 Hz, 1H), 3.85 (s, 3H), 3.50 (dd, J = 17.4, 
9.0 Hz, 1H), 3.32 (dd, J = 17.4, 3.2 Hz, 1H); 
13
C NMR (125 MHz, CDCl3) 
. HRMS calcd for C10H1N2O5 [M+Na]
+
 
261.0482, found 261.0485. 
 
Methyl 2-diazo-5-hydroxy-3-oxo-5-(thiophen-2-yl)-pentanoate (3.22g) 
Yellow oil, 85% yield; Data for 3.22g: 
1
H NMR (500 MHz, CDCl3) 7.25-7.27 (m, 1H), 6.99-7.00 (m, 
1H), 6.96-6.98 (m, 1H), 5.45-5.47 (m, 1H), 3.85 (s, 3H), 3.57 (d, J = 4.1 Hz, 1H), 3.45 (dd, J = 17.3, 8.9 
Hz, 1H), 3.40 (dd, J = 17.3, 3.0 Hz, 1H); 
13
C NMR (125 MHz, CDCl3) 
. HRMS calcd for C10H10N2O4S1 [M+Na]
+
 
277.0254, found: 277.0257. 
 
General procedure for the preparation of pyridazine derivatives 3.24 with HMPT: 
 
To a solution of 3.22 (1 mmol) in 10 mL of acetonitrile under argon was added IBX (1-hydroxy-1,2-
benziodoxol-3(1H)-one 1-oxide) (364 mg, 1.3 mmol). The mixture was refluxed for 2 hours and was 
allowed to warm to room temperature and then filtered. The filtrate was concentrated to afford the -
diazo--ketoester 3.23 used directly without further purification for the next step. 
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To a solution of -diazo--ketoester in 10 mL of CH2Cl2 was added HMPT (hexamethylphosphorous 
triamide) (183 L, 1 mmol). The reaction mixture was stirred under argon at room temperature for 16 
hours. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with the 
addition of water. The organic layer was washed with water (2 x 10 mL), dried over Na2SO4 and 
concentrated in vacuo. A purification by flash column chromatography on silica gel (EtOAc/n-Hexane = 
9:1) afforded the desired pyridazine 3.24. 
 
Methyl 6-ethyl-4-hydroxypyridazine-3-carboxylate (3.24a) 
Pale yellow solid, 68% yield; Data for 3.24a: 
1
H NMR (500 MHz, DMSO-d6)  13.37 (br. s, 1H), 6.40 (s, 
1H), 3.80 (s, 3H), 2.56 (m, 2H), 1.19 (m, 3H); 
13
C NMR (125 MHz, DMSO-d6) 167.8, 164.2, 156.6, 
148.6, 116.2, 52.4, 24.0, 12.5. 
 
Methyl 4-hydroxy-6-isopropylpyridazine-3-carboxylate (3.24b) 
Yellow solid, 75% yield; Data for 3.24b: 
1
H NMR (500 MHz, DMSO-d6)  13.38 (br. s, 1H), 6.42 (s, 
1H), 3.81 (s, 3H), 2.85 (m, 1H), 1.22 (m, 6H); 
13
C NMR (125 MHz, DMSO-d6) 167.9, 164.2, 160.4, 
148.6, 114.4, 52.4, 30.2, 21.0. 
 
Methyl 6-cyclohexyl-4-hydroxypyridazine-3-carboxylate (3.24c) 
Yellow solid, 62% yield; Data for 3.24c: 
1
H NMR (500 MHz, DMSO-d6)  6.37 (s, 1H), 3.80 (s, 3H), 
1.77-1.84 (m, 4H), 1.67-1.69 (m, 1H), 1.18-1.46 (m, 5H); 
13
C NMR (125 MHz, DMSO-d6) 167.9, 
164.1, 159.3, 148.5, 114.9, 52.4, 30.9, 25.7, 25.1. 
 
Methyl 4-hydroxy-6-phenylpyridazine-3-carboxylate (3.24d) 
Brown solid, 60% yield; Data for 3.24d: 
1
H NMR (500 MHz, DMSO-d6)  13.72 (br. s, 1H), 7.79-7.81 
(m, 2H), 7.60 (m, 3H), 6.86 (s, 1H), 3.85 (s, 3H); 
13
C NMR (125 MHz, DMSO-d6) 164.1, 152.2, 148.4, 
131.2, 131.0, 129.2, 127.4, 115.9, 52.4. 
 
Methyl 4-hydroxy-6-(4-methoxyphenyl)pyridazine-3-carboxylate (3.24e) 
Orange solid, 45% yield; Data for 3.24e: 
1
H NMR (500 MHz, DMSO-d6)  7.77 (d, J = 8.8 Hz, 2H), 7.12 
(d, J = 8.8 Hz, 2H), 6.81 (s, 1H), 3.84 (s, 6H); 
13
C NMR (125 MHz, DMSO-d6) 164.2, 161.7, 148.2, 
129.0, 122.8, 115.0, 114.7, 55.6, 52.5. 
 
Methyl 6-(furan-2-yl)-4-hydroxypyridazine-3-carboxylate (3.24f) 
Brown solid, 27% yield; Data for 3.24f: 
1
H NMR (500 MHz, DMSO-d6)  8.04 (m, 1H), 7.44-7.45 (m, 
1H), 6.87 (s, 1H), 6.78 (dd, J = 3.6, 1.8 Hz, 1H), 3.84 (s, 3H); 
13
C NMR (125 MHz, DMSO-d6) 163.9, 
146.8, 113.3, 113.1, 111.5, 52.4. 
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Methyl 4-hydroxy-6-(thiophen-2-yl)-pyridazine-3-carboxylate (3.24g) 
Brown solid, 33% yield; Data for 3.24g: 
1
H NMR (500 MHz, DMSO-d6)  10.91 (s, 1H), 7.76-7.77 (m, 
1H), 7.58-7.59 (m, 1H), 7.32 (s, 1H), 7.19 (dd, J = 5.0, 3.8 Hz, 1H), 4.13 (s, 3H); 
13
C NMR (125 MHz, 
DMSO-d6) 169.1, 160.0, 157.7, 139.6, 136.6, 131.0, 128.4, 127.9, 108.2, 53.5. 
 
Methyl 2-diazo-3-oxobutanoate (3.25) 
To a solution of compound 3.19 (5 g, 43.06 mmol) in 30 mL of acetonitrile under argon at 0 °C was 
added successively triethylamine (7.8 mL, 55.98 mmol) and p-acetamido benzene sulfonyl azide (p-
ABSA) (10.4 g, 43.06 mmol). The mixture was stirred for 2 hours and was allowed to warm to room 
temperature and was diluted with 100 mL of Et2O/n-Hexane (1:1) and then filtered. The filtrate was 
concentrated and the residue purified by flash column chromatography on silica gel (EtOAc/n-Hexane = 
1:2) to afford the desired compound 3.25 in 82% yield as yellow oil. Data for 3.25: 
1
H NMR (500 MHz, 
DMSO-d6) δ 3.65 (s, 3H), 2.18 (s, 3H); 
13
C NMR (125 MHz, DMSO-d6) δ 189.3, 161.5, 52.3, 27.9. 
 
General procedure for the preparation of 3.22 by titanium aldol reaction: 
 
To a solution of 3.25 (1 g, 7.04 mmol) in 50 mL of CH2Cl2 under argon at -78 °C was added dropwise 
TiCl4 (849 L, 7.74 mmol) followed by Et3N (1.08 mL, 7.74 mmol). The resulting red solution was 
stirred at -78 °C for 1 hour, after which a solution of aldehyde (6.34 mmol) in CH2Cl2 was slowly added. 
The reaction mixture was stirred at -78 °C for 4 hours and then the reaction was quenched with 50 mL of 
saturated aqueous NH4Cl and warmed to room temperature. The organic layer was separated and then 
washed with 40 mL of saturated aqueous NaHCO3. The aqueous layers were extracted with 50 mL of 
CH2Cl2. The combined organic layers were dried over Na2SO4 and concentrated in vacuo. The product 
was purified by flash column chromatography on silica gel (EtOAc/n-Hexane = 1:3) to afford the aldol 
product 3.22. 
 
General procedure for the preparation of pyridazine derivatives 3.24 with P(n-Bu)3: 
 
To a solution of 3.22 (1 mmol) in 10 mL of acetonitrile under argon was added IBX (1-hydroxy-1,2-
benziodoxol-3(1H)-one 1-oxide) (364 mg, 1.3 mmol). The mixture was refluxed for 2 hours and was 
allowed to warm to room temperature and then filtered. The filtrate was concentrated to afford the -
diazo--ketoester 3.23 used directly without further purification for the next step. 
To a solution of -diazo--ketoester in 20 mL of i-Pr2O was added P(n-Bu)3 (250 L, 1 mmol). The 
reaction mixture was stirred under argon at room temperature for 30 minutes, which after this time a 
precipitate was formed. The suspension was filtered, washed with i-Pr2O and dried to afford 3.24. 
 
General procedure for the preparation of pyridazine derivatives 3.27: 
 
3.24 (1.0 mmol) was dissolved in 5 mL of phosphorus oxychloride at room temperature. The reaction 
mixture was heated at 95 °C for 4 hours after which the color of the solution became brown. The flask 
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was allowed to cool to room temperature and the excess of phosphorus oxychloride was concentrated in 
vacuo to a brown oil. The oil was dissolved in 15 mL of EtOAc and washed 2 times with 20 mL of 
saturated aqueous NaHCO3, the organic layer was dried over Na2SO4 and concentrated to afford crude 
3.26 as brown oil used directly without further purification. 
To a solution of 3.26 in 5 mL of dioxane under argon was added an amine (1.1 mmol), followed by 
triethylamine (181 L, 1.3 mmol) at room temperature. The reaction mixture was refluxed until the 
completion of the reaction (5-48 hours monitored by TLC) and was allowed to cool to room temperature. 
15 mL of saturated aqueous NaHCO3 was added to the reaction mixture followed by an extraction with 
2x15 mL of CH2Cl2. The combined organic layers were dried over Na2SO4 and concentrated in vacuo. 
The product was purified by flash column chromatography on silica gel (EtOAc/n-Hexane = 8:2) to 
afford the amino substituted pyridazine 3.27. 
 
Methyl 4-(ethylamino)-6-phenylpyridazine-3-carboxylate (3.27a) 
Beige solid, 85% yield; Data for 3.27a: 
1
H NMR (300 MHz, CDCl3)  8.03-8.06 (m, 2H), 7.87 (br. s, 
NH), 7.46-7.48 (m, 3H), 6.94 (s, 1H), 4.00 (s, 3H), 3.25-3.32 (m, 2H), 1.34 (t, J = 7.2 Hz, 3H); 
13
C NMR 
(75 MHz, CDCl3) 166.7, 160.8, 158.2, 147.0, 134.5, 129.6, 128.2, 114.0, 101.9, 52.2, 35.7, 14.2. 
 
Methyl 4-(ethylamino)-6-(4-methoxyphenyl)pyridazine-3-carboxylate (3.27b) 
Beige solid, 83% yield; Data for 3.27b: 
1
H NMR (500 MHz, DMSO-d6)  8.16 (d, J = 8.9 Hz, 2H), 7.79 
(t, J = 5.4 Hz, NH), 7.26 (s, 1H), 7.09 (d, J = 9.0 Hz, 2H), 3.92 (s, 3H), 3.84 (s, 3H), 3.39-3.45 (m, 2H), 
1.23 (t, J = 7.2 Hz, 3H); 
13
C NMR (125 MHz, DMSO-d6) 167.1, 161.1, 157.6, 146.8, 134.2, 128.9, 
128.5, 114.3, 102.2, 55.4, 52.3, 36.0, 13.8. 
 
Methyl 4-(cyclohexylamino)-6-(furan-2-yl)pyridazine-3-carboxylate (3.27d) 
Orange solid, 75% yield; Data for 3.27d: 
1
H NMR (600 MHz, DMSO-d6)  7.97-7.98 (m, 1H), 7.94 (d, J 
= 8.0 Hz, NH), 7.38 (d, J = 3.4 Hz, 1H), 7.14 (s, 1H), 6.74-6.75 (m, 1H), 3.92 (s, 3H), 3.68-3.72 (m, 1H), 
1.91-1.94 (m, 2H), 1.67-1.70 (m, 2H), 1.57-1.61 (m, 1H), 1.42-1.49 (m, 2H), 1.26-1.37 (m, 3H); 
13
C 
NMR (150 MHz, DMSO-d6) 167.3, 150.6, 150.5, 145.8, 145.7, 133.8, 112.7, 111.8, 100.7, 52.5, 48.9, 
31.6, 25.1, 23.9. 
 
Methyl 6-phenyl-4-(phenylamino)pyridazine-3-carboxylate (3.27f) 
Brown solid, 52% yield; Data for 3.27f: 
1
H NMR (500 MHz, DMSO-d6)  9.50 (br. s, NH), 7.96-7.98 (m, 
2H), 7.50-7.53 (m, 3H), 7.47-7.49 (m, 2H), 7.43-7.44 (m, 3H), 7.28-7.31 (m, 1H), 3.99 (s, 3H); 
13
C NMR 
(125 MHz, DMSO-d6) 166.7, 158.5, 144.7, 137.5, 136.2, 136.0, 130.3, 129.9, 129.0, 127.2, 125.9, 
123.9, 104.9, 52.7. 
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Methyl 6-cyclohexyl-4-(phenylamino)pyridazine-3-carboxylate (3.27g) 
Yellow solid, 57% yield; Data for 3.27g: 
1
H NMR (500 MHz, DMSO-d6)  9.33 (br. s, NH), 7.46 (t, J = 
7.5 Hz, 2H), 7.33 (d, J = 7.4 Hz, 2H), 7.26 (t, J = 7.4 Hz, 1H), 6.93 (s, 1H), 3.94 (s, 3H), 2.71-2.77 (m, 
1H), 1.75-1.83 (m, 4H), 1.66-1.69 (m, 1H), 1.17-1.47 (m, 5H); 
13
C NMR (125 MHz, DMSO-d6) 167.9, 
166.8, 144.5, 137.6, 135.9, 129.8, 125.7, 123.8, 105.4, 52.6, 43.9, 31.9, 25.9, 25.5. 
 
Methyl 4-(phenylamino)-6-(thiophen-2-yl)pyridazine-3-carboxylate (3.27h) 
Orange solid, 50% yield; Data for 3.27h: 
1
H NMR (500 MHz, DMSO-d6)  9.52 (br. s, NH), 7.78-7.79 
(m, 1H), 7.72-7.73 (m, 1H), 7.48 (t, J = 7.4 Hz, 2H), 7.40-7.44 (m, 3H), 7.29 (t, J = 7.3 Hz, 1H), 7.17-
7.19 (m, 1H), 3.97 (s, 3H); 
13
C NMR (125 MHz, DMSO-d6) 166.5, 154.2, 144.6, 139.8, 137.4, 136.0, 
130.8, 129.9, 128.6, 127.9, 125.9, 123.8, 102.5, 52.7. 
 
Methyl 6-ethyl-4-(3,4,5-trimethoxyphenylamino)-pyridazine-3-carboxylate (3.27i) 
Orange solid, 62% yield; Data for 3.27i: 
1
H NMR (300 MHz, DMSO-d6)  8.69 (br. s, NH), 7.36 (s, 2H), 
7.28 (s, 1H), 3.95 (s, 3H), 3.82 (s, 6H), 3.77 (s, 3H), 2.49-2.55 (m, 2H), 1.24 (t, J = 7.3 Hz, 3H); 
13
C 
NMR (75 MHz, DMSO-d6) 162.3, 156.1, 153.8, 142.5, 139.6, 137.0, 135.7, 119.2, 99.6, 61.0, 56.9, 
53.2, 22.7, 12.4. 
 
General procedure for the preparation of pyridazine derivatives 3.29 by amide coupling: 
 
To a solution of 3.27 (0.5 mmol) in 5 mL of MeOH/water was added sodium hydroxyde (200 mg, 5 
mmol) dissolved in water, the reaction was heated at 80 °C for 16 hours. After an acidic workup and 
evaporation to the carbolylic acid derivative 3.28, the crude was used directly without further purification. 
To a solution of 3.28 in THF was added triethylamine (83 L, 1.3 mmol) followed by TBTU (209 mg, 1.2 
mmol) and an amine (0.75 mmol). 15 mL of saturated aqueous NaHCO3 was added to the reaction 
mixture followed by an extraction with 2x15 mL of CH2Cl2. The combined organic layers were dried over 
Na2SO4 and concentrated in vacuo. The product was purified by preparative HPLC to afford the 
pyridazine 3.29. 
 
General procedure for the preparation of pyridazine derivatives 3.29 by Dabal-Me3: 
 
A solution of amine (1.5 mmol) and Dabal-Me3 (385 mg, 1.5 mmol) in 5 mL of THF was heated at 40 °C 
for 1 hour, after which 3.27 (0.5 mmol) was added. The reaction mixture was refluxed until completion of 
the reaction (24-96 hours monitored by TLC). 15 mL of saturated aqueous NH4Cl was added to the 
reaction mixture followed by an extraction with 2x15 mL of CH2Cl2. The combined organic layers were 
dried over Na2SO4 and concentrated in vacuo. The product was purified by preparative HPLC to afford 
the pyridazine 3.29. 
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4-(Ethylamino)-N-(3,4,5-trimethoxyphenyl)-6-phenylpyridazine-3-carboxamide (3.29a) 
Brown solid, 37% yield; Data for 3.29a: 
1
H NMR (300 MHz, DMSO-d6)  10.85 (br. s, NH), 8.58-8.62 
(m, 1H), 8.20-8.24 (m, 2H), 7.55-7.5 (m, 3H), 7.40 (s, 2H), 7.37 (s, 1H), 3.79 (s, 6H), 3.66 (s, 3H), 3.42-
3.50 (m, 2H), 1.26 (t, J = 7.2 Hz, 3H); 
13
C NMR (75 MHz, DMSO-d6) 164.9, 158.4, 152.8, 147.0, 
136.5, 135.5, 134.3, 130.2, 129.0, 127.4, 103.7, 98.4, 60.3, 56.0, 36.0, 14.0. 
 
N-cyclohexyl-6-phenyl-4-(phenylamino)pyridazine-3-carboxamide (3.29h) 
Beige solid, 47% yield; Data for 3.29h: 
1
H NMR (600 MHz, DMSO-d6)  10.82 (br. s, NH), 9.12 (d, J = 
8.5 Hz, NH), 7.99-8.01 (m, 2H), 7.52-7.54 (m, 4H), 7.46-7.49 (m, 2H), 7.42-7.44 (m, 2H), 7.24-7.26 (m, 
1H), 3.85-3.90 (m, 1H), 1.60-1.87 (m, 5H), 1.15-1.55 (m, 5H); 
13
C NMR (150 MHz, DMSO-d6) 165.4, 
158.7, 144.5, 137.7, 136.3, 130.2, 129.9, 129.0, 127.1, 125.3, 122.9, 104.5, 48.1, 32.0, 25.2, 24.9. 
 
Morpholino-(6-phenyl-4-(phenylamino)pyridazin-3-yl)-methanone (3.29i) 
Yellow solid, 50% yield; Data for 3.29i: 
1
H NMR (600 MHz, DMSO-d6)  8.71 (br. s, NH), 7.93-7.95 (m, 
2H), 7.49-7.52 (m, 3H), 7.42-7.45 (m, 3H), 7.35-7.36 (m, 2H), 7.21 (t, J = 7.3 Hz, 1H), 3.70-3.75 (m, 
4H), 3.60-3.63 (m, 2H), 3.47-3.50 (m, 2H); 
13
C NMR (150 MHz, DMSO-d6) 164.4, 157.9, 144.4, 141.9, 
138.5, 136.6, 129.9, 129.6, 129.0, 127.0, 125.0, 123.1, 104.9, 66.4, 65.9, 47.2, 42.0. 
 
N-(4-fluorophenyl)-6-phenyl-4-(phenylamino)pyridazine-3-carboxamide (3.29j) 
Brown solid, 47% yield; Data for 3.29j: 
1
H NMR (600 MHz, DMSO-d6)  11.26 (br. s, NH), 10.48 (br. s, 
NH), 8.02-8.04 (m, 2H), 7.94-7.97 (m, 2H), 7.53-7.57 (m, 4H), 7.46-7.51 (m, 4H), 7.23-7.29 (m, 3H); 
13
C 
NMR (150 MHz, DMSO-d6) 165.0, 159.7, 158.8, 158.0, 144.8, 137.6, 136.5, 136.1, 134.4, 130.3, 
129.9, 129.1, 127.2, 125.6, 1234, 123.2, 123.1, 115.4, 115.3, 104.8. 
 
6-Phenyl-4-(phenylamino)-N-(pyridin-2-yl)pyridazine-3-carboxamide (3.29k) 
Brown solid, 33% yield; Data for 3.29k: 
1
H NMR (600 MHz, DMSO-d6)  10.77 (br. s, NH), 10.34 (br. s, 
NH), 8.44-8.46 (m, 1H), 8.24 (d, J = 8.3 Hz, 1H), 8.01-8.04 (m, 2H), 7.92-7.95 (m, 1H), 7.53-7.56 (m, 
4H), 7.48-7.51 (m, 4H), 7.29-7.31 (m, 1H), 7.24-7.27 (m, 1H); 
13
C NMR (150 MHz, DMSO-d6) 164.7, 
159.2, 150.4, 148.7, 145.2, 138.8, 137.2, 135.9, 135.4, 130.4, 130.0, 129.1, 127.3, 125.9, 123.6, 120., 
113.9, 105.2. 
 
6-Cyclohexyl-N-cyclopropyl-4-(phenylamino)pyridazine-3-carboxamide (3.29l) 
Brown solid, 48% yield; Data for 3.29l: 
1
H NMR (300 MHz, DMSO-d6)  10.63 (br. s, NH), 9.25 (d, J = 
4.7 Hz, 1H), 7.43-7.48 (m, 2H), 7.33 (d, J = 7.4 Hz, 2H), 7.22 (t, J = 7.3 Hz, 1H), 7.02 (s, 1H), 2.90-2.99 
(m, 1H), 2.69-2.78 (m, 1H), 1.66-1.87 (m, 5H), 1.18-1.55 (m, 5H), 0.71-0.76 (m, 4H); 
13
C NMR (75 
MHz, DMSO-d6) 167.9, 167.8, 144.0, 137.8, 136.1, 129.9, 125.1, 122.8, 105.2, 43.9, 32.1, 25.9, 25.6, 
22.8, 5.8. 
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(6-Cyclohexyl-4-(phenylamino)pyridazin-3-yl)-morpholino-methanone (3.29m) 
Brown solid, 44% yield; Data for 3.29m: 
1
H NMR (300 MHz, DMSO-d6)  8.50 (br. s, NH), 7.39-7.44 
(m, 2H), 7.26 (d, J = 7.5 Hz, 2H), 7.18 (t, J = 7.3 Hz, 1H), 6.92 (s, 1H), 3.67-3.73 (m, 4H), 3.57-3.61 (m, 
2H), 3.40-3.44 (m, 2H), 2.64-2.75 (m, 1H), 1.64-1.87 (m, 5H), 1.18-1.52 (m, 5H); 
13
C NMR (75 MHz, 
DMSO-d6) 166.6, 164.6, 144.1, 141.6, 138.7, 129.6, 124.7, 122.9, 105.6, 66.4, 66.0, 47.2, 44.1, 42.0, 
32.1, 26.0, 25.6. 
 
6-Cyclohexyl-N-(4-fluorophenyl)-4-(phenylamino)pyridazine-3-carboxamide (3.29n) 
Brown solid, 39% yield; Data for 3.29n: 
1
H NMR (600 MHz, DMSO-d6)  11.14 (br. s, NH), 10.30 (br. s, 
NH), 7.90-7.92 (m, 2H), 7.45-7.48 (m, 2H), 7.36-7.37 (m, 2H), 7.21-7.26 (m, 3H), 7.06 (s, 1H), 2.76-2.81 
(m, 1H), 1.69-1.89 (m, 5H), 1.20-1.56 (m, 5H); 
13
C NMR (150 MHz, DMSO-d6) 168.1, 165.2, 144.5, 
137.6, 136.2, 134.3, 129.9, 125.4, 123.1, 123.0, 122.9, 115.4, 115.2, 105.6, 43.9, 32.0, 25.9, 25.5. 
 
6-Cyclohexyl-4-(phenylamino)-N-(pyridin-2-yl)pyridazine-3-carboxamide (3.29o) 
Beige solid, 31% yield; Data for 3.29o: 
1
H NMR (600 MHz, DMSO-d6)  10.70 (br. s, NH), 10.20 (br. s, 
NH), 8.42-8.44 (m, 1H), 8.22 (d, J = 8.2 Hz, 1H), 7.90-7.94 (m, 1H), 7.47-7.50 (m, 2H), 7.37-7.40 (m, 
2H), 7.23-7.29 (m, 2H), 7.06 (s, 1H), 2.77-2.82 (m, 1H), 1.67-1.89 (m, 5H) 1.19-1.55 (m, 5H); 
13
C NMR 
(150 MHz, DMSO-d6) 168.7, 164.9, 150.4, 148.7, 145.0, 138.8, 137.4, 135.1, 129.9, 125.7, 123.5, 
120.6, 113.8, 106.0, 44.0, 32.0, 25.9, 25.5. 
 
4-(3,4,5-Trimethoxyphenylamino)-6-ethyl-N-methyl-pyridazine-3-carboxamide (3.29p) 
Pale yellow solid, 60% yield; Data for 3.29p: 
1
H NMR (600 MHz, DMSO-d6)  10.52 (br. s, NH), 9.24-
9.29 (m, 1H), 7.13 (s, 1H), 6.63 (s, 2H), 3.78 (s, 6H), 3.67 (s, 3H), 2.85 (d, J = 4.8 Hz, 3H), 2.80 (q, J = 
7.6 Hz, 2H), 1.21 (t, J = 7.6 Hz, 3H); 
13
C NMR (150 MHz, DMSO-d6) 167.0, 165.6, 165.3, 153.7, 
144.4, 135.9, 134.9, 133.5, 106.5, 100.9, 60.4, 56.0, 28.7, 25.9, 13.7. 
 
(4-(3,4,5-Trimethoxyphenylamino)-6-ethylpyridazin-3-yl)-morpholino-methanone (3.29q) 
Yellow solid, 56% yield; Data for 3.29q: 
1
H NMR (600 MHz, DMSO-d6)  8.36 (br. s, NH), 7.06 (s, 1H), 
6.58 (s, 2H), 3.76 (s, 6H), 3.70-3.73 (m, 4H), 3.66 (s, 3H), 3.57-3.59 (m, 2H), 3.41-3.43 (m, 2H), 2.75 (q, 
J = 7.6 Hz, 2H), 1.20 (t, J = 7.6 Hz, 3H); 
13
C NMR (150 MHz, DMSO-d6) 164.6, 164.0, 153.4, 143.7, 
141.7, 134.6, 134.3, 106.7, 100.7, 66.4, 66.0, 60.2, 56.0, 47.2, 42.0, 28.6, 13.7. 
 
4-(3,4,5-Trimethoxyphenylamino)-N-(4-fluorophenyl)-6-phenylpyridazine-3-carboxamide (3.29s) 
Beige solid, 35% yield; Data for 3.29s: 
1
H NMR (300 MHz, DMSO-d6)  11.25 (br. s, NH), 10.35 (br. s, 
NH), 8.04-8.08 (m, 2H), 7.94-7.98 (m, 2H), 7.63 (s, 1H), 7.53-7.57 (m, 3H), 7.25 (t, J = 8.9 Hz, 2H), 6.80 
(s, 2H), 3.80 (s, 6H), 3.70 (s, 3H); 
13
C NMR (75 MHz, DMSO-d6) 165.1, 158.7, 153.8, 145.3, 136.3, 
135.5, 134.9, 134.5, 133.1, 130.4, 129.2, 127.2, 123.2, 115.5, 115.2, 105.3, 101.6, 60.3, 56.3. 
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Methyl 6-isopropyl-4-phenylpyridazine-3-carboxylate (3.30) 
3.24b (196 mg, 1.0 mmol) was dissolved in 5 mL of phosphorus oxychloride at room temperature. The 
reaction mixture was heated at 95 °C for 4 hours after which the color of the solution became brown. The 
flask was allowed to cool to room temperature and the excess of phosphorus oxychloride was 
concentrated in vacuo to a brown oil. The oil was dissolved in 15 mL of EtOAc and washed 2 times with 
20 mL of saturated aqueous NaHCO3, the organic layer was dried over Na2SO4 and concentrated to afford 
crude 3.26b as brown oil used directly without further purification. 
To a solution of 3.26b in 5 mL of dioxane under argon was added phenyl boronic acid (146 mg, 1.2 
mmol), K3PO4 (467 mg, 2.2 mmol) and 1,1’-bis(diphenylphosphino)ferrocenedichloro palladium (82 mg, 
0.1 mmol) at room temperature. The reaction mixture was refluxed until the completion of the reaction 
for 48 hours and then was allowed to cool to room temperature. 15 mL of saturated aqueous NaHCO3 was 
added to the reaction mixture followed by an extraction with 2x15 mL of CH2Cl2. The combined organic 
layers were dried over Na2SO4 and concentrated in vacuo. The product was purified by flash column 
chromatography on silica gel (EtOAc/n-Hexane = 1:1) to afford the aryl substituted pyridazine 3.30 in 
34% yield as beige solid. Data for 3.30: 
1
H NMR (500 MHz, CDCl3) δ 7.34-7.35 (m, 3H), 7.26-7.28 (m, 
3H), 3.71 (s, 3H), 3.27-3.33 (m, 1H), 1.30 (d, J = 7.0 Hz, 6H); 
13
C NMR (125 MHz, CDCl3) 168.1, 
160.7, 154.9, 145.6, 137.0, 129.8, 127.5, 126.3, 117.2, 55.6, 31.7, 22.4. 
 
Pyridazines 3.31a and 3.31b were synthesized following the method with Dabal-Me3 applied to 3.29. 
 
N-(4-fluorophenyl)-6-isopropyl-4-phenylpyridazine-3-carboxamide (3.31a) 
Beige solid, 38% yield; Data for 3.31a: 
1
H NMR (300 MHz, DMSO-d6)  10.62 (br. s, NH), 7.44-7.47 
(m, 2H), 7.37-7.41 (m, 3H), 7.29-7.32 (m, 3H), 7.24-7.27 (m, 2H), 3.19-3.24 (m, 1H), 1.32 (d, J = 6.8 Hz, 
6H); 
13
C NMR (75 MHz, DMSO-d6) 164.6, 158.3, 157.7, 144.8, 137.9, 134.1, 129.0, 127.3, 126.5, 
124.8, 121.6, 116.7, 31.5, 21.9. 
 
General procedure for the preparation of -hydroxy ketone derivatives 3.34 by organocatalysis: 
 
To a solution of aldehyde 3.33 (1 mmol) in a mixture of DMSO (4 mL) and acetone (1 mL) was added L-
proline (29 mg, 0.25 mmol). The resulting mixture was stirred under argon at room temperature for 5 
hours. The reaction mixture was treated with 10 mL of saturated aqueous NH4Cl, the layers were 
separated, and the aqueous layer was extracted several times with EtOAc, dried over Na2SO4, and 
concentrated in vacuo. A purification by flash column chromatography on silica gel (EtOAc/n-Hexane = 
1:2) afforded the desired aldol product 3.34. 
 
4-Hydroxy-(4-nitrophenyl)-2-butanone (3.34a) 
Pink solid, 57% yield; Data for 3.34a: 
1
H NMR (500 MHz, DMSO-d6)  8.19 (d, J = 8.7 Hz, 2H), 7.64 (d, 
J = 8.7 Hz, 2H), 5.70 (d, J = 4.8 Hz, 1H), 5.13-5.16 (m, 1H), 2.75 (d, J = 6.6 Hz, 2H), 2.14 (s, 1H); 
13
C 
NMR (125 MHz, DMSO-d6) 206.3, 153.3, 146.5, 127.0, 123.4, 68.1, 52.4, 30.4; HRMS calcd for 
C10H11NO4 [M+Na]
+
 232.0581, found 232.0584. 
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(4-Cyanophenyl)-4-hydroxy-2-butanone (3.34b) 
Beige solid, 55% yield; Data for 3.34b: 
1
H NMR (500 MHz, DMSO-d6) 7.82 (d, J = 8.1 Hz, 2H), 7.59 
(d, J = 8.0 Hz, 2H), 5.65 (d, J = 4.7 Hz, 1H), 5.10-5.13 (m, 1H), 2.76 (d, J = 5.8 Hz, 2H), 2.16 (s, 3H); 
13
C NMR (125 MHz, DMSO-d6) 151.1, 132.2, 126.8, 119.0, 109.7, 68.3, 52.4, 30.4; HRMS calcd for 
C11H11NO2 [M+Na]
+
 212.0682, found 212.0677. 
 
General procedure for the preparation of -hydroxy ketone derivatives 3.37 by Mukaiyama aldol 
reaction: 
 
To a solution of ketone 3.36 (1 mmol) in 10 mL of THF under argon at -78 °C was slowly added a 
solution of 1 M LiHMDS (1.2 mL, 1.2 mmol) and the reaction mixture was stirred for 1 hour at -78 °C, 
prior to the addition of chlorotrimethylsilane (153 L, 1.2 mmol) in THF. The mixture was further stirred 
for 1 hour, then allowed to warm up to room temperature. The reaction was quenched with 10 mL of 
saturated aqueous NH4Cl, after addition of EtOAc, the layers were separated, and the aqueous layer was 
extracted several times with EtOAc, dried over Na2SO4, and concentrated in vacuo to afford the 
corresponding silyl enol ether used directly without further purification for the next step. 
To a solution of silyl enol ether in 10 mL of CH2Cl2 under argon at -78 °C was added acetaldehyde (85 
L, 1.5 mmol) for 3.37a or propionaldehyde for 3.37b (110 L, 1.5 mmol) followed by a slow addition of 
TiCl4 (121 L, 1.1 mmol). The resulting red solution was stirred at -78 °C for 5 hours and then the 
reaction was quenched with 10 mL of saturated aqueous NH4Cl and warmed to room temperature. The 
organic layer was separated and then washed with 15 mL of saturated aqueous NaHCO3. The aqueous 
layers were extracted with 20 mL of CH2Cl2. The combined organic layers were dried over Na2SO4 and 
concentrated in vacuo. The product was purified by flash column chromatography on silica gel (EtOAc/n-
Hexane = 1:3) to obtain the desired -hydroxy ketone 3.37. 
 
2-Hydroxy-(thiophen-2-yl)-4-butanone (3.37a) 
Colorless oil, 63% yield; Data for 3.37a: 
1
H NMR (500 MHz, DMSO-d6) 7.98 (d, J = 4.9 Hz, 1H), 7.94 
(d, J = 3.8 Hz, 1H), 7.24 (t, J = 4.8 Hz, 1H), 4.70 (d, J = 4.9 Hz, 1H), 4.15-4.17 (m, 1H), 2.85-3.09 (m, 
2H), 1.14 (d, J = 6.2 Hz, 3H); 
13
C NMR (125 MHz, DMSO-d6) 192.1, 144.7, 134.9, 133.6, 128.8, 63.8, 
48.4, 23.8; HRMS calcd for C8H10N2S [M+Na]
+
 193.0294, found 193.0297. 
 
(4-Chlorophenyl)-3-hydroxy-5-pentanone (3.37b) 
Yellow oil, 68% yield; Data for 3.37b: 
1
H NMR (500 MHz, DMSO-d6) 7.97 (d, J = 8.5 Hz, 2H), 7.58 
(d, J = 8.5 Hz, 2H), 4.62 (d, J = 5.5 Hz, 1H), 3.89-3.95 (m, 1H), 3.90-3.94 (m, 1H), 2.94-3.10 (m, 2H), 
1.40-1.48 (m, 2H), 0.89 (t, J = 7.4 Hz, 3H); 
13
C NMR (125 MHz, DMSO-d6) 198.5, 138.0, 136.0, 130.1, 
128.8, 68.6, 45.9, 30.2, 10.0; HRMS calcd for C11H13ClO2 [M+Na]
+
 235.0497, found 235.0502. 
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General procedure for the preparation of -diazo-1,3-diketone 3.35a, 3.35b, 3.38a and 3.38b: 
 
To a solution of -hydroxy ketone (3.34a, 3.34b, 3.37a, 3.37b) (1 mmol) in 10 mL of acetonitrile under 
argon at 0 °C was added IBX (1-hydroxy-1,2-benziodoxol-3(1H)-one 1-oxide) (364 mg, 1.3 mmol). The 
mixture was refluxed for 2 hours and was allowed to warm to room temperature and then filtered. The 
filtrate was concentrated to afford the 1,3-diketone used directly without further purification for the next 
step. 
To a solution of 1,3-diketone in 15 mL of acetonitrile under argon at 0 °C was added successively 
triethylamine (181 L, 1.3 mmol) and p-acetamido benzene sulfonyl azide (p-ABSA) (240 mg, 1 mmol). 
The mixture was stirred for 2 hours and was allowed to warm to room temperature and was diluted with a 
mixture of diethyl ether/hexane (1/1, 30 mL) and then filtered. The filtrate was concentrated and the 
residue purified by flash column chromatography on silica gel (EtOAc/n-Hexane = 1:4) to afford the -
diazo-1,3-diketone 3.35a, 3.35b, 3.38a and 3.38b. 
 
3-Diazo-(4-nitrophenyl)-butan-2,4-dione (3.35a) 
Yellow solid, 85% yield; Data for 3.35a: 
1
H NMR (500 MHz, DMSO-d6) 8.34 (d, J = 8.7 Hz, 2H), 7.95 
(d, J = 8.7 Hz, 2H), 2.46 (s, 3H); 
13
C NMR (125 MHz, DMSO-d6) 188.8, 184.0, 149.3, 142.9, 129.1, 
123.9, 84.8, 28.7. 
 
(4-Cyanophenyl)-3-diazo-butan-2,4-dione (3.35b) 
Beige solid, 77% yield; Data for 3.35b: 
1
H NMR (500 MHz, DMSO-d6) 8.01 (d, J = 8.2 Hz, 2H), 7.87 
(d, J = 8.3 Hz, 2H), 2.45 (s, 3H); 
13
C NMR (125 MHz, DMSO-d6) 189.0, 184.2, 141.4, 132.8, 128.4, 
118.2, 114.4, 84.6, 28.7. 
 
3-Diazo-(thiophen-2-yl)-butan-2,4-dione (3.38a) 
Yellow oil, 87% yield; Data for 3.38a: 
1
H NMR (600 MHz, CDCl3) 7.69-7.70 (m, 1H), 7.60-7.61 (m, 
1H), 7.15-7.16 (m, 1H), 2.60 (s, 3H); 
13
C NMR (150 MHz, CDCl3) 190.8, 175.1, 141.9, 133.5, 130.4, 
127.9, 81.7, 29.3. 
 
(4-Chlorophenyl)-4-diazo-pentan-3,5-dione (3.38b) 
Pale yellow solid, 81% yield; Data for 3.38b: 
1
H NMR (500 MHz, DMSO-d6) 7.75 (d, J = 8.5 Hz, 2H), 
7.59 (d, J = 8.5 Hz, 2H), 2.86 (q, J = 7.3 Hz, 2H), 1.05 (t, J = 7.3 Hz, 3H); 
13
C NMR (125 MHz, DMSO-
d6) 192.6, 184.1, 137.2, 136.4, 129.6, 128.8, 83.2, 33.8, 8.2. 
 
3-Diazo-(phenyl)-butan-2,4-dione (3.40) 
To a solution of compound 3.39 (3 g, 18.50 mmol) in 50 mL of acetonitrile under argon at 0 °C was 
added successively triethylamine (3.3 mL, 24.05 mmol) and p-acetamido benzene sulfonyl azide (p-
ABSA) (4.4 g, 18.50 mmol). The mixture was stirred for 2 hours and was allowed to warm to room 
temperature and was diluted with 100 mL of Et2O/n-Hexane (1:1) and then filtered. The filtrate was 
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concentrated and the residue purified by flash column chromatography on silica gel (EtOAc/n-Hexane = 
1:3) to afford the desired compound 3.40 in 89% yield as yellow solid; Data for 3.40: 
1
H NMR (500 
MHz, DMSO-d6) δ 7.73 (d, J = 7.2 Hz, 2H), 7.62 (t, J = 7.4 Hz, 1H), 7.52-7.55 (m, 2H), 2.46 (s, 3H); 
13
C 
NMR (125 MHz, DMSO-d6) δ 189.8, 185.0, 137.5, 132.5, 128.8, 127.6, 83.6, 28.8. 
 
General procedure for the preparation of 3.41 by titanium aldol reaction: 
 
To a solution of -diazo-1,3-diketone (3.35a, 3.35b, 3.38a, 3.38b and 3.40) (1 mmol) in 10 mL of 
CH2Cl2 under argon at -78 °C was added dropwise TiCl4 (121 L, 1.1 mmol) followed by Et3N (153 L, 
1.1 mmol). The resulting red solution was stirred at -78 °C for 1 hour, after which a solution of aldehyde 
(0.9 mmol) in CH2Cl2 was slowly added. The reaction mixture was stirred at -78 °C for 4 hours and then 
the reaction was quenched with 10 mL of saturated aqueous NH4Cl and warmed to room temperature. 
The organic layer was separated and then washed with 15 mL of saturated aqueous NaHCO3. The 
aqueous layers were extracted with 20 mL of CH2Cl2. The combined organic layers were dried over 
Na2SO4 and concentrated in vacuo. The product was purified by flash column chromatography on silica 
gel (EtOAc/n-Hexane = 1:3) to afford the aldol product 3.41. 
 
6-Diazo-3-hydroxy-(4-nitrophenyl)-heptan-5,7-dione (3.41a) 
Yellow oil, 69% yield; Data for 3.41a: 
1
H NMR (300 MHz, DMSO-d6)  8.33 (d, J = 8.1 Hz, 2H), 7.92 
(d, J = 8.4 Hz, 2H), 4.75-4.77 (m, 1H), 3.82-3.87 (m, 1H), 2.86-2.91 (m, 2H), 1.37-1.47 (m, 2H), 0.88 (t, 
J = 7.5 Hz, 3H); 
13
C NMR (75 MHz, DMSO-d6) 190.0, 184.3, 149.3, 143.1, 129.1, 123.8, 85.2, 68.4, 
47.9, 30.0, 10.0; HRMS calcd for C13H13N3O5 [M+Na]
+
 314.0748, found 314.0752. 
 
(4-Cyanophenyl)-6-diazo-3-hydroxy-heptan-5,7-dione (3.41b) 
Yellow oil, 81% yield; Data for 3.41b: 
1
H NMR (600 MHz, DMSO-d6)  7.99 (d, J = 8.1 Hz, 2H), 7.84 
(d, J = 8.5 Hz, 2H), 4.73-4.75 (m, 1H), 3.85-3.87 (m, 1H), 2.83-2.93 (m, 2H), 1.30-1.46 (m, 2H), 0.87 (t, 
J = 7.4 Hz, 3H); 
13
C NMR (150 MHz, DMSO-d6) 190.1, 184.5, 141.5, 132.7, 128.4, 118.2, 114.4, 84.8, 
68.4, 47.9, 30.0, 10.0; HRMS calcd for C14H13N3O3 [M+Na]
+
 294.0849, found 294.0849. 
 
(4-Cyanophenyl)-4-diazo-1-(2-fluorophenyl)-1-hydroxy-pentan-3,5-dione (3.41c) 
Yellow oil, 50% yield; Data for 3.41c: 
1
H NMR (500 MHz, DMSO-d6)  7.99 (d, J = 8.6 Hz, 2H), 7.83 
(d, J = 8.6 Hz, 2H), 7.52-7.56 (m, 1H), 7.29-7.34 (m, 1H), 7.20-7.23 (m, 1H), 7.12-7.16 (m, 1H), 5.63 (d, 
J = 4.9 Hz, 1H), 5.34-5.38 (m, 1H), 3.36 (m, 1H), 3.01 (m, 1H); 
13
C NMR (125 MHz, DMSO-d6) 189.0, 
184.4, 160.0, 158.0, 141.3, 132.8, 131.7, 129.0, 128.4, 127.9, 124.5, 118.2, 115.1, 114.4, 84.8, 62.8, 48.5; 
HRMS calcd for C18H12FN3O3 [M+Na]
+
 360.0755, found 360.0761. 
 
6-Diazo-3-hydroxy-(thiophen-2-yl)-heptan-5,7-dione (3.41d) 
Yellow oil, 77% yield; Data for 3.41d: 
1
H NMR (500 MHz, DMSO-d6)  8.04-8.05 (m, 1H), 7.92-7.93 
(m, 1H), 7.23-7.25 (m, 1H), 4.66 (d, J = 5.7 Hz, 1H), 3.84-3.88 (m, 1H), 2.91-2.98 (m, 2H), 1.33-1.48 (m, 
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2H), 0.87 (t, J = 7.4 Hz, 3H); 
13
C NMR (125 MHz, DMSO-d6) 175.4, 141.8, 134.6, 132.0, 128.4, 82.4, 
68.3, 48.0, 30.0, 10.0; HRMS calcd for C11H12N2O3S [M+Na]
+
 275.0461, found 275.0468. 
 
(4-Chlorophenyl)-6-diazo-3-hydroxy-4-methyl-heptan-5,7-dione (3.41e) 
Yellow oil, 63% yield; Inseparable diastereomeric mixture; Data for 3.41e (major isomer): 
1
H NMR (300 
MHz, CDCl3) 8.01 (d, J = 8.7 Hz, 2H), 7.47 (d, J = 8.7 Hz, 2H), 4.60-4.67 (m, 1H), 4.18 (d, J = 4.8 Hz, 
1H), 3.10-3.16 (m, 1H), 1.63-1.72 (m, 2H), 0.98-1.20 (m, 6H); 
13
C NMR (75 MHz, CDCl3) 191.3, 
171.6, 140.3, 133.5, 130.5, 128.8, 84.3, 57.4, 36.3, 23.0, 13.2, 10.0; HRMS calcd for C14H15ClN2O3 
[M+Na]
+
 317.0664, found 317.0657. 
 
4-Diazo-1-hydroxy-(phenyl)-1-(thiophen-2-yl)-pentan-3,5-dione (3.41f) 
Yellow oil, 57% yield; Data for 3.41f: 
1
H NMR (300 MHz, DMSO-d6) 7.73 (m, 2H), 7.60 (m, 1H), 7.51 
(t, J = 7.7 Hz, 2H), 7.41 (dd, J = 4.9, 1.3 Hz, 1H), 6.97-7.02 (m, 2H), 5.88-5.90 (m, 1H), 5.38-5.40 (m, 
1H), 3.24-3.46 (m, 2H); 
13
C NMR (75 MHz, DMSO-d6) 189.7, 185.1, 149.7, 137.5, 132.6, 128.8, 127.7, 
126.8, 124.5, 123.2, 83.9, 65.2, 50.4; HRMS calcd for C15H12N2O3S [M+Na]
+
 323.0461, found 323.0460. 
 
4-Diazo-1-hydroxy-(phenyl)-1-(phenyl)-pentan-3,5-dione (3.41g) 
Yellow oil, 52% yield; Data for 3.41g: 
1
H NMR (300 MHz, DMSO-d6)  7.46-7.60 (m, 3H), 7.4-7.44 (m, 
4H), 7.28-7.42 (m, 3H), 5.28 (m, 1H), 3.56 (m, 1H), 3.33-3.44 (m, 2H); 
13
C NMR (125 MHz, DMSO-d6) 
192.4, 184.7, 142.6, 136.7, 132.6, 128.7, 128.2, 127.4, 127.1, 125.5, 83.6, 70.3, 49.4; HRMS calcd for 
C17H14N2O3 [M+Na]
+
 317.0897, found 317.0901. 
 
4-Diazo-1-(cyclohexyl)-1-hydroxy-(phenyl)-pentan-3,5-dione (3.41h) 
Yellow oil, 79% yield; Data for 3.41h: 
1
H NMR (500 MHz, DMSO-d6) 7.71 (d, J = 7.3 Hz, 2H), 7.62 (t, 
J = 7.4 Hz, 1H), 7.52 (t, J = 7.6 Hz, 2H), 4.61 (d, J = 5.8 Hz, 1H), 3.74-3.78 (m, 1H), 2.90 (d, J = 5.7 Hz, 
2H), 1.59-1.76 (m, 5H), 0.95-1.28 (m, 6H); 
13
C NMR (125 MHz, DMSO-d6)  191.4, 185.2, 137.6, 132.5, 
128.7, 127.7, 83.6, 71.0, 45.5, 43.7, 28.8, 27.6, 26.2, 25.9, 25.8; HRMS calcd for C17H20N2O3 [M+Na]
+
 
323.1366, found 323.1363. 
 
6-Diazo-3-hydroxy-2-methyl-(phenyl)-heptan-5,7-dione (3.41i) 
Yellow oil, 85% yield; Data for 3.41i: 
1
H NMR (500 MHz, DMSO-d6) 7.71 (d, J = 7.3 Hz, 2H), 7.62 (t, 
J = 7.5 Hz, 1H), 7.52 (t, J = 7.6 Hz, 2H), 4.65 (br. s, 1H), 3.76-3.78 (m, 1H), 2.85-2.95 (m, 2H), 1.60-1.64 
(m, 1H), 0.85 (m, 6H); 
13
C NMR (125 MHz, DMSO-d6) 191.3, 185.2, 137.6, 132.5, 128.7, 127.7, 83.7, 
71.5, 45.4, 33.6, 18.7, 17.5; HRMS calcd for C14H16N2O3 [M+Na]
+
 283.1053, found 283.1052. 
 
General procedure for the preparation of pyridazine derivatives 3.42: 
 
To a solution of 3.41 (1 mmol) in 10 mL of acetonitrile under argon was added IBX (1-hydroxy-1,2-
benziodoxol-3(1H)-one 1-oxide) (364 mg, 1.3 mmol). The mixture was refluxed for 2 hours and was 
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allowed to warm to room temperature and then filtered. The filtrate was concentrated and used directly 
without further purification for the next step. 
To the previously prepared crude in 15 mL of i-Pr2O was added P(n-Bu)3 (250 L, 1.0 mmol). The 
reaction mixture was stirred under argon at room temperature for 30 minutes, which after this time a 
precipitate was formed. The suspension was filtered, washed with i-Pr2O and dried to afford 3.42a, 3.42b, 
3.42d, 3.42e and 3.42i. 3.42c, 3.42f, 3.42g and 3.42h were purified by flash column chromatography on 
silica gel (EtOAc/n-Hexane = 8:2) due to no formation of precipitate. 
 
(6-Ethyl-4-hydroxy-pyridazinyl)-(4-nitrophenyl)-methanone (3.42a) 
Brown solid, 60% yield; Data for 3.42a: 
1
H NMR (500 MHz, DMSO-d6)  13.54 (br. s, 1H), 8.34 (d, J = 
8.5 Hz, 2H), 8.05 (d, J = 8.4 Hz, 2H), 6.47 (s, 1H), 2.63 (q, J = 7.4 Hz, 2H), 1.24 (t, J = 7.6 Hz, 3H); 
13
C 
NMR (125 MHz, DMSO-d6) 157.0, 152.7, 150.4, 140.2, 130.6, 124.1, 116.5, 24.3, 12.5; HRMS calcd 
for C13H11N3O4 [M+H]
+
 274.0822, found 274.0829. 
 
(4-Cyanophenyl)-(6-ethyl-4-hydroxy-pyridazinyl)-methanone (3.42b) 
Yellow solid, 57% yield; Data for 3.42b: 
1
H NMR (600 MHz, DMSO-d6)  13.55 (br. s, 1H), 8.02 (d, J = 
8.3 Hz, 2H), 7.96 (d, J = 8.3 Hz, 2H), 6.46 (s, 1H), 2.62 (q, J = 7.6 Hz, 2H), 1.24 (t, J = 7.6 Hz, 3H); 
13
C 
NMR (150 MHz, DMSO-d6) 191.9, 169.1, 156.8, 152.8, 138.7, 133.0, 129.8, 118.1, 116.3, 115.9, 24.1, 
12.5; HRMS calcd for C14H11N3O2 [M+H]
+
 254.0924, found 254.0928. 
 
(4-Cyanophenyl)-(6-(2-fluorophenyl)-4-hydroxy-pyridazinyl)-methanone (3.42c) 
Beige solid, 45% yield; Data for 3.42c: 
1
H NMR (600 MHz, DMSO-d6)  13.94 (br. s, 1H), 8.05 (m, 4H), 
7.73-7.76 (m, 1H), 7.66-7.69 (m, 1H), 7.46-7.49 (m, 1H), 7.43-7.45 (m, 1H), 6.78 (s, 1H); 
13
C NMR (150 
MHz, DMSO-d6) 191.7, 159.9, 158.3, 152.9, 138.7, 133.4, 133.3, 133.0, 130.9, 130.0, 125.9, 118.9, 
118.2, 116.6, 116.5, 116.0; HRMS calcd for C18H10FN3O2 [M+H]
+
 320.0830, found 320.0831. 
 
(6-Ethyl-4-hydroxy-pyridazinyl)-(thiophen-2-yl)-methanone (3.42d) 
Orange solid, 55% yield; Data for 3.42d: 
1
H NMR (600 MHz, DMSO-d6) 13.41 (br. s, 1H), 8.13-8.14 
(m, 1H), 7.69-7.70 (m, 1H), 7.24-7.26 (m, 1H), 6.42 (s, 1H), 2.61 (q, J = 7.6 Hz, 2H), 1.23 (t, J = 7.7 Hz, 
3H); 
13
C NMR (150 MHz, DMSO-d6) 184.0, 169.1, 156.5, 153.0, 142.2, 136.8, 136.5, 129.1, 116.0, 
24.1, 12.5; HRMS calcd for C11H10N2O2S [M+H]
+
 235.0536, found 235.0540. 
 
(4-Chlorophenyl)-(6-ethyl-4-hydroxy-5-methyl-pyridazinyl)-methanone (3.42e) 
Colorless oil, 57% yield; Data for 3.42e: 
1
H NMR (600 MHz, DMSO-d6)  13.37 (br. s, 1H), 7.81 (d, J = 
8.4 Hz, 2H), 7.61 (d, J = 8.5 Hz, 2H), 2.69 (q, J = 7.3 Hz, 2H), 1.95 (s, 3H), 1.22 (t, J = 7.5 Hz, 3H); 
13
C 
NMR (150 MHz, DMSO-d6) 191.9, 168.6, 153.1, 150.6, 139.0, 134.4, 131.2, 129.1, 125.5, 22.6, 12.7, 
9.1; HRMS calcd for C14H13ClN2O2 [M+H]
+
 277.0738, found 277.0739. 
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(4-Hydroxy-6-(thiophen-2-yl)-pyridazinyl)-(phenyl)-methanone (3.42f) 
Orange solid, 53% yield; Data for 3.42f: 
1
H NMR (600 MHz, DMSO-d6) 7.88-7.92 (m, 4H), 7.72 (t, J = 
7.4 Hz, 1H), 7.57 (t, J = 7.7 Hz, 2H), 7.29-7.31 (m, 1H), 6.94 (br. s, 1H); 
13
C NMR (150 MHz, DMSO-
d6) 192.4, 135.5, 134.3, 131.0, 129.6, 129.0, 128.9; HRMS calcd for C15H10N2O2S [M+H]
+
 283.0536, 
found 283.0534. 
 
(4-Hydroxy-6-phenyl-pyridazinyl)-(phenyl)-methanone (3.42g) 
Brown solid, 48% yield; Data for 3.42g: 
1
H NMR (600 MHz, DMSO-d6)  7.89 (d, J = 8.4 Hz, 2H), 7.84 
(d, J = 7.8 Hz, 2H), 7.72 (t, J = 7.4 Hz, 1H), 7.56-7.62 (m, 5H), 6.85 (s, 1H); 
13
C NMR (150 MHz, 
DMSO-d6) 192.6, 135.4, 134.3, 131.2, 129.5, 129.3, 129.0, 127.4, 115.3; HRMS calcd for C17H12N2O2 
[M+H]
+
 277.0971, found 277.0978. 
 
(6-Cyclohexyl-4-hydroxy-pyridazinyl)-(phenyl)-methanone (3.42h) 
Beige solid, 52% yield; Data for 3.42h: 
1
H NMR (600 MHz, DMSO-d6)  13.36 (br. s, 1H), 7.81 (d, J = 
8.3 Hz, 2H), 7.69 (t, J = 7.4 Hz, 1H), 7.55 (t, J = 8.1 Hz, 2H), 6.40 (s, 1H), 2.54-2.59 (m, 1H), 1.69-1.90 
(m, 5H), 1.33-1.52 (m, 5H); 
13
C NMR (150 MHz, DMSO-d6) 192.7, 159.5, 154.1, 135.4, 134.3, 129.4, 
129.0, 114.2, 40.1, 31.0, 25.7, 25.1; HRMS calcd for C17H18N2O2 [M+H]
+
 283.1441, found 283.1440. 
 
(4-Hydroxy-6-isopropyl-pyridazinyl)-(phenyl)-methanone (3.42i) 
Beige solid, 55% yield; Data for 3.42i: 
1
H NMR (600 MHz, DMSO-d6)  13.41 (br. s, 1H), 7.81 (d, J = 
8.2 Hz, 2H), 7.70 (t, J = 7.4 Hz, 1H), 7.55 (t, J = 7.9 Hz, 2H), 6.43 (s, 1H), 2.88-2.93 (m, 1H), 1.27 (d, J = 
7.1 Hz, 6H); 
13
C NMR (150 MHz, DMSO-d6) 192.7, 169.3, 160.5, 154.2, 135.4, 134.3, 129.4, 129.0, 
113.8, 30.3, 21.1; HRMS calcd for C14H14N2O2 [M+H]
+
 243.1128, found 243.1130. 
 
2-Diazo-(4-methoxyphenyl)-1-(thiophen-2-yl)-pent-4-ene-1,3-dione (3.43) 
Yellow solid, 62% yield; Data for 3.43: 
1
H NMR (500 MHz, DMSO-d6)  8.07 (d, J = 3.9 Hz, 1H), 7.97 
(d, J = 3.8 Hz, 1H), 7.56-7.74 (m, 4H), 7.26 (t, J = 3.9 Hz, 1H), 7.02 (d, J = 8.8 Hz, 2H), 3.82 (s, 3H); 
13
C 
NMR (125 MHz, DMSO-d6) 181.2, 175.6, 161.6, 142.1, 141.8, 134.7, 132.0, 130.6, 128.4, 126.9, 
120.5, 114.7, 82.9, 55.5. 
 
Method A: preparation of pyrazolo[4,3-c]pyridazine analogues 3.44: 
 
A solution of 3.42 (1 mmol) in 5 mL of POCl3 was heated at 95 °C for 4 hours, after which the reaction 
mixture was cooled down to room temperature. POCl3 was evaporated and the residue was dissolved in 
EtOAc and washed 2 times with 20 mL of saturated aqueous NaHCO3. The organic layer was dried over 
Na2SO4 and concentrated in vacuo to afford the chlorinated pyridazine used directly without further 
purification for the next step. 
To a solution of chlorinated pyridazine in 5 mL of EtOH was added hydrazine hydrate 64% (63 L, 1.3 
mmol) followed by Et3N (181 L, 1.3 mmol) and refluxed for 4 hours. After completion of the reaction 
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(monitored by TLC), the reaction mixture was allowed to cool to room temperature. CH2Cl2 was added 
and the organic layer was then washed 2 times with 10 mL of saturated aqueous NaHCO3, and 1 time 
with 10 mL of saturated aqueous NaCl. The organic layer was dried over Na2SO4 and concentrated in 
vacuo, the residue was purified by flash column chromatography on silica gel (EtOAc) to obtain the 
desired pyrazolo[4,3-c]pyridazine 3.44. 
 
3-(4-Cyanophenyl)-6-ethyl-pyrazolo[4,3-c]pyridazine (3.44a) 
Beige solid, 83% yield; Data for 3.44a: 
1
H NMR (600 MHz, DMSO-d6)  8.76 (d, J = 8.5 Hz, 2H), 8.05 
(d, J = 8.5 Hz, 2H), 7.80 (s, 1H), 3.16 (q, J = 7.6 Hz, 2H), 1.38 (t, J = 7.4 Hz, 3H); 
13
C NMR (150 MHz, 
DMSO-d6) 159.0, 144.1, 141.0, 135.9, 133.8, 133.0, 127.3, 118.9, 111.1, 105.2, 28.9, 14.6; HRMS 
calcd for C14H11N5 [M+H]
+
 250.1087, found 250.1089. 
 
3-(4-Cyanophenyl)-6-(2-fluorophenyl)-pyrazolo[4,3-c]pyridazine (3.44b) 
White solid, 79% yield; Data for 3.44b: 
1
H NMR (300 MHz, DMSO-d6)  14.25 (br. s, 1H), 8.78 (d, J = 
8.3 Hz, 2H), 8.25 (s, 1H), 8.05-8.14 (m, 3H), 7.59-7.61 (m, 1H), 7.45 (t, J = 8.4 Hz, 2H); 
13
C NMR (75 
MHz, DMSO-d6) 161.7, 158.4, 149.6, 144.2, 141.3, 135.7, 133.3, 133.1, 131.7, 127.4, 125.1, 118.9, 
116.7, 116.4, 111.4, 107.8; HRMS calcd for C18H10N5 [M+H]
+
 316.0993, found 316.0989. 
 
3-(4-Chlorophenyl)-7-methyl-6-ethyl-pyrazolo[4,3-c]pyridazine (3.44c) 
Beige solid, 87% yield; Data for 3.44c: 
1
H NMR (500 MHz, DMSO-d6)  8.64 (d, J = 8.6 Hz, 2H), 7.68 
(d, J = 8.6 Hz, 2H), 3.17 (q, J = 7.5 Hz, 2H), 2.61 (s, 3H), 1.37 (t, J = 7.6 Hz, 3H); 
13
C NMR (125 MHz, 
DMSO-d6) 157.2, 143.6, 141.6, 134.7, 133.5, 130.6, 129.1, 128.4, 115.9, 25.6, 13.9, 12.0; HRMS calcd 
for C14H13ClN4 [M+H]
+
 273.0901, found 273.0905. 
 
3-Phenyl-6-(thiophen-2-yl)-pyrazolo[4,3-c]pyridazine (3.44d) 
Pale yellow solid, 81% yield; Data for 3.44d: 
1
H NMR (600 MHz, DMSO-d6)  13.94 (br. s, 1H), 8.59 (d, 
J = 8.4 Hz, 2H), 8.35 (s, 1H), 8.06 (d, J = 3.7 Hz, 1H), 7.76 (d, J = 5.0 Hz, 1H), 7.60 (t, J = 7.9 Hz, 2H), 
7.50 (m, 1H), 7.26 (m, 1H); 
13
C NMR (150 MHz, DMSO-d6) 148.9, 144.5, 143.2, 141.2, 133.5, 131.3, 
129.4, 129.2, 129.0, 128.5, 127.0, 126.5, 101.3; HRMS calcd for C15H10N4S [M+H]
+
 279.0699, found 
279.0701. 
 
3-Phenyl-6-phenyl-pyrazolo[4,3-c]pyridazine (3.44e) 
Beige solid, 79% yield; Data for 3.44e: 
1
H NMR (600 MHz, DMSO-d6)  13.96 (br. s, 1H), 8.63 (d, J = 
7.3 Hz, 2H), 8.34 (s, 1H), 8.30 (d, J = 7.4 Hz, 2H), 7.59-7.62 (m, 4H), 7.49-7.56 (m, 2H); 
13
C NMR (150 
MHz, DMSO-d6) 152.7, 144.6, 143.0, 137.0, 133.8, 131.4, 129.6, 129.2, 129.1, 129.0, 127.5, 127.0, 
103.7; HRMS calcd for C17H12N4 [M+H]
+
 273.1135, found 273.1133. 
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6-Isopropyl-3-phenyl-pyrazolo[4,3-c]pyridazine (3.44f) 
Beige solid, 75% yield; Data for 3.44f: 
1
H NMR (600 MHz, DMSO-d6)  13.70 (br. s, 1H), 8.58 (d, J = 
8.3 Hz, 2H), 7.71 (s, 1H), 7.58 (t, J = 7.4 Hz, 2H), 7.48 (t, J = 7.4 Hz, 1H), 3.46-3.51 (m, 1H), 1.41 (d, J = 
6.9 Hz, 6H); 
13
C NMR (150 MHz, DMSO-d6) 162.2, 144.3, 142.7, 133.6, 131.6, 129.0, 128.9, 126.9, 
103.5, 34.4, 22.9; HRMS calcd for C14H14N4 [M+H]
+
 239.1291, found 239.1293. 
 
Method B: preparation of thieno[3,2-c]pyridazine analogues 3.45: 
 
A solution of 3.42 (1 mmol) in 5 mL of POCl3 was heated at 95 °C for 4 hours, after which the reaction 
mixture was cooled down to room temperature. POCl3 was evaporated and the residue was dissolved in 
EtOAc and washed 2 times with 20 mL of saturated aqueous NaHCO3. The organic layer was dried over 
Na2SO4 and concentrated in vacuo to afford the chlorinated pyridazine used directly without further 
purification for the next step. 
To a solution of chlorinated pyridazine in 5 mL of EtOH was added methyl thioglycolate (134 L, 1.5 
mmol) followed by Et3N (417 L, 3 mmol) and refluxed for 16 hours. After completion of the reaction 
(monitored by TLC), the reaction mixture was allowed to cool to room temperature. CH2Cl2 was added 
and the organic layer was then washed 2 times with 10 mL of saturated aqueous NaHCO3, and 1 time 
with 10 mL of saturated aqueous NaCl. The organic layer was dried over Na2SO4 and concentrated in 
vacuo, the residue was purified by flash column chromatography on silica gel (EtOAc/n-Hexane = 1:9) to 
obtain the desired thieno[3,2-c]pyridazine 3.45. 
 
Ethyl 3-ethyl-7-(4-nitrophenyl)-thieno[3,2-c]pyridazine-6-carboxylate (3.45a) 
Brown solid, 52% yield; Data for 3.45a: 
1
H NMR (500 MHz, DMSO-d6)  8.47 (s, 1H), 8.36 (d, J = 8.8 
Hz, 2H), 7.89 (d, J = 8.9 Hz, 2H), 4.25 (q, J = 7.0 Hz, 2H), 3.12 (q, J = 7.6 Hz, 2H), 1.36 (t, J = 7.6 Hz, 
3H), 1.15 (t, J = 7.1 Hz, 3H); 
13
C NMR (125 MHz, DMSO-d6) 161.1, 159.6, 156.4, 147.5, 139.4, 139.0, 
138.0, 134.4, 132.3, 122.7, 119.6, 62.3, 28.8, 14.2, 13.8; HRMS calcd for C17H15N3O4S [M+H]
+
 
358.0856, found 358.0860. 
 
Ethyl 3-ethyl-7-(thiophen-2-yl)-thieno[3,2-c]pyridazine-6-carboxylate (3.45b) 
Beige solid, 38% yield; Data for 3.45b: 
1
H NMR (600 MHz, CDCl3)  7.81-7.83 (m, 2H), 7.58-7.59 (m, 
1H), 7.19-7.21 (m, 1H), 4.39 (q, J = 7.1 Hz, 2H), 3.20 (q, J = 7.7 Hz, 2H), 1.47 (t, J = 7.7 Hz, 3H), 1.35 
(t, J = 7.1 Hz, 3H); 
13
C NMR (150 MHz, DMSO-d6) 161.8, 159.6, 156.3, 137.9, 134.5, 131.7, 131.5, 
131.0, 128.7, 126.5, 118.1, 62.3, 29.4, 14.0; HRMS calcd for C15H14N2O2S2 [M+H]
+
 319.0569, found 
319.0579. 
 
Ethyl 7-phenyl-3-(thiophen-2-yl)-thieno[3,2-c]pyridazine-6-carboxylate (3.45c) 
Yellow solid, 33% yield; Data for 3.45c: 
1
H NMR (300 MHz, DMSO-d6)  9.03 (s, 1H), 7.97 (d, J = 3.4 
Hz, 1H), 7.81 (d, J = 4.8 Hz, 1H), 7.59-7.61 (m, 2H), 7.51-7.53 (m, 3H), 7.29 (d, J = 4.6 Hz, 1H), 4.25 (q, 
J = 7.0 Hz, 2H), 1.15 (t, J = 7.1 Hz, 3H); 
13
C NMR (75 MHz, DMSO-d6) 161.4, 156.9, 149.5, 141.5, 
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140.4, 138.4, 133.5, 132.0, 130.8, 130.4, 128.9, 128.7, 127.7, 127.3, 115.8, 62.1, 13.8; HRMS calcd for 
C19H14N2O2S2 [M+H]
+
 367.0569, found 367.0570. 
 
Methyl 3-phenyl-7-phenyl-thieno[3,2-c]pyridazine-6-carboxylate (3.45d) 
Brown solid, 41% yield; Data for 3.45d: 
1
H NMR (500 MHz, DMSO-d6)  9.09 (s, 1H), 8.25 (d, J = 7.3 
Hz, 2H), 7.60-7.64 (m, 4H), 7.53-7.57 (m, 4H), 3.81 (s, 3H); 
13
C NMR (125 MHz, DMSO-d6) 161.7, 
157.0, 153.2, 141.6, 138.5, 136.1, 133.1, 132.0, 130.8, 130.2, 129.3, 128.7, 127.7, 127.3, 117.9, 53.1; 
HRMS calcd for C20H14N2O2S [M+H]
+
 347.0849, found 347.0846. 
 
Method C: preparation of dihydro-pyridazino[4,3-e][1,4]diazepine analogues 3.46: 
 
A solution of 3.42 (1 mmol) in 5 mL of POCl3 was heated at 95 °C for 4 hours, after which the reaction 
mixture was cooled down to room temperature. POCl3 was evaporated and the residue was dissolved in 
EtOAc and washed 2 times with 20 mL of saturated aqueous NaHCO3. The organic layer was dried over 
Na2SO4 and concentrated in vacuo to afford the chlorinated pyridazine used directly without further 
purification for the next step. 
To a solution of chlorinated pyridazine in 5 mL of EtOH was added ethylene diamine (87 L, 1.3 mmol) 
followed by Et3N (181 L, 1.3 mmol) and refluxed for 16 hours. After completion of the reaction 
(monitored by TLC), the reaction mixture was allowed to cool to room temperature. CH2Cl2 was added 
and the organic layer was then washed 2 times with 10 mL of saturated aqueous NaHCO3, and 1 time 
with 10 mL of saturated aqueous NaCl. The organic layer was dried over Na2SO4 and concentrated in 
vacuo, the residue was purified by flash column chromatography on silica gel (MeOH/EtOAc = 1:9) to 
obtain the desired dihydro-pyridazino[4,3-e][1,4]diazepine 3.46. 
 
3-Ethyl-6,7-dihydro-9-(4-nitrophenyl)-5H-pyridazino[4,3-e][1,4]diazepine (3.46a) 
Pale yellow solid, 77% yield; Data for 3.46a: 
1
H NMR (500 MHz, DMSO-d6)  8.21 (d, J = 8.8 Hz, 2H), 
7.65 (m, 3H), 6.72 (s, 1H), 4.10-4.11 (m, 2H), 3.51-3.52 (m, 2H), 2.75 (q, J = 7.6 Hz, 2H), 1.23 (t, J = 7.6 
Hz, 3H); 
13
C NMR (125 MHz, DMSO-d6) 168.0, 161.7, 148.6, 147.3, 146.6, 139.8, 130.3, 122.7, 109.9, 
53.3, 47.5, 28.0, 13.4; HRMS calcd for C15H15N5O2 [M+H]
+
 298.1298, found 298.1306. 
 
9-(4-Cyanophenyl)-6,7-dihydro-3-(2-fluorophenyl)-5H-pyridazino[4,3-e][1,4]diazepine (3.46b) 
White solid, 79% yield; Data for 3.46b: 
1
H NMR (500 MHz, DMSO-d6)  8.02-8.05 (m, 1H), 7.96-7.97 
(m, 1H), 7.84 (d, J = 8.2 Hz, 2H), 7.64 (d, J = 7.8 Hz, 2H), 7.53-7.57 (m, 1H), 7.36-7.41 (m, 2H), 7.32 (s, 
1H), 4.16-4.17 (m, 2H), 3.56-3.57 (m, 2H); 
13
C NMR (125 MHz, DMSO-d6) 168.0, 161.1, 159.1, 151.8, 
146.5, 131.8, 131.7, 131.5, 130.7, 130.0, 125.0, 124.3, 118.9, 116.5, 112.3, 111.0, 53.4, 47.6; HRMS 
calcd for C20H14FN5 [M+H]
+
 344.1306, found 344.1301. 
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3-Ethyl-6,7-dihydro-9-(thiophen-2-yl)-5H-pyridazino[4,3-e][1,4]diazepine (3.46c) 
Yellow solid, 81% yield; Data for 3.46c: 
1
H NMR (500 MHz, DMSO-d6)  7.58 (d, J = 4.9 Hz, 1H), 7.36 
(d, J = 3.0 Hz, 1H), 7.31 (br. s, 1H), 7.05 (t, J = 4.0 Hz, 1H), 6.69 (s, 1H), 3.98-3.99 (m, 2H), 3.52-3.53 
(m, 2H), 2.78 (q, J = 7.6 Hz, 2H), 1.26 (t, J = 7.6 Hz, 3H); 
13
C NMR (125 MHz, DMSO-d6) 162.6, 
162.1, 146.0, 145.1, 139.9, 130.5, 129.2, 127.2, 110.2, 51.4, 48.3, 28.0, 13.4; HRMS calcd for C13H14N4S 
[M+H]
+
 259.1012, found 259.1007. 
 
9-(4-Chlorophenyl)-3-Ethyl-6,7-dihydro-4-methyl-5H-pyridazino[4,3-e][1,4]diazepine (3.46d) 
Beige solid, 82% yield; Data for 3.46d: 
1
H NMR (300 MHz, DMSO-d6)  7.40 (m, 4H), 6.64 (br. s, 1H), 
4.01-4.04 (m, 2H), 3.58-3.60 (m, 2H), 2.86 (q, J = 7.6 Hz, 2H), 1.22 (t, J = 7.5 Hz, 3H); 
13
C NMR (75 
MHz, DMSO-d6) 168.6, 159.7, 144.6, 141.2, 139.7, 133.3, 130.8, 127.5, 117.6, 52.5, 48.7, 26.7, 13.3, 
11.7; HRMS calcd for C16H17ClN4 [M+H]
+
 301.1214, found 301.1217. 
 
6,7-Dihydro-9-phenyl-3-(thiophen-2-yl)-5H-pyridazino[4,3-e][1,4]diazepine (3.46e) 
White solid, 79% yield; Data for 3.46e: 
1
H NMR (600 MHz, DMSO-d6)  7.73-7.74 (m, 1H), 7.69-7.70 
(m, 1H), 7.61-7.62 (m, 1H), 7.34-7.44 (m, 5H), 7.25 (s, 1H), 7.21-7.23 (m, 1H), 4.07-4.08 (m, 2H), 3.56-
3.58 (m, 2H); 
13
C NMR (150 MHz, DMSO-d6) 169.1, 151.2, 146.7, 141.8, 141.0, 140.5, 129.5, 129.1, 
128.7, 128.4, 127.5, 126.1, 106.2, 52.3, 48.3; HRMS calcd for C17H14N4S [M+H]
+
 307.1012, found 
307.1016. 
 
6,7-Dihydro-3-phenyl-9-phenyl-5H-pyridazino[4,3-e][1,4]diazepine (3.46f) 
Yellow solid, 77% yield; Data for 3.46f: 
1
H NMR (600 MHz, DMSO-d6)  8.01 (m, 2H), 7.60-7.61 (m, 
1H), 7.35-7.56 (m, 9H), 7.31 (s, 1H), 4.09-4.10 (m, 2H), 3.58-3.60 (m, 2H); 
13
C NMR (150 MHz, 
DMSO-d6) 169.3, 155.3, 146.8, 141.9, 140.9, 136.3, 129.8, 129.1, 129.0, 128.7, 127.5, 126.7, 108.5, 
52.4, 48.3; HRMS calcd for C19H16N4 [M+H]
+
 301.1448, found 301.1446. 
 
3-Cyclohexyl-6,7-dihydro-9-phenyl-5H-pyridazino[4,3-e][1,4]diazepine (3.46g) 
White solid, 79% yield; Data for 3.46g: 
1
H NMR (500 MHz, DMSO-d6)  7.34-7.39 (m, 6H), 6.67 (s, 
1H), 4.01-4.03 (m, 2H), 3.51-3.52 (m, 2H), 2.68-2.72 (m, 1H), 1.70-1.90 (m, 5H), 1.24-1.50 (m, 5H); 
13
C 
NMR (125 MHz, DMSO-d6) 169.4, 164.3, 146.7, 142.0, 140.6, 129.1, 128.6, 127.4, 108.9, 52.3, 48.3, 
43.3, 32.2, 26.1, 25.8; HRMS calcd for C19H2N4 [M+H]
+
 307.1917, found 307.1909. 
 
6,7-Dihydro-3-isopropyl-9-phenyl-5H-pyridazino[4,3-e][1,4]diazepine (3.46h) 
White solid, 78% yield; Data for 3.46h: 
1
H NMR (500 MHz, DMSO-d6)  7.34-7.39 (m, 6H), 6.70 (s, 
1H), 4.01-4.02 (m, 2H), 3.52-3.53 (m, 2H), 3.02-3.07 (m, 1H), 1.25 (d, J = 6.9 Hz, 6H); 
13
C NMR (125 
MHz, DMSO-d6) 169.4, 165.2, 146.7, 142.0, 140.6, 129.1, 128.6, 127.4, 108.5, 52.3, 48.3, 33.5, 22.2; 
HRMS calcd for C16H18N4 [M+H]
+
 267.1604, found 267.1602. 
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Method D: preparation of isoxazolo[4,5-c]pyridazine analogues 3.47: 
 
A solution of 3.42 (1 mmol) in 5 mL of POCl3 was heated at 95 °C for 4 hours, after which the reaction 
mixture was cooled down to room temperature. POCl3 was evaporated and the residue was dissolved in 
EtOAc and washed 2 times with 20 mL of saturated aqueous NaHCO3. The organic layer was dried over 
Na2SO4 and concentrated in vacuo to afford the chlorinated pyridazine used directly without further 
purification for the next step. 
To a solution of chlorinated pyridazine in 5 mL of EtOH and 1 mL of pyridine was added hydroxylamine 
hydrochloride (208 mg, 3 mmol) and refluxed for 16 hours. After conversion of the ketone into the 
corresponding oxime (monitored by TLC), the reaction mixture was allowed to cool to room temperature. 
CH2Cl2 was added and the organic layer was then washed 2 times with 10 mL of saturated aqueous 
NaHCO3, and 1 time with 10 mL of saturated aqueous NaCl. The organic layer was dried over Na2SO4 
and concentrated in vacuo, to the residue obtained dissolved in THF was slowly added NaH 60% (52 mg, 
1.3 mmol) under argon at room temperature. The reaction mixture was heated at 40 °C for 2 hours, after 
completion of the reaction (monitored by TLC), the reaction mixture was allowed to cool to room 
temperature. CH2Cl2 was added and the organic layer was then washed 2 times with 10 mL of saturated 
aqueous NaHCO3, and 1 time with 10 mL of saturated aqueous NaCl. The organic layer was dried over 
Na2SO4 and concentrated in vacuo, the residue was purified by flash column chromatography on silica gel 
(EtOAc/n-Hexane = 1:4) to obtain the desired isoxazolo[4,5-c]pyridazine 3.47. 
 
3-(4-Chlorophenyl)-7-methyl-6-ethyl-isoxazolo[4,5-c]pyridazine (3.47a) 
Beige solid, 61% yield; Data for 3.47a: 
1
H NMR (600 MHz, DMSO-d6) 8.55 (d, J = 8.7 Hz, 2H), 7.78 
(d, J = 8.7 Hz, 2H), 3.20 (q, J = 7.5 Hz, 2H), 2.60 (s, 3H), 1.37 (t, J = 7.5 Hz, 3H); 
13
C NMR (150 MHz, 
DMSO-d6) 162.3, 156.2, 154.4, 144.6, 136.8, 129.9, 129.7, 125.2, 117.3, 25.8, 13.3, 10.4; HRMS calcd 
for C14H12ClN3O [M+H]
+
 274.0742, found 274.0743. 
 
3-Phenyl-6-(thiophen-2-yl)-isoxazolo[4,5-c]pyridazine (3.47b) 
Orange solid, 46% yield; Data for 3.47b: 
1
H NMR (600 MHz, DMSO-d6)  8.80 (s, 1H), 8.52-8.54 (m, 
2H), 8.15 (d, J = 3.7 Hz, 1H), 7.88 (d, J = 5.0 Hz, 1H), 7.71-7.72 (m, 3H), 7.32 (t, J = 5.0 Hz, 1H); 
13
C 
NMR (150 MHz, DMSO-d6) 156.7, 155.1, 153.0, 145.9, 139.6, 132.1, 131.4, 129.5, 128.9, 128.7, 
128.3, 125.9, 101.8; HRMS calcd for C15H9N3OS [M+H]
+
 280.0539, found 280.0543. 
 
Sodium benzene sulfinate (3.49) 
A solution of sodium sulfite (627 mg, 4.98 mmol) and sodium bicarbonate (418 mg, 4.98 mmol) in 20 mL 
of water was stirred vigorously with benzenesulfonyl chloride (301 L, 2.36 mmol) at 75 °C for 5 h. 
After cooling to ambient temperature, the reaction mixture was directly lyophilized. The resulting white 
solid was stirred with 20 mL of methanol for 10 minutes and the insoluble inorganic salts removed by 
filtration. The filtrate was concentrated in vacuo to approximately 5 mL and an equal volume of diethyl 
ether was added. The precipitated solid containing residual inorganic salts was filtered and set aside. The 
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remaining filtrate was diluted with excess diethyl ether, filtered and the filtered solid dried in vacuo to 
give sodium 3-chloro-benzenesulfinate in 73% as a white solid used directly without further purification. 
 
1-Phenylsulfonyl-2-propanone (3.51) 
To a solution of chloroacetone (80 L, 1.0 mmol) in 10 mL of DMF was added at room temperature 3.49 
(246 mg, 1.5 mmol). After stirring 24 h at room temperature, the reaction mixture was diluted with 20 mL 
of Et2O and 20 mL of water. The aqueous phase was extracted with 3x15 mL Et2O before washing with 
10 mL of saturated aqueous NaCl. The organic layer was dried over Na2SO4 and concentrated in vacuo, 
the residue was purified by flash column chromatography on silica gel (EtOAc/n-Hexane = 1:3) to afford 
the sulfonyl acetone 3.51 in 52% yield as pale yellow solid. Data for 3.51: 
1
H NMR (300 MHz, CDCl3) δ 
7.80-7.92 (m, 2H), 7.58-7.72 (m, 3H), 4.15 (s, 2H), 2.24 (s, 2H); 
13
C NMR (75 MHz, CDCl3) δ 195.3, 
141.2, 135.7, 131.0, 128.7, 68.9, 33.2. 
 
General procedure for the preparation of sulfonyl derivatives 3.52: 
 
To a solution of lithium diisopropylamine 2M (1.1 mL, 2.2 mmol) in 40 mL of anhydrous THF at -78 °C 
was added dropwise a solution of 1-phenylsulfonyl-2-propanone 3.51 (198 mg, 1.0 mmol) in 10 mL of 
THF. After 4 h at -78 °C, an aldehyde (1.1 mmol) was added to the resulting orange heterogenous 
solution and the reaction mixture was allowed to warm to room temperature overnight. Hydrolysis was 
achieved at 0 °C with 30 mL of saturated aqueous NH4Cl, fllowed by an addition of AcOEt. The organic 
layer was dried over Na2SO4 and concentrated in vacuo, the residue was purified by flash column 
chromatography on silica gel (EtOAc/n-Hexane = 1:3) to afford the aldol derivatives 3.52. 
 
4-Hydroxy-1-(phenylsulfonyl)-hexan-2-one (3.52a) 
Yellow oil, 70% yield; Data for 3.52a: 
1
H NMR (300 MHz, DMSO-d6)  7.91 (d, J = 7.1 Hz, 2H), 7.76 
(t, J = 7.4 Hz, 1H), 7.66 (t, J = 7.1 Hz, 2H), 4.71 (d, J = 3.6 Hz, 2H), 4.67 (d, J = 5.6 Hz, 1H), 3.72-3.78 
(m, 1H), 2.58 (d, J = 6.3 Hz, 2H), 1.25-1.36 (m, 2H), 0.81 (t, J = 7.4 Hz, 3H); 
13
C NMR (75 MHz, 
DMSO-d6) 196.4, 144.8, 140.3, 133.7, 129.1, 66.9, 64.7, 53.1, 28.7, 12.2. 
 
4-Hydroxy-4-(4-methoxyphenyl)-1-(phenylsulfonyl)-butan-2-one (3.52b) 
Yellow oil, 63% yield; Data for 3.52b: 
1
H NMR (300 MHz, DMSO-d6)  7.87 (d, J = 7.3 Hz, 2H), 7.76 
(t, J = 7.4 Hz, 1H), 7.64 (t, J = 7.3 Hz, 2H), 7.21 (d, J = 8.7 Hz, 2H), 6.86 (d, J = 8.6 Hz, 2H), 5.34 (d, J = 
4.6 Hz, 1H), 4.88-4.94 (m, 1H), 4.73 (d, J = 4.5 Hz, 2H), 3.73 (s, 3H), 2.74-2.93 (m, 2H); 
13
C NMR (75 
MHz, DMSO-d6) 197.4, 145.7, 139.5, 134.0, 130.8, 129.3, 128.0, 127.0, 123.8, 67.7, 65.5, 55.1, 53.2. 
 
4-Hydroxy-1-(phenylsulfonyl)-4-(thiophen-2-yl)-butan-2-one (3.52c) 
Yellow oil, 50% yield; Data for 3.52c: 
1
H NMR (300 MHz, DMSO-d6)  7.88 (d, J = 7.2 Hz, 2H), 7.76 
(t, J = 7.4 Hz, 1H), 7.65 (t, J = 7.2 Hz, 2H), 7.38-7.40 (m, 1H), 6.93-6.96 (m, 1H), 6.89-6.90 (m, 1H), 
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5.84 (d, J = 5.1 Hz, 1H), 5.18-5.24 (m, 1H), 4.76 (d, J = 2.3 Hz, 2H), 2.90-3.08 (m, 2H); 
13
C NMR (75 
MHz, DMSO-d6) 196.9, 149.3, 139.4, 134.1, 129.4, 128.0, 126.7, 124.5, 123.1, 65.5, 64.1, 53.2. 
 
General procedure for the preparation of pyridazine derivatives 3.54: 
 
To a solution of compound 3.52 (1.0 mmol) in 30 mL of acetonitrile under argon at 0°C was added 
successively triethylamine (181 L, 1.3 mmol) and p-acetamido benzene sulfonyl azide (p-ABSA) (240 
mg, 1.0 mmo). The mixture was stirred for 2 hours and was allowed to warm to room temperature and 
was diluted with 50 mL of Et2O/n-Hexane (1:1) and then filtered. The filtrate was concentrated and the 
residue purified by flash column chromatography on silica gel (EtOAc/n-Hexane = 1:2) to afford the 
desired diazo derivative 3.53. 
To a solution of 3.53 (1 mmol) in 10 mL of acetonitrile under argon was added IBX (1-hydroxy-1,2-
benziodoxol-3(1H)-one 1-oxide) (364 mg, 1.3 mmol). The mixture was refluxed for 2 hours and was 
allowed to warm to room temperature and then filtered. The filtrate was concentrated and used directly 
without further purification for the next step. 
To the previously prepared crude in 15 mL of i-Pr2O was added P(n-Bu)3 (250 L, 1.0 mmol). The 
reaction mixture was stirred under argon at room temperature for 30 minutes, after which a purification 
by flash column chromatography on silica gel (EtOAc/n-Hexane = 9:1) due to no formation of precipitate 
was performed to obtain the desired sulfonyl pyridazine analogues 3.54. 
 
6-Ethyl-3-(phenylsulfonyl)-pyridazin-4-ol (3.54a) 
Beige solid, 40% yield; Data for 3.54a: 
1
H NMR (300 MHz, DMSO-d6)  7.98 (d, J = 7.2 Hz, 2H), 7.74 
(t, J = 7.4 Hz, 1H), 7.63 (t, J = 7.3 Hz, 2H), 6.47 (s, 1H), 2.57 (q, J = 7.6 Hz, 2H), 1.17 (t, J = 7.6 Hz, 
3H); 
13
C NMR (75 MHz, DMSO-d6) 165.9, 157.7, 151.8, 138.6, 134.3, 129.1, 128.8, 119.3, 23.8, 12.3. 
 
6-(4-Methoxyphenyl)-3-(phenylsulfonyl)pyridazin-4-ol (3.54b) 
Orange solid, 29% yield; Data for 3.54b: 
1
H NMR (600 MHz, DMSO-d6)  8.02 (d, J = 7.4 Hz, 2H), 
7.73-7.76 (m, 3H), 7.65 (t, J = 7.7 Hz, 2H), 7.10 (d, J = 8.9 Hz, 2H), 6.86 (s, 1H), 3.83 (s, 3H); 
13
C NMR 
(150 MHz, DMSO-d6) 161.9, 151.9, 138.8, 134.3, 129.2, 129.1, 129.0, 122.1, 118.0, 114.8, 55.7. 
 
3-(Phenylsulfonyl)-6-(thiophen-2-yl)pyridazin-4-ol (3.54c) 
Pale yellow solid, 20% yield; Data for 3.54c: 
1
H NMR (300 MHz, DMSO-d6)  8.02 (d, J = 7.3 Hz, 2H), 
7.93 (d, J = 4.4 Hz, 1H), 7.85 (d, J = 3.7 Hz, 1H), 7.76 (t, J = 7.4 Hz, 1H), 7.66 (t, J = 7.2 Hz, 2H), 7.27-
7.30 (m, 1H), 6.89 (s, 1H); 
13
C NMR (125 MHz, DMSO-d6) 163.4, 151.8, 138.8, 134.3, 131.8, 129.7, 
129.3, 129.1, 129.0. 
 
Methyl 2-diazo-3-oxopentanoate (3.25b) 
To a solution of methyl 3-oxopentanoate (5 g, 38.42 mmol) in 30 mL of acetonitrile under argon at 0°C 
was added successively triethylamine (6.9 mL, 49.95 mmol) and p-acetamido benzene sulfonyl azide (p-
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ABSA) (9.2 g, 38.42 mmol). The mixture was stirred for 2 hours and was allowed to warm to room 
temperature and was diluted with 100 mL of Et2O/n-Hexane (1:1) and then filtered. The filtrate was 
concentrated and the residue purified by flash column chromatography on silica gel (EtOAc/n-Hexane = 
1:2) to afford the desired compound methyl 2-diazo-3-oxopentanoate in 85% yield as yellow oil. Data for 
3.25b: 
1
H NMR (300 MHz, DMSO-d6) δ 3.77 (s, 3H), 2.78 (q, J = 7.3 Hz, 2H), 1.02 (t, J = 7.3 Hz, 3H); 
13
C NMR (75 MHz, DMSO-d6) δ 192.5, 161.5, 52.3, 33.0, 8.2. Diazo carbon was not detected in 
13
C 
NMR. 
 
Methyl 2-diazo-5-(2-fluorophenyl)-5-hydroxy-3-oxopentanoate (3.22h) 
Yellow oil, 69% yield; Data for 3.22h: 
1
H NMR (300 MHz, DMSO-d6)  7.50-7.55 (m, 1H), 7.27-7.30 
(m, 1H), 7.10-7.23 (m, 2H), 5.51 (d, J = 5.0 Hz, 1H), 5.33-5.39 (m, 1H), 3.77 (s, 3H), 3.34-3.43 (m, 1H), 
2.93 (dd, J = 15.8 Hz, J = 4.2 Hz, 1H); 
13
C NMR (75 MHz, DMSO-d6) 189.3, 161.4, 160.7, 157.4, 
131.8, 129.0, 127.9, 124.5, 115.2, 75.9, 62.6, 52.4, 47.6; HRMS calcd for C12H13N2O2 [M+H]
+
 243.1128, 
found 243.1130. 
 
Methyl 2-diazo-5-hydroxy-4-methyl-3-oxoheptanoate (3.22i) 
Yellow oil, 88% yield; Inseparable diastereomeric mixture; Data for 3.22i (major isomer): 
1
H NMR (300 
MHz, DMSO-d6)  4.54 (d, J = 6.2 Hz, 1H), 3.77 (s, 3H), 3.48-3.60 (m, 2H), 1.25-1.42 (m, 2H), 1.01 (d, 
J = 6.6 Hz, 3H), 0.86 (t, J = 6.4 Hz, 3H); 
13
C NMR (75 MHz, DMSO-d6) 194.6, 161.4, 72.4, 52.3, 47.1, 
27.9, 11.6, 10.6; HRMS calcd for C14H14N2O2 [M+Na]
+
 243.1128, found 243.1130. Diazo carbon was not 
detected in 
13
C NMR. 
 
Methyl 5-cyclohexyl-2-diazo-5-hydroxy-4-methyl-3-oxopentanoate (3.22k) 
Yellow oil, 63% yield; Inseparable diastereomeric mixture; Data for 3.22k (major isomer): 
1
H NMR (300 
MHz, DMSO-d6)  4.41 (d, J = 6.8 Hz, 1H), 3.78 (s, 3H), 3.60-3.64 (m, 1H), 3.42-3.48 (m, 1H), 1.51-
1.87 (m, 6H), 1.08-1.28 (m, 5H), 0.98 (d, J = 6.8 Hz, 3H); 
13
C NMR (75 MHz, DMSO-d6) 194.6, 161.3, 
75.9, 74.5, 52.3, 44.7, 41.0, 29.3, 28.4, 26.2, 26.0, 25.9, 10.6; HRMS calcd for C14H14N2O2 [M+Na]
+
 
243.1128, found 243.1130. 
 
Methyl 2-diazo-5-hydroxy-5-(4-methoxyphenyl)-4-methyl-3-oxopentanoate (3.22l) 
Yellow oil, 53% yield; Data for 3.22l: 
1
H NMR (300 MHz, DMSO-d6)  7.25 (d, J = 8.7 Hz, 2H), 6.87 (d, 
J = 8.7 Hz, 2H), 5.21-5.23 (m, 1H), 4.79-4.80 (m, 1H), 3.78 (s, 3H), 3.73 (s, 3H), 3.30-3.31 (m, 1H), 0.97 
(d, J = 6.8 Hz, 3H); 
13
C NMR (75 MHz, DMSO-d6) 193.5, 161.4, 158.2, 135.9, 127.3, 113.3, 72.3, 55.1, 
52.4, 49.3, 11.0; HRMS calcd for C14H14N2O2 [M+H]
+
 243.1128, found 243.1130. Diazo carbon was not 
detected in 
13
C NMR. 
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Methyl 2-diazo-5-(2-fluorophenyl)-5-hydroxy-4-methyl-3-oxopentanoate (3.22m) 
Yellow oil, 51% yield; Data for 3.22m: 
1
H NMR (300 MHz, DMSO-d6)  7.47 (m, 1H), 7.31-7.38 (m, 
1H), 7.22-7.30 (m, 1H), 7.12-7.18 (m, 1H), 5.52 (t, J = 4.4 Hz, 1H), 5.04-5.09 (m, 1H), 3.90-3.95 (m, 
1H), 3.80 (s, 3H), 0.76 (t, J = 6.9 Hz, 2H); 
13
C NMR (75 MHz, DMSO-d6) 194.3, 161.3, 158.0, 130.5, 
129.3, 128.8, 124.7, 115.1, 75.8, 67.9, 52.4, 47.8, 13.2; HRMS calcd for C14H14N2O2 [M+H]
+
 243.1128, 
found 243.1130. 
 
General procedure for the catalytic Diaza-Wittig reaction: 
 
To a solution of 3.22 (1 mmol) in 10 mL of acetonitrile under argon at 0°C was added IBX (1-hydroxy-
1,2-benziodoxol-3(1H)-one 1-oxide) (364 mg, 1.3 mmol). The mixture was refluxed for 2 hours and was 
allowed to warm to room temperature and then filtered. The filtrate was concentrated and used directly 
without further purification for the next step. 
To the previously prepared crude in 5 mL of toluene under argon was added 3.57 (19 mg, 0.1 mmol) 
followed by diphenylsilane (205 L, 1.1 mmol). The reaction mixture was heated at 100°C for 16 hours. 
After completion of the reaction monitored by TLC, the reaction mixture was allowed to cool to room 
temperature and a precipitate was formed. The precipitate was filtered and washed with diisopropyl ether 
to afford the pyridazine 3.24. 
 
Methyl 6-(2-fluorophenyl)-4-hydroxy-pyridazine-3-carboxylate (3.24h) 
Pale yellow solid, 82% yield; Data for 3.24h: 
1
H NMR (300 MHz, DMSO-d6)  13.77 (br. s, 1H), 7.65-
7.73 (m, 2H), 7.39-7.49 (m, 2H), 6.74 (s, 1H), 3.86 (s, 3H); 
13
C NMR (75 MHz, DMSO-d6) 164.0, 
160.7, 157.4, 133.5, 133.4, 131.0, 130.9, 125.4, 125.3, 118.9, 116.5, 52.6; HRMS calcd for C12H9FN2O3 
[M+H]
+
 249.0670, found 249.0675. 
 
Methyl 6-ethyl-4-hydroxy-5-methyl-pyridazine-3-carboxylate (3.24i) 
White solid, 81% yield; Data for 3.24i: 
1
H NMR (300 MHz, DMSO-d6)  13.27 (br. s, 1H), 3.80 (s, 3H), 
2.64 (q, J = 7.5 Hz, 2H), 1.93 (s, 3H), 1.17 (t, J = 7.5 Hz, 3H); 
13
C NMR (75 MHz, DMSO-d6) 167.4, 
164.6, 152.8, 145.7, 125.9, 52.3, 22.5, 12.8, 9.3; HRMS calcd for C9H12N2O3 [M+H]
+
 197.0921, found 
197.0927. 
 
Methyl 4-hydroxy-5-methyl-6-phenyl-pyridazine-3-carboxylate (3.24j) 
White solid, 63% yield; Data for 3.24j: 
1
H NMR (300 MHz, DMSO-d6)  13.54 (br. s, 1H), 7.57-7.58 (m, 
5H), 3.84 (s, 3H), 1.85 (s, 3H); 
13
C NMR (75 MHz, DMSO-d6) 167.8, 164.4, 149.8, 145.5, 130.9, 130.4, 
129.2, 128.9, 126.8, 52.4, 11.3; HRMS calcd for C13H12N2O3 [M+H]
+
 245.0921, found 245.0921. 
 
Methyl 6-cyclohexyl-4-hydroxy-5-methyl-pyridazine-3-carboxylate (3.24k) 
White solid, 75% yield; Data for 3.24k: 
1
H NMR (300 MHz, DMSO-d6)  12.97 (br. s, 1H), 3.80 (s, 3H), 
2.82-2.90 (m, 1H), 1.97 (s, 3H), 1.56-1.83 (m, 7H), 1.20-1.44 (m, 3H); 
13
C NMR (75 MHz, DMSO-d6) 
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167.4, 164.5, 154.7, 145.3, 125.4, 52.3, 38.4, 29.7, 25.9, 25.2, 9.3; HRMS calcd for C13H18N2O3 
[M+H]
+
 251.1390, found 251.1391. 
 
Methyl 4-hydroxy-6-(4-methoxyphenyl)-5-methyl-pyridazine-3-carboxylate (3.24l) 
White solid, 70% yield; Data for 3.24l: 
1
H NMR (600 MHz, DMSO-d6)  13.45 (br. s, 1H), 7.49 (d, J = 
8.8 Hz, 2H), 7.12 (d, J = 8.8 Hz, 2H), 3.84 (s, 3H), 3.83 (s, 3H), 1.86 (s, 3H); 
13
C NMR (150 MHz, 
DMSO-d6) 167.8, 164.4, 160.7, 149.6, 145.3, 130.7, 126.6, 122.9, 114.2, 55.5, 52.3, 11.3; HRMS calcd 
for C14H14N2O4 [M+H]
+
 275.1026, found 275.1028. 
 
Methyl 6-(2-fluorophenyl)-4-hydroxy-5-methyl-pyridazine-3-carboxylate (3.24m) 
White solid, 78% yield; Data for 3.24m: 
1
H NMR (300 MHz, DMSO-d6)  13.70 (br. s, 1H), 7.60-7.71 
(m, 2H), 7.41-7.50 (m, 2H), 3.85 (s, 3H), 1.78 (s, 3H); 
13
C NMR (75 MHz, DMSO-d6) 167.5, 164.3, 
160.6, 157.3, 145.7, 144.5, 133.2, 131.5, 128.6, 125.2, 118.3, 116.2, 52.5, 11.2; HRMS calcd for 
C13H11FN2O3 [M+H]
+
 263.0826, found 263.0826. 
 
(2-azido-acetamido)-5-chloro-benzophenone (3.64) 
To a solution of 2-amino-5-chloro-benzophenone 3.62 (500 mg, 2.16 mmol) and azido acetic acid 3.63 
(262 mg, 2.59 mmol) in 5 mL of CH2Cl2 under argon at room temperature was added 1-(3-
dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (497 mg, 2.59 mmol). After stirring at room 
temperature overnight, 10 mL of saturated aqueous NH4Cl was added. The organic layer was separated 
and then washed with 20 mL of saturated aqueous NaHCO3. The aqueous layers were extracted with 20 
mL of CH2Cl2. The combined organic layers were dried over Na2SO4 and concentrated in vacuo. The 
product was purified by flash column chromatography on silica gel (EtOAc/n-Hexane = 1:3) to afford the 
desired amide 3.64 in 88% yield as Pale yellow solid; Data for 3.64: 
1
H NMR (300 MHz, DMSO-d6) δ 
10.33 (br. s, 1H), 7.64-7.70 (m, 5H), 7.53 (t, J = 7.7 Hz, 2H), 7.45 (s, 1H), 3.79 (s, 2H); 
13
C NMR (75 
MHz, DMSO-d6) δ 193.9, 166.5, 136.6, 134.6, 133.2, 132.5, 131.8, 129.7, 129.6, 128.9, 128.5, 125.9, 
51.2; HRMS calcd. for C15H11ClN4O2 [M+H]
+
 315.0643, found 315.0641. 
 
7-Chloro-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-one (3.65) 
To a solution of 3.64 (598 mg, 1.90 mmol) in 5 mL of toluene under argon was added 3.57 (37 mg, 0.19 
mmol) followed by diphenylsilane (389 L, 2.09 mmol). The reaction mixture was heated at 100°C for 16 
hours. After completion of the reaction monitored by TLC, 10 mL of saturated aqueous NH4Cl was 
added. The organic layer was separated and then washed with 10 mL of saturated aqueous NaHCO3. The 
aqueous layers were extracted with 10 mL of CH2Cl2. The combined organic layers were dried over 
Na2SO4 and concentrated in vacuo. The product was purified by flash column chromatography on silica 
gel (EtOAc/MeOH = 9:1) to obtain 3.65 in 77% yield) as white solid; Data for 3.65: 
1
H NMR (600 MHz, 
DMSO-d6) δ 10.65 (br. s, 1H), 7.65 (dd, J = 8.8 Hz, J = 2.3 Hz, 1H), 7.44-7.64 (m, 5H), 7.27 (d, J = 8.8 
Hz, 1H), 7.21 (d, J = 2.2 Hz, 1H), 4.16 (br. s, 2H); 
13
C NMR (150 MHz, DMSO-d6) δ 170.3, 168.5, 149.7, 
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138.7, 131.6, 130.5, 129.8, 129.3, 128.5, 127.8, 126.5, 123.2, 57.1; HRMS calcd. for C15H11ClN2O 
[M+H]
+
 271.0633, found 271.0637. 
 
Diazepam (3.66) 
To a solution of 3.65 (100 mg, 0.37 mmol) in 5 mL of THF under argon was added NaH 60% (18 mg, 
0.44 mmol), and after 30 minutes iodomethane (24 L, 0.39 mmol). The reaction mixture was stirred at 
room temperature overnight. After completion of the reaction monitored by TLC, 10 mL of saturated 
aqueous NaHCO3 was added. The organic layer was separated, dried over Na2SO4 and concentrated in 
vacuo. The product was purified by flash column chromatography on silica gel (EtOAc/n-Hexane = 8:2) 
to afford the Diazepam 3.66 in 52% yield as white solid; Data for 3.66: 
1
H NMR (600 MHz, CDCl3) δ 
7.59 (d, J = 7.0 Hz, 2H), 7.47-7.52 (m, 2H), 7.41 (t, J = 6.6 Hz, 2H), 7.30 (d, J = 5.8 Hz, 1H), 7.29 (s, 
1H), 4.84 (d, J = 10.8 Hz, 2H), 3.77 (d, J = 10.8 Hz, 2H), 3.39 (s, 3H); 
13
C NMR (150 MHz, CDCl3) δ 
169.9, 168.9, 142.6, 138.2, 131.4, 130.7, 129.9, 129.5, 128.4, 122.5, 56.9, 34.9; HRMS calcd. for 
C16H13ClN2O [M+H]
+
 285.0789, found 285.0783. 
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Chapter IV. Synthesis and biological evaluation of triazolo[4,3-a]pyridine, 
triazolo[4,5-b]pyridine and triazolo[1,5-a]pyridine libraries 
1. Introduction 
The last thirty years have seen an increasing interest in the use of various 
triazolopyridines in pharmaceutical industry.
1
 Five isomers can be distinguished and 
have been studied and evaluated by several groups.  
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Figure 1. Triazolopyridine isomers. 
 
Among these isomers of triazolopyridine, it is possible to divide them in two 
categories. Three of them possess a bridgehead nitrogen in the fusion (4.1, 4.2, 4.4) in 
contrast to the two others isomers which contain a free amine on the triazole part (4.3, 
4.5) and could be used as point of substitution. One project of the PhD was dedicated to 
the construction of libraries based on the scaffold 4.1, 4.2, 4.3.  
The resemblance between purine and the triazolo[4,5-b]pyridine 4.3 have led to 
glycosyl derivatives such as 4.6 tested against HIV-l.
2
 This class of fused ring has been 
associated with a wide range of different biological applications, in kinase inhibition, 
several analogues displayed activity towards various targets. Galapagos discovered the 
first selective JAK1 inhibitor
3
 based on triazolo[1,5-a]pyridine 4.7. Almirall Research
4
 
has designed a kinase inhibitor by combining a tolyl amide motif and a triazolo[4,3-
a]pyridine to obtain a selective and potent p38 MAP inhibitor 4.8. 
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Figure 2. Biologically active triazolopyridine derivatives. 
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In 2012, Pastor et al.
5
 published a study concerning a hit to lead evaluation of novel 
Pim kinase inhibitors. Their research led to the discovery of a triazolo[4,5-b]pyridine 
with a pattern of substitution similar to the scaffold investigated during the PhD 
research. 4.9 showed potency and selectivity towards Pim-1 kinase (IC50 = 1 nM), but 
further data proved risk of cardiotoxicity. 
N N
N
N
OCF3
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H
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4.9  
Figure 3. Pim-1 kinase inhitor. 
 
2. Results and discussion 
The first scaffold investigated was the triazolo[4,3-a]pyridine 4.1, for the project it 
was decided to design a scaffold with two points of substitution. After a review of the 
existing literature, the positions 5 and 8 have been chosen for the development of library 
based on the structure 4.10. 
N
N
N
4.10  
Figure 4. Scaffold investigated. 
 
A large number of methods of synthesis exist to obtain the triazolo[4,3-a]pyridine 
such as palladium cross-coupling with hydrazides followed by condensation
6
 but in our 
case a simple nucleophilic substitution prior to the final condensation
7
 was studied. The 
first step was the hydrazinolysis of 2,6-dichloro-3-nitro-pyridine 4.11 in ethanol at room 
temperature for 1 hour to afford the hydrazino derivative 4.12. The condensation has 
been attempted with (trialkyl)orthoformate reagent but did not deliver the desired 
product 4.13, the condensation reagent has been used also as solvent or with catalytic 
amount of acid, no improvements have been observed, the cyclization has been tried 
with a more reactive condensation reagent, the Vilsmeier-Hack reagent generated by 
doing the reaction in DMF with a stoechiometric amount of phosphorus oxychloride, 
unfortunately the same results have been obtained. 
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Scheme 1. Attempts of synthesis of 5-chloro-8-nitro-triazolo[4,3-a]pyridine. 
 
In order to complete the pathway for the synthesis of the scaffold, another reagent 
has been investigated, the formic acid hydrazide could allow, after a nucleophilic 
substitution, the formation of a reactive intermediate in phosphorus oxychloride towards 
the attack of the nitrogen of the pyridine leading to the triazolo[4,3-a]pyridine 4.13. 
This conversion is a one-pot reaction, 4.13 was obtained in 26% yield. 
N Cl
NO2
N NH
NO2
dioxane, RT, 2h N
N
N
NO2
4.11 4.13
Cl Cl Cl
NH2NHCHO
NH
H
O
POCl3
N NH
NO2
Cl
N
H
Cl
26%reflux, 16h
 
Scheme 2. Synthesis of 5-chloro-8-nitro-triazolo[4,3-a]pyridine with formic acid hydrazide. 
 
The synthesis of 4.13 achieved, the substitution of the chloride was the next step and 
due to the presence of the nitro group in the para position to increase the reactivity, it 
was expected that a strategy based on palladium cross-coupling or nucleophilic 
substitution could be straightforward. Our first attempt was to perform a Suzuki cross-
coupling between 4.13 and phenyl boronic acid, various conditions have been used but 
the starting material was always recovered and no desired product 4.14 or unchlorinated 
by-product 4.15 were observed. 
N
N
N
NO2
4.13
Cl
Suzuki
coupling
X
N
N
N
NO2
4.14
N
N
N
NO2
4.15  
Scheme 3. Attempts of Suzuki reaction. 
 
Instead of a palladium cross-coupling, we evaluated the substrate towards 
nucleophilic substitution with simple amines such as ethylamine or morpoline. After 16 
hours of reaction in refluxing dioxane, substituted triazolo[4,3-a]pyridine 4.16 were 
obtained in low yields. 
N
N
N
NO2
4.13
Cl
amine, Et3N
dioxane, reflux, 16h N
N
N
NO2
4.16a
N
N
N
NO2
4.16b
N
H
N
O
35% 24%  
Scheme 4. Nucleophilic substitution. 
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The derivative 4.16 has been then reduced with zinc to the corresponding amine, 
used directly without further purification for the next step. 4.16a has been acyclated by 
acetyl chloride after reduction and the amine derivative obtained from 4.16b was 
subjected to a reductive amination with benzaldehyde. The overall yield of this strategy 
is very low, and the first step leading to the intermediate 4.13 was not correctly 
reproducible, for all these reasons 4.17a and 4.17b are the only examples synthesized 
with this pattern of substitution for the triazolo[4,3-a]pyridine. Our interest was then 
directed towards the same scaffold with an additional substitution such as methyl at the 
position 3, for this purpose 4.12 was acylated with acetyl chloride at room temperature 
for 2 hours, after which time, phosphorus oxychloride was added to perform the 
cyclization at 100°C for 16 hours, 4.18 was obtained in 35%. 
 
N
N
N
NO2
4.16a
N
N
N
NO2
4.16b
N
H
N
O
a. Zn, cat. AcOH, MeOH, RT, 5h
b. AcCl, Et3N, CH2Cl2, RT, 16h
a. Zn, cat. AcOH, MeOH, RT, 5h
b. C6H5CHO, NaBH3CN, EtOH, RT, 16h
N
N
N
H
N
4.17a
N
H
N
N
N
H
N
4.17b
N
O
O
Ph
7%
10%
 
Scheme 5. Synthesis of triazolo[4,3-a]pyridine derivatives 4.17. 
 
4.18 was subjected to Suzuki cross-coupling with phenyl boronic acid but led to 
identical results than 4.13. The non reactivity of the scaffold towards previously 
discussed reaction and the low yields obtained forced us to modify the pattern of 
substitution. In fact, the nitro group has been kept at the position 8 but instead of to 
attempt palladium coupling at the position 5 to attach aryl group, it was envisioned to 
introduce substitution at the position 3 of the triazole part. 
 
N NHNH2
NO2
N
N
N
NO2
4.12 4.18
Cl
Cl
a. AcCl, Et3N, dioxane, RT, 2h
b. POCl3, 100°C, 16h
35%
Pd(dppf)Cl2, K3PO4
dioxane, reflux, 16h
PhB(OH)2
X
N
N
N
NO2
4.19  
Scheme 6. Attempt of Suzuki coupling with 3-methyl-triazolo[4,3-a]pyridine derivatives 4.18. 
 
It was decided to remove the chloride at the position 5 and to have a scaffold with a 
point of substitution on the pyridine and the second one on the triazole part. The 
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introduction of variety at the position 3 was possible by using an appropriate acid 
chloride during the cyclization to afford 8-nitro-3-substituted-triazolo[4,3-a]pyridine. 
A similar method than the synthesis of 4.18 could be used the 2-chloro-3-nitro-
pyridine 4.20 has been selected as starting material, in fact this starting material had two 
advantages for the procedure envisioned, the first one was a functional group (nitro 
group) allowing the possible synthesis of a library, then the second advantage was the 
chloride easily replaceable by nucleophilic substitution due to the electron withdrawing 
effect of the nitro group at its ortho position. 
The first step was the hydrazinolysis of 4.20 with hydrazine hydrate in ethanol at 
room temperature for 3 hours to afford a yellow solid 4.21 in 93% yield, then the 
formation of the scaffold was performed in a two steps one-pot reaction. An acylation of 
the hydrazino derivative 4.21 was first done with an acid chloride to obtain an 
intermediate 4.22 which after complete disappearance of 4.21 (monitored by TLC) was 
treated with a dehydrating reagent allowing the cyclization to lead to the triazolo[4,3-
a]pyridine 4.23. Different dehydrating reagents have been screened, but the phosphorus 
oxychloride gave the best results for the cyclization. 
 
N Cl
NO2
N NHNH2
NO2NH2NH2, EtOH
2h, RT
93%
R1COCl, Et3N
N
N
N
NO2
R14.20 4.21 4.23
dioxane, 2h, RT
N N
H
NO2
H
N R1
O
POCl3
16h, reflux
4.22
63-77%
 
Scheme 7. Synthesis of triazolo[4,3-a]pyridine derivatives 4.23. 
 
This method led to the synthesis of nine triazolo[4,3-a]pyridine derivatives 4.23 
containing various substitutions at the position 3, the introduction of (hetero)aryl, 
cycloalkyl or aliphatic groups was possible in good yields. This pathway showed that a 
library based on the triazolo[4,3-a]pyridine substituted at the position 3 was simpler to 
build in contrast to the initially investigated scaffold with a hydrogen on the triazole 
part, one possible explanation is tendency of the triazole part to reopen as it will be 
discussed later.  
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Table 1. Synthesis of 8-nitro-triazolo[4,3-a]pyridine derivatives 4.23.
a
 
entry 
starting 
material 
acid chloride triazolo[4,3-a]pyridine  yield (%)
b
 
1 4.21 
O
O
Cl
 
N
N
N
NO2
O
 
4.23a 77 
2 4.21 
O
Ph
Cl
 
N
N
N
NO2
Ph  
4.23b 65 
3 4.21 
O
Cl
 
N
N
N
NO2
 
4.23c 71 
4 4.21 
O
O
Cl
 
N
N
N
NO2
O  
4.23d 67 
5 4.21 
O
TosN
Cl
 
N
N
N
NO2
TosN  
4.23
e
 63 
6 4.21 
OMe
O
Cl
 
N
N
N
NO2
OMe  
4.23f 75 
7 4.21 
O
F
Cl
 
N
N
N
NO2
F  
4.23g 70 
8 4.21 
O
OMe
MeO
MeO
Cl
 
N
N
N
NO2
OMe
MeO
MeO
 
4.23h 63 
9 4.21 
O
N
Cl
 
N
N
N
NO2
N  
4.23i 69 
a
All reactions were performed using 1 mmol of 4.21, 1.05 mmol of acid chloride and 181 L of 
triethylamine in dioxane at room temperature for 2 hours, after which 135 L of POCl3 was added, the 
reaction mixture was refluxed for 16 hours. 
b
Isolated yield. 
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The nitro derivative 4.23 in hands, the synthesis of a library could start. The 
corresponding amine was obtained by reduction of 4.23 with zinc and a catalytic 
amount of acetic acid and then subjected to a series of reaction such as acylation or 
reductive amination to afford a collection of analogues 4.24.  
 
Table 2. Synthesis of triazolo[4,3-a]pyridine derivatives 4.24.
a
 
entry 
starting 
material 
reagent triazolo[4,3-a]pyridine  yield (%)
b
 
1 4.23a 
N
H
O
 
N
N
N
H
N
O
N
 
4.24a 29 
2 4.23a 
Cl
O
OMe  
N
N
N
H
N
O
O
OMe
 
4.24b 31 
3 4.23b 
H
O
OMe  
N
N
N
H
N
Ph
OMe
 
4.24c 23 
4 4.23b 
O
N
H H  
N
N
N
H
N
Ph
N
H
 
4.24d 14 
5 4.23c CN OF
 
N
N
N
H
N
H
N
O
F
 
4.24
e
 11 
6 4.23d H
O
 
N
N
N
H
N
O  
4.24f 19 
7 4.23d Cl
O
F  
N
N
N
H
N
O
O
F
 
4.24g 33 
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8 4.23e H
O
 
N
N
N
H
N
TosN  
4.24h 19 
9 4.23f H
O
F3CO  
N
N
N
H
N
OMe
OCF3
 
4.24i 22 
10 4.23g 
O
H  
N
N
N
H
N
F  
4.24j 28 
11 4.23g Cl
O
F  
N
N
N
H
N
F
O
F
 
4.24k 25 
12 4.23h 
O
H  
N
N
N
H
N
OMe
MeO
MeO
 
4.24l 27 
a
See the experimental section for details. 
b
Isolated yield. 
 
Based on this strategy, the synthesis of triazolo[4,3-a]pyridine with nitrogen linker 
at the position 3 has been done by replacing the acid chloride by an isocyanate or 
isothiocyanate reagents for the cyclization step. Intermediate 4.21 was treated with these 
reagents to generate a (thio)semicarbazide derivative 4.25 which after treatment with 
phosphorus oxychloride led to the desired triazolo[4,3-a]pyridine 4.26 with a 
substitution at the position 3 attached by a nitrogen, this modification allowed the 
formation of a hinge binder with the aromatic nitrogen at the position 2 and the new one 
added.  
N NHNH2
NO2 R1NCO or R1NCS
N
N
N
NO2
HN4.21 4.26
dioxane, 2h, RT
N N
H
NO2
H
N
H
N
X
POCl3
16h, reflux
4.25
47-61%
R1
X=O or S
R1
 
Scheme 8. Synthesis of 3-amino substituted triazolo[4,3-a]pyridine derivatives 4.26. 
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R1 was covering a five different decoration from aryl substituted or not to heteroaryl 
groups.  
The amino substituted triazolo[4,3-a]pyridine 4.26 was obtained in moderate yields, 
most of the starting materials were isocyanate derivatives and proved to be better 
cyclization partner compared to the isothiocyanate analogue which gave the lower yield. 
It was possible to synthesize a scaffold with a sulfonamide linker instead of a simple 
amine by using a sulfonyl isocyanate reagent. The initial purpose of the derivative 4.26e 
containing a sulfonamide was the possible cleavage of the p-toluene sulfonyl group with 
a solution of sodium hydroxide but due to the sensitivity of the triazolo[4,3-a]pyridine 
towards acidic or basic conditions, the removal of the protective group has been 
abandoned. 
 
Table 3. Synthesis of 8-nitro-triazolo[4,3-a]pyridine derivatives 4.26.
a
 
entry 
starting 
material 
reagent triazolo[4,3-a]pyridine  yield (%)
b
 
1 4.21 
C
O
N
 
N
N
N
HN
NO2
 
4.26a 58 
2 4.21 
C
O
N
F  
N
N
N
HN
NO2
F  
4.26b 61 
3 4.21 
C
S
N
OMe
MeO OMe
 
N
N
N
HN
NO2
OMe
MeO
OMe
 
4.26c 49 
4 4.21 
 
N
N
N
HN
NO2
N
 
4.26d 55 
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5 4.21 
C
O
N
SO O
 
N
N
N
HN
NO2
SO
O
 
4.26e 47 
a
All reactions were performed using 1 mmol of 4.21 and 1.05 mmol of isocyanate or isothiocyanate in 
dioxane at room temperature for 2 hours, after which 135 L of POCl3 was added, the reaction mixture 
was refluxed for 16 hours. 
b
Isolated yield.  
 
The nitro group was then reduced like previously discussed to the corresponding 
amine and different reactions have been done to build a library of 4.27. Due to the 
presence of two amines after the reduction of the nitro group, further modification could 
lead to a mixture, it was necessary to check the reactivity of the secondary amine 
attached at the position 3 of the scaffold. A review of the existing literature
8
 removed 
the doubts concerning a possible competitive substitution, in fact the conditions used to 
react with the nitrogen linked to the triazole ring were harsher compared to the 
conditions used for the amine at the position 8.  
 
Table 4. Synthesis of triazolo[4,3-a]pyridine derivatives 4.27.
a
 
entry 
starting 
material 
reagent triazolo[4,3-a]pyridine  yield (%)
b
 
1 4.26a H
O
S  
N
N
N
HN
H
N
S
 
4.27a 28 
2 4.26a 
Cl
O
MeO
MeO
OMe  
N
N
N
HN
H
N
OMe
O
OMe
OMe
 
4.27b 13 
3 4.26b 
O
H  
N
N
N
HN
H
N
F  
4.27c 21 
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4 4.26b 
O
Cl  
N
N
N
HN
H
N
F
O
 
4.27d 37 
5 4.26c H
O
 
N
N
N
HN
H
N
OMe
MeO
OMe
 
4.27
e
 23 
6 4.26c Cl
O
 
 
4.27f 12 
7 4.26c 
O
Cl  
 
4.27g 13 
8 4.26d 
N
H
O
 
N
N
N
HN
H
N
N
N
 
4.27h 11 
9 4.26e H
O
F  
N
N
N
HN
H
N
SO
O
F
 
4.27i 16 
10 4.26b H
O
 
 
4.27j 10 
135 
 
a
See the experimental section for details. 
b
Isolated yield. 
During the quality control of the different derivatives 4.24 and 4.27 synthesized, it 
has been observed two distinct peaks in the LC/MS analysis with the same mass, after a 
review of the literature concerning this chemistry,
9
 it has been found that a possible 
rearrangement could occur in acidic or basic pH to convert the triazolo[4,3-a]pyridine 
4.1 to the triazolo[1,5-a]pyridine 4.2, this transformation is known as the Dimroth 
rearrangement,
10
 moreover it was described that the rearrangement was favored in the 
presence of a nitro group at the position 8 like in our case, in fact the electron 
withdrawing nitro group enhances the reactivity of the position 5 towards possible 
attack in acidic or basic conditions. In our particular case with a nitro group at the 
position 8 and no substitution at the position 5 of the triazolo[4,3-a]pyridine, the 
Dimroth rearrangement was observed frequently. A proposed mechanism of this 
rearrangement is depicted below. 
 
N
N
N
R2
R1
N
N
N
R2
R1
O
H
acidic or basic
HN
N
N
R2
R1
O
N
N
NH
R2
O
R1
HN
N
N
R2
O
R1
N
N
N
R2
HO
R1
H
N
N
N
R2
R1
4.28 4.29 4.30
4.31 4.32 4.33 4.34
conditions
 
Scheme 9. Proposed mechanism for the Dimroth rearrangement. 
 
Derivative 4.28 generated an intermediate 4.29 by in acidic or basic conditions, 4.29 
was then ring opened leading to the triazole 4.30. Due to the possible rotation, the 
triazole ring turned in order to obtain 4.31 which is in equilibrium with 4.32. Finally, an 
attack of the nitrogen of the triazole to the previously formed aldehyde led to 4.33 and 
after aromatization gave the expected isomer triazolo[1,5-a]pyridine 4.34. 
Further studies have been done to confirm this rearrangement, in fact the NOE effect 
allowed us to determinate by NMR, the structure associated to each peak from LC/MS. 
Most of the triazolo[4,3-a]pyridine derivatives were converted into their corresponding 
Dimroth rearranged structures and we were to obtain simultaneously two libraries with 
triazolo[4,3-a]pyridine 4.24 and 4.27 and triazolo[1,5-a]pyridine 4.35 and 4.36. 
Nevertheless, the scaffold containing a nitrogen linker on the triazole ring were 
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rearranged in lower yields, the additional nitrogen could have been involved in the 
increase of stability of the scaffold 4.27.  
N
N
N
NHR2
R1
N
N
N
NHR2
HN
4.35 4.36
N
N
N
NHR2
N
N
N
NHR2
4.24 4.27
N
H
R1
R1
R1  
Figure 5. Triazolo[4,3-a]pyridine derivatives and triazolo[1,5-a]pyridine derivatives. 
 
Table 5. Dimroth rearrangement: triazolo[1,5-a]pyridine derivatives 4.35 and 4.36. 
entry 
starting 
material 
triazolo[1,5-a]pyridine  yield (%)
a
 
1 4.24b N
N
N
H
N
O
O
OMe
 
4.35a 15 
2 4.24d N
N
N
H
N
Ph
N
H
 
4.35b 12 
3 4.24e 
N
N
N
H
N
H
N
O
F
 
4.35c 16 
4 4.24i N
N
N
H
N
OMe
OCF3
 
4.35d 17 
5 4.24j 
N
N
N
H
N
F  
4.35e 9 
6 4.24l 
N
N
N
H
N
OMe
MeO OMe  
4.35f 13 
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7 4.27a N
N
N
HN
H
N
S
 
4.36a 9 
8 4.27e N
N
N
HN
H
N
OMe
OMe
OMe
 
4.36b 7 
a
Isolated yield. 
 
The Dimroth rearrangement directed our efforts towards the synthesis of 
triazolo[1,5-a]pyridine aiming the evaluation of such chemistry for future projects. It 
was decided to use the 2-amino-4-methyl-pyridine 4.37 as model to assess this 
chemistry. Two possible pathways were available in literature
11
 to synthesize the 
desired product, the first one leading to the scaffold not substituted on the triazole ring 
4.38 and the second method allow the introduction of an amine group at the position 3 
of the triazolo[1,5-a]pyridine 4.39, both of these pathways have been attempted.  
 
N
N
N N
N
N
NH24.38 4.39  
Figure 6. Triazolo[1,5-a]pyridine derivatives. 
 
The synthesis started with the treatment of 4.37 in ethanol with DMF-DMA in order 
to obtain the intermediate 4.40 used directly without further purification, with 
hydroxylamine to lead to 4.41. This late derivative was treated with a dehydrating 
reagent, the polyphosphoric acid at 80°C for 2 hours to obtain the desired scaffold 4.42 
but the reaction with PPA degraded the starting material instead of to form a nitrene 
intermediate prior to final cyclization. To avoid this problem, we used a “self 
dehydrative reagent”, the hydroxylamine-O-sulfonic acid, while this reagent was 
subjected to 4.41 in ethanol at room temperature for 16 hours, 4.42 was obtained in 
good yield.  
The second part was dedicated to the synthesis of the scaffold containing an amine 
group, the same starting material 4.37 was used. 2-amino-4-methyl-pyridine reacted 
with the intermediate 4.44, obtained from the reaction between ethyl chloroformate 4.43 
and potassium thiocyanate in acetone, to afford the thiourea derivative 4.45, which was 
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cyclized by treatment with hydroxylamine leading the 3-amino-7-methyl-triazolo[1,5-
a]pyridine 4.46. 
We were able to synthesize two analogues of triazolo[1,5-a]pyridine 4.42 and 4.46 
in order to evaluate this chemistry and to make it available for future projects. 
 
N NH2 N N NEtOH, RT, 2h
93%
NH2OH, pyridine
EtOH, RT, 2h N N N
H
OH
86%
N
N
N
PPA
80°C, 2h
X
N
N
N
67%
Cl O
O
KSCN, acetone
40°C, 2h SCN O
O
N NH2
Et3N, dioxane
RT, 3h N N
H
N
H
S
O
O
61%
NH2OH, pyridine
EtOH, RT, 2h N
N
N
NH2
48%
NH2OSO3H, pyridine
EtOH, RT, 16h
4.37 4.40 4.41 4.42
4.42
4.43 4.44
4.37
4.45 4.46
DMF-DMA
N NH2 N N NEtOH, RT, 2h
93%
4.37 4.40
DMF-DMA
 
Scheme 10. Synthesis of triazolo[1,5-a]pyridine derivatives. 
 
In order to extend the scope of this project, our interest led us to another 
triazolopyridine isomer, in fact the two previous examples involved the nitrogen of the 
pyridine during the cyclization. The triazolo[4,5-b]pyridine 4.3 as discussed in the 
introduction is structurally close to the purine, the fused ring involved in the kinase 
mechanisms.
12
 The synthesis started with the nucleophilic substitution of the 2,6-
dichloro-3-nitro pyridine 4.11 by an amine using sodium hydride as a base to afford the 
amino derivative 4.47. The nitro group was then reduced by using zinc and a catalytic 
amount of acetic acid followed by a cyclization performed under Sandmeyer like 
conditions
13
 to lead to the scaffold 4.49, in fact the amino derivative was treated with 
sodium nitrite in water and hydrochloric acid at a tempertaure of 0°C for 2 hours. The 
use of the Sandmeyer like conditions led to the formation of a diazonium salt 
intermediate 4.48 which was attacked by the amine at the position 2 of the pyridine ring 
to afford the desired fused ring 4.49. The last step of the pathway was the substitution of 
the chloride by an amine, due to the low reactivity of the chloro derivative 4.49 towards 
nucleophilic substitution, the reaction was performed using microwaves irradiation and 
high boiling solvent such as NMP. The intermediate 4.49 was microwaves irradiated 
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with an excess of various amines in N-methyl pyrrolidine at 165°C for 30 minutes to 
give the substituted triazolo[4,5-b]pyridine 4.50. 
 
a. Zn, cat. AcOH, MeOH, RT, 2h
b. NaNO2, H2O, HCl, 0°C, 2hN ClCl
NO2
R1NH2, NaH
THF, RT, 16h N N
H
Cl
NO2
R1
62-89%
N NCl
N
R1
N
39-56%
R2NH2, Et3N, NMP
MW, 165°C, 30min N
NN
H
N
R1
N
R2
34-48%
4.11 4.47
4.48 4.49
N N
H
Cl
N2
+Cl-
R1
4.50  
Scheme 11. Synthesis of triazolo[4,5-b]pyridine derivatives 4.50. 
 
Table 6. Synthesis of triazolo[4,5-b]pyridine derivatives.
a
 
entry 
starting 
material 
reagent triazolo[4,5-b]pyridine  yield (%)
b
 
1 4.49a 
NH
O  
N NN
N
N
O
F
 
4.50a 48 
2 4.49a 
NH2
OMe  
N NN
H
N
N
F
OMe
 
4.50b 37 
3 4.49b NH2  
N NN
H
N
N
CN  
4.50c 41 
4 4.49c NH2HO  
N NN
H
N
N
OMe
OMe
MeO
HO
 
4.50d 35 
5 4.49c 
NH2  
N NN
H
N
N
OMe
OMe
MeO
 
4.50
e
 48 
6 4.49c 
NH2
 
N NN
H
N
N
OMe
OMe
MeO
 
4.50f 44 
140 
 
7 4.49d NH2
NHN
 
N NN
H
N
N
N
NHN
 
4.50g 34 
8 4.49e 
NH
O  
N NN
N
N
O N
CN  
4.50h 45 
9 4.49f 
 
 
4.50i 43 
10 4.49g 
N
B(OH)2
 
N N
N
N
N
O
O
 
4.51a 51 
11 4.49g 
N
B(OH)2
 
N N
N
N
N
O
O
 
4.51b 49 
12 4.49h 
O
O
B(OH)2
 
N N
N
N
N
O
O
 
4.51c 53 
a
See the experimental section for details. 
b
Isolated yield. 
 
Three examples of Suzuki cross-coupling reaction have been synthesized from the 
derivative 4.49 and boronic acid leading to 4.51 with moderate yields. R1 was generally 
an aryl or a heteroaryl group, R2 was selected among aliphatic or cycloalkyl groups, 
nevertheless some analogues have been chosen as anilines in order to expand the 
library.  
 
3. Biological evaluation 
The libraries of the three isomers of triazolopyridine described in this chapter have 
been screened towards selected kinases of ongoing projects of Galapagos. The 
compounds were first tested in an enzymatic assay at constant concentration and for the 
analogues displaying an interesting percentage of inhibition for a specified kinase, a 
further assay was performed at different concentrations in order to obtain the half 
maximal inhibitory concentration IC50.    
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Table 7. Biological evaluation of pyridazine derivatives (N/A not active). 
entry compounds 
CDK9 
(% inhibition 
at 10 M) 
IC50 (nM) 
TGF- II 
(% inhibition 
at 10 M) 
IC50 (nM) 
1 4.24a N/A N/A N/A N/A 
2 4.24b N/A N/A N/A N/A 
3 4.24c N/A N/A N/A N/A 
4 4.24d N/A N/A N/A N/A 
5 4.24
e
 N/A N/A N/A N/A 
6 4.24f 13 N/A 8 N/A 
7 4.24g 11 N/A 4 N/A 
8 4.24h 22 N/A 10 N/A 
9 4.24i N/A N/A N/A N/A 
10 4.24j 21 N/A N/A N/A 
11 4.24k 4 N/A 16 N/A 
12 4.24l 4 N/A N/A N/A 
13 4.27a N/A N/A N/A N/A 
14 4.27b 98 N/A 27 N/A 
15 4.27d 87 2800 49 N/A 
16 4.27i N/A N/A N/A N/A 
17 4.27j N/A N/A N/A N/A 
18 4.35a N/A N/A N/A N/A 
19 4.35b N/A N/A N/A N/A 
20 4.35c N/A N/A N/A N/A 
21 4.35d N/A N/A N/A N/A 
22 4.35
e
 8 N/A 8 N/A 
23 4.35f 12 N/A 8 N/A 
24 4.36a N/A N/A N/A N/A 
25 4.36b 16 N/A 5 N/A 
26 4.50a N/A N/A N/A N/A 
27 4.50b N/A N/A N/A N/A 
28 4.50c N/A N/A 29 N/A 
29 4.50d 2 N/A 35 N/A 
30 4.50
e
 11 N/A 53 N/A 
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31 4.50f 3 N/A 27 N/A 
32 4.50g N/A N/A N/A N/A 
33 4.50h N/A N/A N/A N/A 
34 4.50i N/A N/A N/A N/A 
35 4.51a 47 N/A 99 600 
36 4.51b 59 N/A 52 N/A 
37 4.51c 35 N/A 36 N/A 
 
entry compounds 
GSK3 
(% inhibition 
at 20 M) 
IC50 (nM) 
IRAK4 
(% inhibition 
at 20 M) 
IC50 (nM) 
38 4.27c 22 ˃20000 6 ˃20000 
39 4.27
e
 38 ˃20000 13 ˃20000 
40 4.27f 86 3644 65 ˃4000 
41 4.27g 25 ˃20000 13 ˃20000 
42 4.27h 28 ˃20000 8 ˃20000 
 
The triazolo[4,3-a]pyridine has been the first scaffold screened towards CDK9 and 
TGF- II receptor and only the 3-amino substituted derivative 4.27d displayed a 
biological activity against the target (IC50= 2800 nM), in fact only the analogues with a 
nitrogen linker at the position 3 of the triazolopyridine and an acylated group at the 
position 8 showed an interesting profile to develop such as 4.27f  (IC50= 3644 nM 
towards GSK3). Most of the other congeners did not show a percentage of inhibition 
higher than 50 % and thus have not been screened at different concentrations. The 
analogues obtained from the Dimroth rearrangement leading to the triazolo[1,5-
a]pyridine 4.35 and 4.36 have not displayed significant biological activity. The last 
scaffold assayed was the triazolo[4,5-b]pyridine 4.50 and 4.51, the 5-amino substituted 
analogues did not give activity towards the kinases targeted but the compound 4.51a 
without linker at the position 5 obtained from a palladium cross-coupling displayed a 
half maximal inhibitory concentration IC50= 600 nM towards TGF- II receptor. 
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4. Conclusion 
This chapter dealt with the synthesis of three different isomers of triazolopyridine, 
despite the fact that this collection corresponds to the largest library of derivatives 
explored during this PhD, only a partial part has been discussed.  
In a first part, a study concerning the synthesis of triazolo[4,3-a]pyridine derivatives 
with two points of substitution at the positions 5 and 8 has been envisioned, several 
problems appeared during the attempts of cyclization with trialkyl orthoformate. By 
using formic acid hydrazide, it was possible to obtain the desired scaffold, two 
examples of final product have been synthesized but due to the low overall yield of the 
process and the difficulty to reproduce the experiments, we decided to change the 
pattern of substitution of the triazolo[4,3-a]pyridine. In fact, the modification of the 
decoration position to the triazole ring was made by using acid chloride derivatives with 
the 2-hydrazino-3-nitro-pyridine intermediate followed by a treatment with phosphorus 
oxychloride to afford the scaffold substituted at the position 3. It was possible to obtain 
a (hetero)aryl group directly attached to the triazolo[4,3-a]pyridine with the use of acid 
chloride, in order to cover others analogues, isocyanate and isothiocyanate reagents 
have been used to introduce a nitrogen linker between the (hetero)aryl group and the 
scaffold, Various examples have been synthesized to build a library of triazolo[4,3-
a]pyridine. 
The second part discussed was related to the partial conversion of the initial scaffold 
triazolo[4,3-a]pyridine into triazolo[1,5-a]pyridine by Dimroth rearrangement under 
acidic or basic conditions. The presence of the electron withdrawing nitro group 
promotes this conversion but the separation of the two isomers was possible and the 
NOE effect allowed us to determinate which structures correspond to the desired 
scaffold and to the other isomer. Due to this rearrangement and in order to prepare 
pathways for future projects, the synthesis of triazolo[1,5-a]pyridine has been studied 
and we were able to obtain two examples of such scaffold by using 2-amino-4-methyl-
pyridine as a model. 
The last part of this chapter dealt with the development of a library of triazolo[4,5-
b]pyridine derivatives starting from 2,6-dichloro-3-nitro-pyridine and using a 
cyclization based on Sandmeyer like conditions through a diazonium salt intermediate. 
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5. Experimental section 
For all reactions, analytical grade solvents were used. All moisture-sensitive reactions were carried 
out in oven-dried glassware (135 ºC) under a nitrogen or argon atmosphere. Reaction temperatures are 
reported as bath temperature. Precoated aluminum sheets (Fluka Silica gel/TLC-cards, 254 nm) were used 
for TLC. Compounds were visualized with UV light (λ = 254 nm). Products were purified by flash 
chromatography on ICN silica gel 63-200, 60 Å. Melting points were obtained on a melting point 
apparatus Electrothermal IA9200 with open capillary tubes. 
1
H and 
13
C NMR spectra were recorded on 
300 MHz, 500 MHz and 600 MHz spectrometer using CDCl3 and DMSO-d6 as the solvent. The 
1
H and 
13C chemical shifts were referenced to residual solvent signals at δ H/C 7.26/77.00 (CDCl3), 3.31/49.10 
and 2.50/39.50 (DMSO-d6) relative to TMS as internal standard. Coupling constants J [Hz] were directly 
taken from the spectra. Splitting patterns are designated as s (singlet), d (doublet), t (triplet), q (quartet), 
m (multiplet) and br (broad). High resolution mass spectra were acquired on a quadrupole orthogonal 
acceleration time-of-flight mass spectrometer (Synapt G2 HDMS, Waters, Milford, MA). Samples were 
infused at 3 µL/min and spectra were obtained in positive (or negative) ionization mode with a resolution 
of 15000 (FWHM) using leucine enkephalin as lock mass. Electrospray MS spectra were obtained on a 
Micromass platform LC/MS spectrometer. Column used for all LC/MS analysis: Waters Acquity UPLC 
BEH C18 1.7 m, 2.1 mm ID x 50 mm L. All the methods are using MeCN/H2O gradients. Water 
contains either 0.1 % TFA or 0.1 % NH3. 
 
6-Chloro-2-hydrazinyl-3-nitropyridine (4.12) 
To a solution of 2,6-dichloro-3-nitropyridine 4.11 (1 g, 5.2 mmol) in 20 mL of EtOH under argon at room 
temperature was added a solution of hydrazine hydrate 64% (252 L, 5.2 mmol). The reaction mixture 
was stirred for 2 hours. 15 mL of saturated aqueous NaHCO3 was added to the reaction mixture followed 
by an extraction with 2x15 mL of CH2Cl2. The combined organic layers were dried over Na2SO4 and 
concentrated in vacuo. The filtrate was concentrated to afford the desired compound 4.12 in 62% yield as 
orange solid. Data for 4.12: 
1
H NMR (300 MHz, DMSO-d6) δ 8.89-8.98 (m, 1H), 8.47 (d, J = 7.8 Hz, 
1H), 8.22 (d, J = 7.9 Hz, 1H), 6.53-6.64 (m, 2H); 
13
C NMR (75 MHz, DMSO-d6) δ 160.3, 155.0, 136.7, 
128.2, 110.4. 
 
5-Chloro-8-nitro-triazolo[4,3-a]pyridine (4.13) 
To a solution of 2,6-dichloro-3-nitropyridine 4.11 (1 g, 5.2 mmol) in 20 mL of dioxane under argon at 
room temperature was added formic acid hydrazide (312 mg, 5.2 mmol). The reaction mixture was stirred 
for 2 hours at room temperature. After which POCl3 (634 L, 6.8 mmol) was added and the reaction 
refluxed for 16 hours. The completion of the reaction was monitored by TLC. The solvent was 
concentrated in vacuo and 30 mL of saturated aqueous NaHCO3 was added to the residue, then extracted 
with 2x15 mL of CH2Cl2. The combined organic layers were dried over Na2SO4 and concentrated in 
vacuo. The filtrate was concentrated and the residue purified by flash column chromatography on silica 
gel (EtOAc/MeOH = 10:1) to afford the desired compound 4.13 in 26% yield as orange solid. Data for 
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4.13: 
1
H NMR (300 MHz, DMSO-d6) δ 9.41 (s, 1H), 8.32 (d, J = 10.2 Hz, 1H), 5.94 (d, J = 9.2 Hz, 1H); 
13
C NMR (75 MHz, DMSO-d6) δ 155.2, 136.5, 127.1, 118.9, 113.0, 109.1. 
 
General procedure for the preparation of triazolo[4,3-a]pyridine derivatives 4.16: 
 
To a solution of 4.13 (199 mg, 1.0 mmol) in 5 mL of dioxane under argon was added an amine (1.1 
mmol), followed by triethylamine (181 L, 1.3 mmol) at room temperature. The reaction mixture was 
refluxed until the completion of the reaction (16 hours monitored by TLC) and was allowed to cool to 
room temperature. 15 mL of saturated aqueous NaHCO3 was added to the reaction mixture followed by 
an extraction with 2x15 mL of CH2Cl2. The combined organic layers were dried over Na2SO4 and 
concentrated in vacuo. The product was purified by flash column chromatography on silica gel (EtOAc) 
to afford the amino substituted triazolo[4,3-a]pyridine 4.16. 
 
N-ethyl-8-nitro-triazolo[4,3-a]pyridin-5-amine (4.16a) 
Brown solid, 35% yield; Data for 4.16a: 
1
H NMR (300 MHz, DMSO-d6)  8.98 (s, 1H), 8.31 (d, J = 9.2 
Hz, 1H), 6.24 (m, 1H), 5.74 (d, J = 9.5 Hz, 1H), 3.37 (m, 2H), 1.16 (t, J = 6.9 Hz, 3H); 
13
C NMR (75 
MHz, DMSO-d6) 151.4, 149.0, 137.3, 132.3, 128.6, 121.8, 36.5, 14.9. 
 
4-(8-Nitro-triazolo[4,3-a]pyridin-5-yl)morpholine (4.16b) 
Brown solid, 24% yield; Data for 4.16b: 
1
H NMR (300 MHz, DMSO-d6)  9.01 (s, 1H), 8.24 (d, J = 9.5 
Hz, 1H), 5.55 (d, J = 9.6 Hz, 1H), 3.78-3.81 (m, 4H), 3.12-3.15 (m, 4H); 
13
C NMR (75 MHz, DMSO-d6) 
153.0, 148.1, 138.6, 135.3, 128.2, 119.9, 65.7, 48.4. 
 
N-(5-(ethylamino)-triazolo[4,3-a]pyridin-8-yl)acetamide (4.17a) 
To a solution of 4.16a (207 mg, 1.0 mmol) in 5 mL of MeOH under argon was added a catalytic amount 
of acetic acid (6 L, 0.1 mmol) followed by zinc (327 mg, 5.0 mmol) at room temperature. The reaction 
mixture was stirred for 5 hours. 15 mL of saturated aqueous NaHCO3 was added to the reaction mixture 
followed by an extraction with 2x15 mL of CH2Cl2. The combined organic layers were dried over Na2SO4 
and concentrated in vacuo. The reduced derivative was directly used for the next step without further 
purification. 
To a solution of the amine (1.0 mmol) in 5 mL of CH2Cl2 under argon was added an acetyl chloride (86 
L, 1.2 mmol) followed by triethylamine (181 L, 1.3 mmol) at room temperature. The reaction mixture 
was stirred for 16 hours, after which 15 mL of saturated aqueous NaHCO3 was added to the reaction 
mixture followed by an extraction with 2x15 mL of CH2Cl2. The combined organic layers were dried over 
Na2SO4 and concentrated in vacuo. The product was purified by preparative HPLC to afford the amino 
substituted triazolo[4,3-a]pyridine 4.17a in 7% yield as brown solid. Data for 4.17a: 
1
H NMR (500 MHz, 
DMSO-d6) δ 9.78 (br. s, NH), 8.42 (s, 1H), 7.89 (d, J = 8.4 Hz, 1H), 6.93-6.95 (t, J = 5.8 Hz, 1H), 6.14 
(d, J = 8.5 Hz, 1H), 2.09 (s, 3H), 1.23 (t, J = 7.1 Hz, 3H); 
13
C NMR (125 MHz, DMSO-d6) δ 168.9, 152.2, 
145.9, 140.8, 124.4, 114.2, 88.7, 36.8, 23.7, 14.3. 
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N-benzyl-5-morpholino-triazolo[4,3-a]pyridin-8-amine (4.17b) 
To a solution of 4.16b (249 mg, 1.0 mmol) in 5 mL of MeOH under argon was added a catalytic amount 
of acetic acid (6 L, 0.1 mmol) followed by zinc (327 mg, 5.0 mmol) at room temperature. The reaction 
mixture was stirred for 5 hours. 15 mL of saturated aqueous NaHCO3 was added to the reaction mixture 
followed by an extraction with 2x15 mL of CH2Cl2. The combined organic layers were dried over Na2SO4 
and concentrated in vacuo. The reduced derivative was directly used for the next step without further 
purification. 
To a solution of the amine (1.0 mmol) in 5 mL of EtOH under argon was added benzaldehyde (111 L, 
1.1 mmol) followed by sodium cyanoborohydride (126 mg, 2.0 mmol) at room temperature. The reaction 
mixture was stirred for 16 hours, after which 15 mL of saturated aqueous NaHCO3 was added to the 
reaction mixture followed by an extraction with 2x15 mL of CH2Cl2. The combined organic layers were 
dried over Na2SO4 and concentrated in vacuo. The product was purified by preparative HPLC to afford 
the amino substituted triazolo[4,3-a]pyridine 4.17b in 10% yield as brown solid. Data for 4.17b: 
1
H NMR 
(300 MHz, DMSO-d6) δ 8.13 (d, J = 4.8 Hz, 1H), 7.66 (s, 1H), 7.41-7.48 (m, 2H), 7.27-7.41 (m, 3H), 
5.99 (d, J = 4.8 Hz, 1H), 4.41 (s, 2H), 3.93-4.01 (m, 4H), 366-3.74 (m, 4H); 
13
C NMR (75 MHz, DMSO-
d6) δ 149.8, 145.5, 139.0, 138.8, 131.9, 128.2, 127.5, 126.9, 120.8, 91.2, 66.0, 51.7, 47.9. 
 
5-Chloro-3-methyl-8-nitro-triazolo[4,3-a]pyridine (4.18) 
To a solution of 4.12 (189 mg, 1.0 mmol) in 20 mL of dioxane under argon at room temperature was 
added acetyl chloride (79 L, 1.1 mmol) followed by triethylamine (181 L, 1.3 mmol). The reaction 
mixture was stirred for 2 hours at room temperature. After which POCl3 (121 L, 1.3 mmol) was added 
and the reaction refluxed for 16 hours. The completion of the reaction was monitored by TLC. The 
solvent was concentrated in vacuo and 30 mL of saturated aqueous NaHCO3 was added to the residue, 
then extracted with 2x15 mL of CH2Cl2. The combined organic layers were dried over Na2SO4 and 
concentrated in vacuo. The filtrate was concentrated and the residue purified by flash column 
chromatography on silica gel (EtOAc/MeOH = 10:1) to afford the desired compound 4.18 in 35% yield as 
orange solid. Data for 4.18: 
1
H NMR (300 MHz, DMSO-d6) δ 8.22 (d, J = 9.9 Hz, 1H), 5.85 (d, J = 9.9 
Hz, 1H), 2.80 (s, 3H); 
13
C NMR (75 MHz, DMSO-d6) δ 147.9, 136.4, 128.1, 126.9, 111.7, 15.5. 
 
2-Hydrazinyl-3-nitropyridine (4.21) 
To a solution of 2-chloro-3-nitropyridine 4.20 (5 g, 31.5 mmol) in 20 mL of EtOH under argon at room 
temperature was added a solution of hydrazine hydrate 64% (3.0 mL, 63.0 mmol). The reaction mixture 
was stirred for 2 hours. The suspension formed was filtered, then washed several times with EtOH, and 
dried to yield 4.21 in 93% yield as yellow solid. Data for 4.21: 
1
H NMR (300 MHz, DMSO-d6) δ 9.01-
9.67 (m, 1H), 8.48-8.52 (m, 1H), 8.34-8.40 (m, 1H), 6.92-7.57 (m, 2H), 6.70-6.76 (m, 1H); 
13
C NMR (75 
MHz, DMSO-d6) δ 156.2, 152.1, 135.4, 126.6, 111.8. 
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General procedure for the preparation of triazolo[4,3-a]pyridine derivatives 4.23: 
 
To a solution of 4.21 (154 mg, 1 mmol) in 20 mL of dioxane under argon at room temperature was added 
an acid chloride (1.1 mmol) followed by triethylamine (181 L, 1.3 mmol). The reaction mixture was 
stirred for 2 hours at room temperature. After which POCl3 (121 L, 1.3 mmol) was added and the 
reaction refluxed for 16 hours. The completion of the reaction was monitored by TLC. The suspension 
formed was filtered, then washed several times with EtOH, and dried to afford 4.23. 
 
3-(Methoxymethyl)-8-nitro-triazolo[4,3-a]pyridine (4.23a) 
Brown solid, 77% yield; Data for 4.23a: 
1
H NMR (300 MHz, DMSO-d6)  8.98-9.13 (m, 1H), 8.67 (d, J 
= 7.5 Hz, 1H), 7.39 (t, J = 7.3 Hz, 1H), 5.07 (s, 2H), 3.34 (s, 3H); 
13
C NMR (75 MHz, DMSO-d6) 
145.7, 142.3, 135.1, 132.0, 130.1, 113.6, 63.1, 58.1. 
 
3-cyclohexyl-8-nitro-[1,2,4]triazolo[4,3-a]pyridine (4.23c) 
Brown solid, 71% yield; Data for 4.23c: 
1
H NMR (300 MHz, DMSO-d6)  9.20 (d, J = 6.3 Hz, 1H), 8.68 
(d, J = 7.5 Hz, 1H), 7.39 (t, J = 7.0 Hz, 1H), 3.38-3.47 (m, 1H), 2.00-2.09 (m, 2H), 1.30-1.89 (m, 8H); 
13
C 
NMR (75 MHz, DMSO-d6) 152.5, 141.0, 134.9, 131.8, 130.3, 113.4, 33.0, 30.3, 25.4, 25.3. 
 
3-(methoxymethyl)-N-(pyridin-3-ylmethyl)-triazolo[4,3-a]pyridin-8-amine (4.24a) 
Brown solid, 29% yield; Data for 4.24a: 
1
H NMR (300 MHz, DMSO-d6)  8.62-8.65 (m, 1H), 8.43-8.46 
(m, 1H), 7.77-7.80 (m, 1H), 7.66 (d, J = 6.7 Hz, 1H), 7.31-7.37 (m, 2H), 6.74 (t, J = 7.1 Hz, 1H), 6.09 (d, 
J = 7.4 Hz, 1H), 4.89 (s, 2H), 4.54 (d, J = 6.4 Hz, 2H), 3.29 (s, 3H); 
13
C NMR (75 MHz, DMSO-d6) 
148.9, 148.3, 144.6, 135.1, 135.0, 134.8, 123.6, 115.5, 111.3, 98.3, 63.4, 57.7, 43.4. 
 
3-Methoxy-N-(3-(methoxymethyl)-triazolo[4,3-a]pyridin-8-yl)benzamide (4.24b) 
Brown solid, 31% yield; Data for 4.24b: 
1
H NMR (600 MHz, DMSO-d6)  10.37 (br. s, NH), 8.28 (d, J = 
6.8 Hz, 1H), 7.93 (d, J = 7.2 Hz, 1H), 7.62 (d, J = 7.6 Hz, 1H), 7.57-7.58 (m, 1H), 7.49 (t, J = 8.0 Hz, 
1H), 7.20-7.22 (m, 1H), 7.08 (t, J = 7.1 Hz, 1H), 4.99 (s, 2H), 3.86 (s, 3H), 3.32 (s, 3H); 
13
C NMR (150 
MHz, DMSO-d6) 165.9, 159.4, 145.9, 145.0, 135.2, 129.9, 125.8, 120.2, 120.1, 118.2, 117.3, 114.3, 
113.0, 63.3, 57.8, 55.5. 
 
N-((1H-pyrrol-2-yl)methyl)-3-phenethyl-triazolo[4,3-a]pyridin-8-amine (4.24d) 
Beige solid, 14% yield; Data for 4.24d: 
1
H NMR (300 MHz, DMSO-d6)  10.70 (br. s, NH), 7.62 (d, J = 
6.7 Hz, 1H), 7.17-7.30 (m, 5H), 6.64-6.73 (m, 2H), 6.48 (t, J = 5.9 Hz, 1H), 6.17 (d, J = 7.3 Hz, 1H), 
5.98-6.01 (m, 1H), 5.90-5.93 (m, 1H), 4.38 (d, J = 6.0 Hz, 2H), 3.28-3.32 (m, 2H), 3.09-3.15 (m, 2H); 
13
C 
NMR (75 MHz, DMSO-d6) 146.9, 144.5, 140.8, 135.4, 128.7, 128.6, 128.4, 126.3, 117.3, 115.0, 110.7, 
107., 106.4, 97.6, 32.3, 25.9. 
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1-(3-Cyclohexyl-triazolo[4,3-a]pyridin-8-yl)-3-(4-fluorophenyl)urea (4.24e) 
White solid, 11% yield; Data for 4.24e: 
1
H NMR (600 MHz, DMSO-d6)  9.61 (br. s, NH), 9.24 (br. s, 
NH), 8.11 (d, J = 6.6 Hz, 1H), 7.88 (d, J = 6.9 Hz, 1H), 7.47-7.50 (m, 2H), 7.14-7.17 (m, 2H), 6.90 (t, J = 
7.1 Hz, 1H), 3.20-3.26 (m, 1H), 1.99-2.04 (m, 2H), 1.80-1.85 (m, 2H), 1.62-1.76 (m, 3H), 1.44-1.51 (m, 
2H), 1.30-1.36 (m, 1H); 
13
C NMR (150 MHz, DMSO-d6) 158.5, 156.9, 152.4, 151.8, 144.0, 135.6, 
127.2, 120.0, 116.3, 115.7, 115.5, 114.2, 108.4, 33.4, 30.4, 25.6, 25.5. 
 
3-(3-Methoxyphenyl)-N-(4-(trifluoromethoxy)benzyl)-triazolo[4,3-a]pyridin-8-amine (4.24i) 
Orange solid, 22% yield; Data for 4.24i: 
1
H NMR (600 MHz, DMSO-d6)  7.78 (d, J = 6.8 Hz, 1H), 7.51-
7.54 (m, 3H), 7.46 (t, J = 6.4 Hz, 1H), 7.41-7.43 (m, 1H), 7.37-7.38 (m, 1H), 7.32 (d, J = 8.3 Hz, 2H), 
7.13-7.15 (m, 1H), 6.75 (t, J = 7.1 Hz, 1H), 6.04 (d, J = 7.4 Hz, 1H), 4.56 (d, J = 6.4 Hz, 1H), 3.85 (s, 
3H); 
13
C NMR (150 MHz, DMSO-d6) 159.8, 147.3, 146.8, 145.2, 138.9, 135.4, 130.5, 128.9, 128.3, 
121.1, 120.2, 116.2, 115.9, 113.2, 110.8, 98.2, 55.4, 44.9. 
 
3-(4-Fluorophenyl)-N-propyl-triazolo[4,3-a]pyridin-8-amine (4.24j) 
Yellow solid, 28% yield; Data for 4.24j: 
1
H NMR (300 MHz, DMSO-d6)  7.90-7.96 (m, 2H), 7.74 (d, J 
= 6.7 Hz, 1H), 7.42-7.48 (m, 2H), 6.83 (t, J = 7.1 Hz, 1H), 6.57 (t, J = 5.9 Hz, 1H), 6.17 (d, J = 7.4 Hz, 
1H), 3.23 (q, J = 6.3 Hz, 2H), 1.61-1.73 (m, 2H), 0.96 (t, J = 7.4 Hz, 3H); 
13
C NMR (75 MHz, DMSO-d6) 
164.6, 161.3, 146.1, 145.2, 136.1, 130.6, 123.7, 116.6, 116.3, 110.0, 97.1, 44.2, 21.4, 11.6. 
 
General procedure for the preparation of triazolo[4,3-a]pyridine derivatives 4.26: 
 
To a solution of 4.21 (154 mg, 1 mmol) in 20 mL of dioxane under argon at room temperature was added 
an isocyanate or isothiocyanate (1.1 mmol). The reaction mixture was stirred for 2 hours at room 
temperature. After which POCl3 (121 L, 1.3 mmol) was added and the reaction refluxed for 16 hours. 
The completion of the reaction was monitored by TLC. The suspension formed was filtered, then washed 
several times with EtOH, and dried to afford 4.26. 
 
N-(4-fluorophenyl)-8-nitro-triazolo[4,3-a]pyridin-3-amine (4.26b) 
Beige solid, 61% yield; Data for 4.26b: 
1
H NMR (300 MHz, DMSO-d6)  10.38 (br. s, NH), 9.23 (d, J = 
6.7 Hz, 1H), 8.65 (d, J = 7.2 Hz, 1H), 7.89-7.96 (m, 2H), 7.11 (t, J = 6.8 Hz, 1H), 6.54-6.59 (m, 2H); 
13
C 
NMR (75 MHz, DMSO-d6) 159.9, 155.6, 144.2, 136.0, 135.7, 123.1, 121.4, 118.3, 116.0, 113.8. 
 
8-Nitro-N-(pyridin-2-yl)-triazolo[4,3-a]pyridin-3-amine (4.26d) 
Brown solid, 55% yield; Data for 4.26d: 
1
H NMR (300 MHz, DMSO-d6)  10.61 (br. s, NH), 9.26 (d, J = 
6.4 Hz, 1H), 8.59 (d, J = 7.2 Hz, 1H), 8.29-8.31 (m, 1H), 8.09-8.12 (m, 1H), 7.71-7.85 (m, 2H), 7.22-7.27 
(m, 1H); 
13
C NMR (75 MHz, DMSO-d6) 162.7, 148.2, 147.5, 138.7, 138.2, 134.7, 130.9, 128.8, 117.2, 
111.1, 110.9. 
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N3-(4-fluorophenyl)-N8-isobutyl-triazolo[4,3-a]pyridine-3,8-diamine (4.27c) 
Yellow solid, 21% yield; Data for 4.27c: 
1
H NMR (300 MHz, DMSO-d6)  9.42 (br. s, NH), 7.96 (d, J = 
6.0 Hz, 1H), 7.68-7.73 (m, 2H), 7.11 (t, J = 8.9 Hz, 2H), 6.77-6.84 (m, 1H), 6.44-6.46 (m, 1H), 5.67 (t, J 
= 6.0 Hz, 1H), 3.08 (t, J = 6.5 Hz, 2H), 1.93-2.03 (m, 1H), 0.95 (d, J = 6.7 Hz, 6H); 
13
C NMR (75 MHz, 
DMSO-d6) 160.7, 157.9, 142.6, 138.3, 135.5, 117.7, 115.5, 115.1, 113.5, 102.3, 50.3, 27.3, 20.4. 
 
N-(3-((4-fluorophenyl)amino)-triazolo[4,3-a]pyridin-8-yl)butyramide (4.27d) 
Beige solid, 37% yield; Data for 4.27d: 
1
H NMR (600 MHz, CDCl3)  8.42 (d, J = 7.9 Hz, 1H), 8.12 (d, J 
= 6.4 Hz, 1H), 8.09 (br. s, NH), 7.52-7.54 (m, 2H), 7.39 (br. s, NH), 7.03-7.05 (m, 2H), 6.86-6.88 (m, 
1H), 2.38 (t, J = 7.5 Hz, 2H), 1.73-1.79 (m, 2H), 1.00 (t, J = 7.2 Hz, 3H); 
13
C NMR (150 MHz, CDCl3) 
172.1, 161.2, 158.7, 157.1, 143.4, 136.1, 125.0, 122.2, 118.7, 116.3, 115.7, 112.7, 39.4, 18.8, 13.7.  
 
N-(3-((3,4,5-trimethoxyphenyl)amino)-triazolo[4,3-a]pyridin-8-yl)cyclohexanecarboxamide (4.27f) 
Brown solid, 12% yield; Data for 4.27f: 
1
H NMR (300 MHz, DMSO-d6)  9.62 (br. s, NH), 9.42 (br. s, 
NH), 8.48-8.50 (m, 1H), 8.01 (d, J = 7.8 Hz, 1H), 7.14 (s, 2H), 6.95-6.99 (m, 1H), 3.80 (s, 6H), 3.62 (s, 
3H), 2.55-2.66 (m, 1H), 1.61-1.92 (m, 5H), 1.17-1.49 (m, 5H); 
13
C NMR (75 MHz, DMSO-d6) 175.2, 
161.6, 153.1, 144.5, 137.7, 131.5, 124.8, 123.4, 118.8, 112.2, 95.0, 60.3, 55.8, 44.3, 29.4, 25.5, 25.3. 
 
N-(3-((3,4,5-trimethoxyphenyl)amino)-triazolo[4,3-a]pyridin-8-yl)butyramide (4.27g) 
Brown solid, 13% yield; Data for 4.27g: 
1
H NMR (600 MHz, DMSO-d6)  9.78 (br. s, NH), 9.41 (br. s, 
NH), 8.49 (d, J = 6.4 Hz, 1H), 8.03 (d, J = 7.6 Hz, 1H), 7.13 (s, 2H), 6.97 (t, J = 6.7 Hz, 1H), 3.79 (s, 
6H), 3.61 (s, 3H), 2.45 (t, J = 7.2 Hz, 2H), 1.61-1.66 (m, 2H), 0.93 (t, J = 7.4 Hz, 3H); 
13
C NMR (150 
MHz, DMSO-d6) 172.3, 161.5, 153.0, 144.4, 137.6, 131.4, 124.7, 123.5, 118.9, 112.1, 94.9, 60.3, 55.8, 
38.0, 18.7, 13.7. 
 
N8-benzyl-N3-(4-fluorophenyl)-triazolo[4,3-a]pyridine-3,8-diamine (4.27j) 
Beige solid, 10% yield; Data for 4.27j: 
1
H NMR (600 MHz, DMSO-d6)  9.13 (br. s, NH), 7.57-7.60 (m, 
3H), 7.39 (d, J = 7.3 Hz, 2H), 7.32 (t, J = 7.5 Hz, 2H), 7.22 (t, J = 7.2 Hz, 1H), 7.15 (t, J = 8.9 Hz, 2H), 
7.09 (t, J = 6.2 Hz, 1H), 6.62 (t, J = 7.1 Hz, 1H), 5.85 (d, J = 7.3 Hz, 1H), 4.48 (d, J = 6.2 Hz, 2H); 
13
C 
NMR (150 MHz, DMSO-d6) 157.4, 155.8, 145.4, 141.7, 139.4, 138.1, 135.4, 128.5, 127.1, 126.9, 
117.7, 115.5, 114.1, 109.6, 96.6, 45.8. 
 
3-Methoxy-N-(2-(methoxymethyl)-triazolo[1,5-a]pyridin-8-yl)benzamide (4.35a) 
Brown solid, 15% yield; Data for 4.35a: 
1
H NMR (300 MHz, DMSO-d6)  10.37 (br. s, NH), 8.77 (d, J = 
6.8 Hz, 1H), 8.09 (d, J = 7.7 Hz, 1H), 7.57-7.64 (m, 2H), 7.49 (t, J = 8.0 Hz, 1H), 7.19-7.27 (m, 2H), 4.64 
(s, 2H), 3.86 (s, 3H), 3.37 (s, 3H); 
13
C NMR (75 MHz, DMSO-d6) 165.7, 162.3, 159.3, 146.7, 135.2, 
129.8, 126.7, 125.2, 121.3, 120.1, 118.1, 114.2, 113.1, 67.1, 58.1, 55.5. 
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2-(3-Methoxyphenyl)-N-(4-(trifluoromethoxy)benzyl)-triazolo[1,5-a]pyridin-8-amine (4.35d) 
Orange solid, 17% yield; Data for 4.35d: 
1
H NMR (600 MHz, DMSO-d6)  8.14 (d, J = 7.1 Hz, 1H), 7.79 
(d, J = 7.7 Hz, 1H), 7.72-7.73 (m, 1H), 7.53 (d, J = 8.6 Hz, 2H), 7.44 (t, J = 8.0 Hz, 1H), 7.31 (d, J = 8.3 
Hz, 2H), 7.19 (t, J = 6.3 Hz, 1H), 7.05-7.07 (m, 1H), 6.88 (t, J = 7.2 Hz, 1H), 6.33 (d, J = 7.7 Hz, 1H), 
4.55 (d, J = 6.2 Hz, 2H), 3.84 (s, 3H); 
13
C NMR (150 MHz, DMSO-d6) 161.4, 159.9, 147.6, 144.9, 
139.2, 136.7, 132.6, 130.4, 129.2, 121.4, 119.4, 116.6, 116.2, 115.9, 111.8, 102.7, 55.6, 45.4.  
 
N-propyl-2-(3,4,5-trimethoxyphenyl)-triazolo[1,5-a]pyridin-8-amine (4.35f) 
Brown solid, 13% yield; Data for 4.35f: 
1
H NMR (300 MHz, DMSO-d6)  8.13 (d, J = 6.2 Hz, 1H), 7.48 
(s, 2H), 6.95 (t, J = 7.6 Hz, 1H), 6.46 (d, J = 7.7 Hz, 1H), 6.36 (t, J = 5.7 Hz, NH), 3.89 (s, 6H), 3.74 (s, 
3H), 3.22 (q, J = 6.2 Hz, 2H), 1.61-1.75 (m, 2H), 0.96 (t, J = 7.4 Hz, 3H); 
13
C NMR (75 MHz, DMSO-d6) 
160.9, 153.2, 144.6, 138.9, 137.0, 126.5, 115.7, 115.5, 103.8, 101.4, 60.2, 56.0, 44.3, 21.4, 11.6. 
 
7-Methyl-triazolo[1,5-a]pyridine (4.42) 
To a solution of 4.37 (108 mg, 1.0 mmol) in 10 mL of EtOH under argon at room temperature was added 
DMF-DMA (201 L, 1.5 mmol). The reaction mixture was stirred for 2 hours at room temperature. After 
completion of the reaction monitored by TLC, 20 mL of water was added to quench the excess of 
dimethyl formamide-dimethyl acetal, an extraction with 2x15 mL of CH2Cl2 was performed, and the 
organic layer was dried over Na2SO4 and concentrated in vacuo. The orange oil was directly used for the 
next step without further purification. 
To a solution of 4.40 in 10 mL of EtOH under argon at room temperature was added hydroxylamine-O-
sulfonic acid (170 mg, 1.5 mmol) followed by pyridine (121 L, 1.5 mmol). The reaction mixture was 
stirred for 16 hours at room temperature. After completion of the reaction monitored by TLC, 30 mL of 
saturated aqueous NaHCO3 was added to the residue, then extracted with 2x15 mL of CH2Cl2. The 
combined organic layers were dried over Na2SO4 and concentrated in vacuo. The filtrate was 
concentrated and the residue purified by flash column chromatography on silica gel (EtOAc/MeOH = 8:1) 
to afford the desired compound 4.42 in 67% yield as white solid. Data for 4.42: 
1
H NMR (500 MHz, 
DMSO-d6) δ 8.80 (d, J = 6.8 Hz, 1H), 8.39 (s, 1H), 7.60 (br. s, 1H), 7.02 (dd, J = 6.8, 1.6 Hz, 1H), 2.42 
(s, 3H); 
13
C NMR (125 MHz, DMSO-d6) δ 154.2, 150.5, 141.5, 128.4, 116.9, 114.9, 21.2. 
 
7-Methyl-triazolo[1,5-a]pyridin-2-amine (4.46) 
To a solution of 4.43 (109 mg, 1.0 mmol) in 20 mL of acetone under argon at room temperature was 
added potassium thiocyanate (117 mg, 1.2 mmol). The reaction mixture was heated at 40 °C for 2 hours. 
After which the formation of a precipitate has been observed (NaCl), then 20 mL of water was added and 
an extraction with 2x15 mL of CH2Cl2 was performed, and the organic layer was dried over Na2SO4 and 
concentrated in controlled vacuo (4.44 has a low boiling point). The yellow liquid was directly used for 
the next step without further purification. 
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To a solution of 4.44 in 10 mL of dioxane under argon at room temperature was added 4.37 (108 mg, 1.0 
mmol) followed by triethylamine (181 L, 1.3 mmol). The reaction mixture was stirred for 3 hours at 
room temperature. After completion of the reaction monitored by TLC, 30 mL of saturated aqueous 
NaHCO3 was added to the residue, then extracted with 2x15 mL of CH2Cl2. The combined organic layers 
were dried over Na2SO4 and concentrated in vacuo. The pink oil was directly used for the next step 
without further purification. 
To a solution of 4.45 in 10 mL of EtOH under argon at room temperature was added hydroxylamine 
hydrochloride (104 mg, 1.5 mmol) followed by pyridine (121 L, 1.5 mmol). The reaction mixture was 
stirred for 2 hours at room temperature. After completion of the reaction monitored by TLC, 30 mL of 
saturated aqueous NaHCO3 was added to the residue, then extracted with 2x15 mL of CH2Cl2. The 
combined organic layers were dried over Na2SO4 and concentrated in vacuo. The filtrate was 
concentrated and the residue purified by flash column chromatography on silica gel (EtOAc/MeOH = 8:1) 
to afford the desired compound 4.46 in 48% yield as pale yellow solid. Data for 4.46: 
1
H NMR (300 
MHz, DMSO-d6) δ 8.38 (d, J = 6.8 Hz, 1H), 7.14 (s, 1H), 6.68-6.69 (m, 1H), 5.86 (br. s, NH2), 2.34 (s, 
3H); 
13
C NMR (75 MHz, DMSO-d6) δ 147.9, 145.2, 139.0, 127.1, 116.9, 115.8, 20.6. 
 
General procedure for the preparation of pyridine derivatives 4.47: 
 
To a solution of 4.11 (193 mg, 1.0 mmol) in 20 mL of THF under argon was added sodium hydride 
(60%) (44 mg, 1.1 mmol), followed after 30 minutes by an amine (1.1 mmol) at room temperature. The 
reaction mixture was stirred until the completion of the reaction (16 hours monitored by TLC) and was 
allowed to cool to room temperature. 50 mL of saturated aqueous NaHCO3 was added to the reaction 
mixture followed by an extraction with 2x20 mL of CH2Cl2. The combined organic layers were dried over 
Na2SO4 and concentrated in vacuo to afford the amino substituted pyridine 4.47. 
 
General procedure for the preparation of triazolo[4,5-b]pyridine derivatives 4.49: 
 
To a solution of 4.47 (1.0 mmol) in 5 mL of MeOH under argon was added a catalytic amount of acetic 
acid (6 L, 0.1 mmol) followed by zinc (327 mg, 5.0 mmol) at room temperature. The reaction mixture 
was stirred for 2 hours. 15 mL of saturated aqueous NaHCO3 was added to the reaction mixture followed 
by an extraction with 2x15 mL of CH2Cl2. The combined organic layers were dried over Na2SO4 and 
concentrated in vacuo. The reduced derivative was directly used for the next step without further 
purification. 
To a solution of the amine (1.0 mmol) in 5 mL of HCl was added dropwise a solution of sodium nitrite 
(104 mg, 1.5 mmol) in 5 mL of water at 0 °C. The reaction mixture was stirred for 2 hours, after which 50 
mL of water was added to the reaction mixture followed by a portionwise addition of K2CO3 until basic 
pH, an extraction with 2x20 mL of AcOEt was performed. The combined organic layers were dried over 
Na2SO4 and concentrated in vacuo. The residue was purified by flash column chromatography on silica 
gel (EtOAc/MeOH = 9:1) to afford the desired triazolo[4,5-b]pyridine derivatives 4.49. 
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General procedure for the preparation of triazolo[4,5-b]pyridine derivatives 4.50: 
 
To a solution of 4.49 (1.0 mmol) in 3 mL of NMP was added an amine (1.5 mmol), followed by 
triethylamine (181 L, 1.3 mmol) at room temperature. The reaction mixture was irradiated by 
microwaves at 165 °C for 30minutes and then was allowed to cool to room temperature. 15 mL of 
saturated aqueous NaHCO3 was added to the reaction mixture followed by an extraction with 2x15 mL of 
CH2Cl2. The combined organic layers were dried over Na2SO4 and concentrated in vacuo. The product 
was purified by preparative HPLC to afford the triazolo[4,5-b]pyridine analogues 4.50. 
 
4-(3-(3-Fluorophenyl)-3H-triazolo[4,5-b]pyridin-5-yl)morpholine (4.50a) 
White solid, 48% yield; Data for 4.50a: 
1
H NMR (300 MHz, DMSO-d6)  8.31 (d, J = 9.4 Hz, 1H), 8.08-
8.17 (m, 2H), 7.66-7.74 (m, 1H), 7.29-7.37 (m, 1H), 7.16 (d, J = 9.4 Hz, 1H), 3.71-3.77 (m, 8H); 
13
C 
NMR (75 MHz, DMSO-d6) 159.3, 131.8, 131.7, 130.0, 116.3, 114.5, 114.2, 107.8, 107.4, 66.0, 45.4. 
 
3-(3-Fluorophenyl)-N-(3-methoxyphenyl)-3H-triazolo[4,5-b]pyridin-5-amine (4.50b) 
Brown solid, 37% yield; Data for 4.50b: 
1
H NMR (300 MHz, DMSO-d6)  9.97 (br. s, NH), 8.30-8.34 
(m, 1H), 8.09-8.17 (m, 2H), 7.61-7.75 (m, 2H), 7.33-7.42 (m, 1H), 7.24-7.27 (m, 2H), 7.01-7.05 (m, 1H), 
6.61-6.65 (m, 1H), 3.74 (s, 3H); 
13
C NMR (75 MHz, DMSO-d6) 159.9, 156.4, 141.4, 132.4, 131.6, 
129.6, 116.9, 114.9, 114.6, 112.4, 111.7, 108.3, 104.8, 55.1. 
 
6-(5-morpholino-3H-triazolo[4,5-b]pyridin-3-yl)nicotinonitrile (4.50h) 
Beige solid, 45% yield; Data for 4.50h: 
1
H NMR (300 MHz, DMSO-d6)  9.15-9.16 (m, 1H), 8.761-8.66 
(m, 1H), 8.55-8.58 (m, 1H), 8.34 (d, J = 9.4 Hz, 1H), 7.17 (d, J = 9.3 Hz, 1H), 3.72-3.77 (m, 8H); 
13
C 
NMR (75 MHz, DMSO-d6) 156.7, 152.9, 143.3, 130.1, 127.6, 122.8, 115.4, 107.7, 65.9, 45.3. 
 
N-(tetrahydro-2H-pyran-4-yl)-3-(3,4,5-trimethoxyphenyl)-3H-triazolo[4,5-b]pyridin-5-amine (4.50i) 
Brown solid, 43% yield; Data for 4.50i: 
1
H NMR (300 MHz, DMSO-d6)  8.08 (d, J = 9.1 Hz, 1H), 7.72 
(d, J = 7.0 Hz, 1H), 7.66 (s, 2H), 6.70 (d, J = 9.1 Hz, 1H), 4.06-4.17 (m, 1H), 3.87-3.95 (m, 8H), 3.74 (s, 
3H), 3.36-3.43 (m, 2H), 1.95-2.04 (m, 2H), 1.45-1.59 (m, 2H); 
13
C NMR (75 MHz, DMSO-d6) 158.6, 
153.4, 145.0, 132.8, 131.6, 128.9, 97.8, 66.1, 60.4, 56.1, 46.8, 32.3. 
 
3-(Benzo[d][1,3]dioxol-5-yl)-5-(pyridin-4-yl)-3H-triazolo[4,5-b]pyridine (4.51b) 
Beige solid, 49% yield; Data for 4.51b: 
1
H NMR (300 MHz, DMSO-d6)  8.74-8.89 (m, 3H), 8.32 (d, J = 
8.8 Hz, 1H), 8.17-8.21 (m, 2H), 7.73-7.81 (m, 2H), 7.25 (d, J = 8.4 Hz, 1H), 6.22 (s, 2H); 
13
C NMR (75 
MHz, DMSO-d6) 150.8, 148.2, 137.5, 130.5, 121.7, 118.8, 116.2, 109.9, 108.9, 103.8, 102.3.  
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Chapter V. General discussion 
Protein kinases have long been recognized as important drug targets, there are more 
than 500 kinases in the human genome, a large number of putative kinase inhibitors are 
in clinical studies and they are present in the portfolios of most of the pharmaceutical 
companies. 
In fact, many of them are known to play a critical role in biological systems and will 
become potential drug targets for various human diseases including cancer, 
cardiovascular disorders, and inflammation in the future. The main approach to inhibit a 
kinase is to block the ATP-binding, the vast majority of kinase inhibitors make at least 
one hydrogen bond interaction with the hinge region. 
Selectivity seems to be a major issue and it was feared that use of such kinase 
directed cores would lead to unselective compounds. However, various examples are 
described where selectivity is obtained by choosing the right decoration on a particular 
scaffold that has itself interactions with the hinge region. 
 
 
Figure 1. List of the scaffolds synthesized during the PhD. 
 
This PhD research was devoted to the design and synthesis of new compound 
libraries targeting kinases. The elaboration of 19 scaffolds has been performed and more 
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than 250 analogues have been synthesized and screened towards different kinases of 
ongoing projects from Galapagos NV. 
In the chapter II, the research has been focused on the synthesis of pyrazolo[1,5-
a]pyrimidine and libraries associated, after different attempts of synthesis, the method 
chosen has been the one described by Gavrin et al. Two points of decoration has been 
selected and various linkers have been applied to a large number of derivatives. In order 
to evaluate fluorinated analogues, a simple approach has been elaborated and applied to 
the synthesis of 3-fluoro pyrazolo[1,5-a]pyrimidine. A 37-member has been screened 
towards ongoing kinase projects of Galapagos and the compound 2.29b gave an IC50 of 
859 nM towards MAP4K4. 
 
 
Scheme 1. Simple approach to the synthesis of 3-fluoro pyrazolo[1,5-a]pyrimidine. 
 
In the chapter III, an emphasis has been done on the pyridazine ring and related 
fused rings. In fact, a number of methodology has been developed aiming to access 
particular 1,2-diazines with different functional groups in order to build a library. A first 
route has been elaborated to methyl 6-substituted 4-hydroxypyridazine carboxylate from 
the readily available methyl acetoacetate allowing a large number of substitutions. 
 
 
Scheme 2. Strategy for the synthesis of pyridazine heterocycles and their derivatives. 
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This strategy has been optimized with the replacement of the toxic HMPT by P(n-
Bu)3, this modification led to a reduction of the reaction time to 15 minutes instead of 
16 hours and to obtain the pyridazines as precipitate without further purification. 
Based on this methodology, it was possible to synthesize unknown heterocycles 
such as 5H,6H,7H-pyridazino[4,3-e][1,4]diazepine or isoxazolo[4,5-c]pyridazine 
analogues. 
We were then concerned about the underexplored Diaza-Wittig reaction, in fact we 
believed that such reaction needed a catalytic alternative and inspired by the work 
performed by numerous groups, we developed the first catalytic Diaza-Wittig applied to 
the synthesis of pyridazines and a novel catalytic Aza-Wittig reaction applied to the 
synthesis of 1,4-benzodiazepines. 
 
 
Scheme 3. Catalytic Diaza-Wittig reaction. 
 
A library of 44 analogues has been developed and screened towards kinase, the best 
derivative 3.29d displayed a half maximal inhibitory concentration IC50 = 290 nM. 
 
In the chapter IV, we discussed about three isomers of the triazolopyridine scaffold. 
Our first interest was the synthesis of a library of triazolo[4,3-a]pyridine analogues. 
After a short evaluation of the pattern of substitution, it was decided to have two point 
of attachments on the pyridine ring and on the triazole ring. The introduction of 
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substitution was made possible by selecting the appropriate acid chloride or 
iso(thio)cyanate. 
We observed the formation of an isomer during the LC/MS control, after NMR 
study and literature review, the isomer was identified as the triazolo[1,5-a]pyridine 
obtained from the Dimroth rearrangement enhanced by the presence of a nitro group. 
We explored routes for the synthesis of such derivatives and screened the isomers 
obtained. 
The last isomer studied was the triazolo[4,5-b]pyridine, which do not involve the 
nitrogen from the pyridine in the fused cyclization, the key step of the synthesis was the 
formation of the triazole ring by the generation of a diazonium salt intermediate under 
"Sandmeyer-like" conditions. 
A 42-member library has been screened towards kinase by Galapagos and we 
obtained one derivative 4.51a with an IC50= 600 nM towards TGF- II receptor. 
 
Figure 2. Triazolopyridine isomers. 
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Appendix I: Synthesis of Phthalazine derivatives 
 
Scheme 1. Synthesis of phthalazine derivatives from an aryne precursor. 
 
 
Representative procedure for I.3: To a solution of ethyl 3-(4-nitrophenyl)-3-oxopropanoate I.2 (261 mg, 
1.1 mmol) and 4,5-dimethoxy-2-(trimethylsilyl)phenyl trifluoromethanesulfonate I.1 (500 mg, 1.4 mmol) 
in 15 mL of CH3CN under argon was added anhydrous Cesium fluoride (425 mg, 2.8 mmol) at room 
temperature. The reaction mixture was refluxed for 1 h. After completion of the reaction (monitored by 
TLC), the reaction mixture was cooled down to room temperature, and a saturated solution of NaCl (15 
mL) was added. The phases were separated and the aqueous layer was extracted two times with CH2Cl2 
(15 mL). The combined organic layers were dried over Na2SO4 and filtered. The filtrate was concentrated 
under reduced pressure and purified by flash chromatography (hexane/EtOAc 4:1) to provide the ethyl 2-
[4,5-dimethoxy-2-(4-nitrobenzoyl)phenyl]acetate I.3 as a yellow oil (227 mg, 55%);
 1
H NMR (300 MHz, 
CDCl3): 8.30 (d, J = 8.8 Hz, 2H), 7.94 (d, J = 8.8 Hz, 2H), 6.87 (s, 1H), 6.86 (s, 1H), 4.08 (q, J = 7.1 
Hz, 2H), 3.97 (s, 3H), 3.89 (s, 2H), 3.77 (s, 3H), 1.19 (t, J = 7.1 Hz, 3H); 
13
C NMR (75 MHz, CDCl3): 
194.9, 171.0, 151.5, 149.6, 146.8, 143.4, 130.6, 128.9, 128.6, 123.1, 114.6, 113.8, 60.6, 55.9, 55.8, 38.5, 
13.8. 
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Representative procedure for I.4: To a solution of acyl-alkyl derivative I.3 (372 mg, 1 mmol) in 10 mL of 
CH3CN under argon at 0 °C was added p-acetamido benzene sulfonyl azide (p-ABSA) (240 mg, 1 mmol) 
followed by DBU (194 L, 1.3 mmol). The mixture was stirred for 16 h and after completion of the 
reaction (monitored by TLC), a saturated solution of NH4Cl (15 mL) was added. The phases were 
separated and the aqueous layer was extracted two times with CH2Cl2 (15 mL). The combined organic 
layers were dried over Na2SO4 and filtered. The filtrate was concentrated under reduced pressure and 
purified by flash chromatography (hexane/EtOAc 3:1) to provide the methyl 2-diazo-2-{3-[3-
(trifluoromethyl)benzoyl]naphthalen-2-yl}acetate I.4 as an orange oil (203 mg, 51%);
 1
H NMR (300 
MHz, CDCl3):  8.18 (s, 1H), 8.07 (d, J = 7.7 Hz, 1H), 8.00 (s, 1H), 7.87-7.94 (m, 4H), 7.57-7.68 (m, 
3H), 3.64 (s, 3H); 
13
C NMR (75 MHz, DMSO-d6): 194.9, 166.1, 138.3, 134.8, 134.4, 133.5, 131.7, 
131.4, 129.5, 129.4, 129.1, 129.0, 128.9, 128.8, 127.9, 127.8, 127.0, 126.9, 122.1, 52.2. Diazo carbon was 
not detected in 
13
C NMR. 
 
 
Representative procedure for I.5: To a solution of diazo compound I.4 (324 mg, 1 mmol) in 10 mL of i-
Pr2O was added P(n-Bu)3 (250 L, 1 mmol) at room temperature. The reaction mixture was stirred at 
room temperature for 30 minutes and a yellow suspension has been formed. The suspension was filtered, 
washed with i-Pr2O and dried to afford the ethyl 4-(4-methoxyphenyl)phthalazine-1-carboxylate I.5 as a 
pale yellow solid (182 mg, 59%); mp 126-129°C;
 1
H NMR (300 MHz, DMSO-d6):  8.49 (d, J = 8.2 Hz, 
1H), 8.10-8.14 (m, 3H), 7.74 (d, J = 8.3 Hz, 2H), 7.21 (d, J = 8.4 Hz, 2H), 4.57 (q, J = 7.0 Hz, 2H), 3.90 
(s, 3H), 1.44 (t, J = 7.0 Hz, 3H); 
13
C NMR (75 MHz, DMSO-d6): 165.0, 160.7, 160.6, 149.7, 133.7, 
131.8, 127.8, 126.7, 125.0, 124.1, 114.3, 62.4, 55.5, 14.2. HRMS calcd for C18H16N2O3 (M+H)
+
: 
309.1234, found: 309.1237. 
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Appendix II: Synthesis of 4-azaindole derivatives 
 
Scheme 2. Synthesis of 4-azaindole derivatives. 
 
 
Representative procedure for II.2: To a solution of 2-Chloro-5-aminopyridine II.1 (129 mg, 1.0 mmol) in 
15 mL of CH3CN under argon was added NBS (214 mg, 1.2 mmol) at room temperature. The reaction 
mixture was stirred for 2 h. After completion of the reaction (monitored by TLC), a saturated solution of 
NaHCO3 (30 mL) as well as CH2Cl2 were added. The phases were separated and the aqueous layer was 
extracted two times with CH2Cl2 (15 mL). The combined organic layers were dried over Na2SO4 and 
filtered. The filtrate was concentrated under reduced pressure to provide the 2-Bromo-6-chloropyridin-3-
amine II.2 as a brown solid in 86% yield;
 1
H NMR (300 MHz, DMSO-d6): 7.30 (d, J = 8.3 Hz, 1H), 
7.09 (d, J = 8.3 Hz, 1H), 5.79 (br. s, NH2); 
13
C NMR (75 MHz, DMSO-d6): 143.1, 133.9, 124.9, 124.7, 
124.2. 
 
 
Representative procedure for II.3: To a solution of 2-Bromo-6-chloropyridin-3-amine II.2 (208 mg, 1.0 
mmol) in 12 mL of toluene and 3 mL of water under argon was added 1-ethynyl-4-fluorobenzene (138 
L, 1.2 mmol), Pd(PPh3)2Cl2 (70 mg, 0.1 mmol), CuI (19 mg, 0.1 mmol) and triethylamine (306 L, 2.2 
mmol) at room temperature. The reaction mixture was stirred for 4 h at 50°C. After completion of the 
reaction (monitored by TLC), a saturated solution of NaHCO3 (30 mL) as well as CH2Cl2 were added. 
The phases were separated and the aqueous layer was extracted two times with CH2Cl2 (15 mL). The 
combined organic layers were dried over Na2SO4 and filtered. The filtrate was concentrated under 
reduced pressure and purified by flash chromatography (hexane/EtOAc 3:1) to provide the 6-chloro-2-
((4-fluorophenyl)ethynyl)pyridin-3-amine II.3 as a pale yellow solid in 53% yield;
 1
H NMR (300 MHz, 
DMSO-d6): 7.69-7.74 (m, 2H), 7.52 (d, J = 8.6 Hz, 1H), 7.37 (d, J = 8.6 Hz, 1H), 7.23-7.27 (m, 2H), 
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5.55 (br. s, NH2); 
13
C NMR (75 MHz, DMSO-d6): 158.7, 145.3, 142.1, 129.8, 127.3, 123.9, 117.8, 
116.0, 98.4, 67.6. 
 
 
Representative procedure for II.5: To a solution of 6-chloro-2-((trimethylsilyl)ethynyl)pyridin-3-amine 
II.3 (225 mg, 1.0 mmol) in 15 mL of CH2Cl2 under argon was added butyryl chloride (136 L, 1.3 mmol) 
followed by pyridine (105 mg, 1.3 mmol) at 0°C. The reaction mixture was stirred at room temperature 
for 4 h. After completion of the reaction (monitored by TLC), a saturated solution of NaHCO3 (30 mL) 
was added. The phases were separated and the aqueous layer was extracted two times with CH2Cl2 (15 
mL). The combined organic layers were dried over Na2SO4 and filtered. The filtrate was concentrated 
under reduced pressure and directly used for the next step without further purification. 
To a solution of the previously prepared crude II.4 in 10 mL of DMF was added portionwise KOtBu (281 
mg, 2.5 mmol), the reaction mixture was heated at 70°C for 2 h and after completion of the reaction 
(monitored by TLC), a saturated solution of NaHCO3 (30 mL) and CH2Cl2 were added. The phases were 
separated and the aqueous layer was extracted two times with CH2Cl2 (15 mL). The combined organic 
layers were dried over Na2SO4 and filtered. The filtrate was concentrated under reduced pressure and 
purified by flash chromatography (CH2Cl2/MeOH 9:1) to provide the 5-chloro-pyrrolo[3,2-b]pyridine II.5 
as a white solid 15% in yield;
 1
H NMR (300 MHz, DMSO-d6): 11.56 (br. s, NH), 7.84 (d, J = 8.4 Hz, 
1H), 7.72 (d, J = 3.2 Hz, 1H), 7.12 (d, J = 8.5 Hz, 1H), 6.54 (d, J = 3.2 Hz, 1H); 
13
C NMR (75 MHz, 
DMSO-d6): 145.7, 142.5, 130.8, 127.3, 122.0, 115.9, 101.3.  
 
 
Representative procedure for II.6: To a solution of 5-chloro-2-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridine 
II.5 (230 mg, 1.0 mmol) in 5 mL of dioxane under argon was added (3,4,5-trimethoxyphenyl)boronic 
acid (254 mg, 1.2 mmol), K3PO4 (467 mg, 2.2 mmol) and 1,1’-bis(diphenylphosphino)ferrocenedichloro 
palladium (82 mg, 0.1 mmol) at room temperature. The reaction mixture was refluxed until the 
completion of the reaction for 16 hours and then was allowed to cool to room temperature. 15 mL of 
saturated aqueous NaHCO3 was added to the reaction mixture followed by an extraction with 2x15 mL of 
CH2Cl2. The combined organic layers were dried over Na2SO4 and concentrated in vacuo. The product 
was purified by preparative HPLC to afford the 2-(pyridin-2-yl)-5-(3,4,5-trimethoxyphenyl)-1H-
pyrrolo[3,2-b]pyridine II.6 as a brown solid in 42% yield;
 1
H NMR (600 MHz, DMSO-d6): 11.93 (br. s, 
NH), 8.68 (d, J = 4.2 Hz, 1H), 8.11 (d, J = 7.9 Hz, 1H), 7.93 (t, J = 8.2 Hz, 1H), 7.84 (d, J = 8.6 Hz, 1H), 
7.77 (d, J = 8.6 Hz, 1H), 7.38-7.42 (m, 4H), 3.90 (s, 6H), 3.72 (s, 3H); 
13
C NMR (150 MHz, DMSO-d6): 
153.1, 149.9, 149.8, 149.4, 146.4, 140.5, 137.8, 137.3, 131.5, 129.4, 123.1, 120.8, 119.7, 15.1, 103.8, 
101.1, 60.2, 56.0. 
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Appendix III: Synthesis of furo[3,2-c]pyridine derivatives 
 
Scheme 2. Synthesis of furo[3,2-c]pyridine derivatives. 
 
 
Representative procedure for III.2: To a solution of 4-hydroxy-3-nitropyridine III.1 (140 mg, 1.0 mmol) 
in 10 mL of water was slowly added bromine (67 L, 1.3 mmol) at room temperature. The reaction 
mixture was heated for 2 h at 50°C and then cooled to room temperature. The resulting precipitate was 
filtered, washed with water, and then dried to give the 3-bromo-5-nitropyridin-4-ol III.2 as a white solid 
in 82% yield. The product was directly used without further purification for the next step;
 1
H NMR (300 
MHz, DMSO-d6): 12.76 (br. s, OH), 8.83 (s, 1H), 8.37 (s, 1H); 
13
C NMR (75 MHz, DMSO-d6): 163.7, 
139.2, 138.9, 137.1, 118.8. 
 
 
Representative procedure for III.3: To a solution of 3-bromo-5-nitropyridin-4-ol III.2 (219 mg, 1.0 
mmol) in 12 mL of toluene and 3 mL of water under argon was added phenylacetylene (132 L, 1.2 
mmol), Pd(PPh3)2Cl2 (70 mg, 0.1 mmol), CuI (19 mg, 0.1 mmol) and triethylamine (306 L, 2.2 mmol) at 
room temperature. The reaction mixture was stirred for 16 h at 70°C. After completion of the reaction 
(monitored by TLC), a saturated solution of NaHCO3 (30 mL) as well as CH2Cl2 were added. The phases 
were separated and the aqueous layer was extracted two times with CH2Cl2 (15 mL). The combined 
organic layers were dried over Na2SO4 and filtered. The filtrate was concentrated under reduced pressure 
and purified by flash chromatography (hexane/EtOAc 2:1) to provide the 7-nitro-2-phenylfuro[3,2-
c]pyridine III.3 as a beige solid in 52% yield;
 1
H NMR (300 MHz, DMSO-d6): 9.24 (s, 1H), 9.17 (s, 
1H), 7.97 (d, J = 7.8 Hz, 2H), 7.74 (s, 1H), 7.49-7.60 (m, 3H); 
13
C NMR (75 MHz, DMSO-d6): 159.6, 
150.9, 148.0, 140.1, 130.1, 129.5, 128.8, 128.2, 127.7, 125.4, 98.3. 
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Representative procedure for III.4: To a solution of III.3 (240 mg, 1.0 mmol) in 5 mL of MeOH under 
argon was added a catalytic amount of acetic acid (6 L, 0.1 mmol) followed by zinc (327 mg, 5.0 mmol) 
at room temperature. The reaction mixture was stirred for 5 hours. 15 mL of saturated aqueous NaHCO3 
was added to the reaction mixture followed by an extraction with 2x15 mL of CH2Cl2. The combined 
organic layers were dried over Na2SO4 and concentrated in vacuo. The reduced derivative was directly 
used for the next step without further purification.  
To a solution of the amine (1.0 mmol) in 5 mL of EtOH under argon was added 4-cyanobenzaldehyde 
(170 mg, 1.3 mmol) followed by sodium cyanoborohydride (126 mg, 2.0 mmol) at room temperature. The 
reaction mixture was stirred for 16 hours, after which 15 mL of saturated aqueous NaHCO3 was added to 
the reaction mixture followed by an extraction with 2x15 mL of CH2Cl2. The combined organic layers 
were dried over Na2SO4 and concentrated in vacuo. The product was purified by preparative HPLC to 
afford the 4-(((2-phenylfuro[3,2-c]pyridin-7-yl)amino)methyl)benzonitrile III.4 as a white solid in 31% 
yield;
 1
H NMR (300 MHz, DMSO-d6): 8.23 (s, 1H), 7.98 (d, J = 7.2 Hz, 2H), 7.81 (d, J = 8.2 Hz, 2H), 
7.72 (s, 1H), 7.64 (d, J = 8.2 Hz, 2H), 7.54 (t, J = 7.1 Hz, 2H), 7.42-7.47 (m, 2H), 6.93 (t, J = 6.3 Hz, 
NH), 4.67 (d, J = 6.3 Hz, 2H); 
13
C NMR (75 MHz, DMSO-d6): 155.4, 146.7, 146.3, 132.4, 132.3, 130.2, 
129.4, 129.3, 129.1, 128.1, 127.4, 126.0, 124.9, 119.0, 109.6, 100.2, 46.1.  
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